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The computational analysis of Post-Translational modifications 
Summary:  
The post translational modification (PTMs) of proteins presents a means to 
increase the proteome size and diversity of an organism through the inclusion of 
structural elements not encoded at the sequence-level alone. Their erroneous 
inclusion or exclusion has been linked to a variety of diseases and disorders 
thus their characterisation has the potential to present viable drug targets. The 
proliferation of newer high-throughput methods, such as mass spectrometry, to 
identify such modifications has led to a rapid increase in the number of 
databases and tools to display and analyse such vast amounts of data 
effectively.   This study covers the development of one such tool; PTM Browser, 
and the construction of the underlying database that it is based upon.  This new 
database was initially seeded with annotations from the Swiss-Prot and 
Phospho.ELM resources.  The initial database of PTMs was then expanded to 
include a large repertoire of previously unannotated proteins for a selection of 
topical species (e.g. Danio rerio and Tetraodon nigroviridis).  Orthologue 
assignments have also been added to the database – to allow for queries to be 
performed regarding the conservation of modifications between homologous 
proteins.  The PTM Browser tool allows for a full exploration of this new 
database of PTMs – with a special focus on allowing users to identify 
modifications that are both shared between and are specific to particular 
species.  This tool is freely available for non-commercial use at the following 
URL: http://www.ptmbrowser.org.  An analysis is presented on the conservation 
of modifications between members of the tumour suppressor family, p53, using 
this new tool.  This tool has also been used to analysis the conservation of 
modifications between super-kingdoms and Eukaryote species. 
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Chapter 1  
 
Introduction 
This chapter begins with an overview of the diversity of PTMs (Post-
translational modifications) with particular emphasis on the important functions 
that they play in protein: structure; function and regulation.  This is followed by a 
review of the experimental detection techniques that are commonly used to 
identify PTMs.  The second half of this chapter discusses current PTM 
databases and the nomenclature that is used in them to represent PTMs. 
Section 1.1  The diversity of post-translation 
modifications: 
It is a common statement that humans have 98% sequence similarity with the 
chimp genome, leaving a miniscule 2% to account for the differences between 
us. This figure is however based purely upon sequence-level comparison, and 
therefore does not take account of differences in gene expression, alternate 
splicing and post-translational modification. The PTM of a protein is any form of 
structural alteration that occurs at the post-translational level. This provides an 
extra degree of proteome diversity and complexity, which is not determined by 
the primary sequence alone.  There are a great number of different PTM 
classes – 24 of which are shown in Table 1.  A small selection of these PTMs 
will now be reviewed in detail. 
N-linked Glycosylation O-linked Glycosylation C-linked Glycosylation 
S-linked Glycosylation Phosphorylation Methylation 
Hydroxylation Acetylation Palmitoylation 
Myristoylation Prenylation Formylation 
Amidation GPI-anchor Sulfation 
ADP-Ribosylation Citrullination Bromination 
S-nitrosylation Glutathionylation Oxidation 
Iodination Disulphide bonds  Cleavage 
Table 1:  List of main PTM types. This list is in-part based on those modification classes stored in the Swiss-Prot 
database (see Table 9 for the complete list). 
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Section 1.1.1  Phosphorylation 
Phosphate is one of the smallest ligands that can be used to modify a protein 
but is perhaps the most abundant form of PTM.  Phosphorylation is carried out 
by protein kinases, which are highly residue-specific.  The protein kinases are 
commonly associated with cell signalling cascades, however the 
serine/threonine-specific protein kinase is not the only type that exists in nature, 
in eukaryotes the other main type is tyrosine-specific and in bacteria it is 
histidine that is most commonly phosphorylated for this purpose (Choi et al. 
2008; Khorchid and Ikura 2006).  The addition of phosphate to the hydroxyl 
group of serine, threonine and tyrosine produces a stable phosphoester (P-O) 
bond, whereas the phosphorylation of histidine results in an acid-labile 
phosporamidate (P-N) bond (Attwood et al. 2007).  Figure 1 shows these amino 
acids in their native and modified forms. 
Histidine Serine Threonine Tyrosine 
    
  
+ Phosphate 
Phosphohistidine Phosphoserine Phosphothreonine Phosphotyrosine 
    
Figure 1: Common amino acids targeted for phosphorylation in both their native and modified states.  
The amino acids shown are from the following PDB entries: phosphoserine 3NAY (Nagashima et al. 2011), 
phosphotyrosine 3N8M (Delorbe et al. 2010), phosphothreonine 3MY1 (Baumli, Endicott, and Johnson 2010) and N3-
phosphohistidine 1QWO (Xiang et al. 2004). 
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The reason for the difference in phosphorelay preferences between these 
groups is not fully understood, however Choi et al. postulate that the 
serine/threonine/tyrosine multi-step system may have presented an evolutionary 
advantage due to its ability to incorporate different signal sources as well as the 
ability to tightly control the duration of the signalling burst (Choi et al. 2008).  
Whereas Attwood et al. suggest that the propensity for hydrolysis of the 
phosphoramidate bond would present an evolutional advantage for systems 
requiring a rapid „on/off switch‟, by removing the requirement for additional 
components to terminate the signal (Attwood et al. 2007).  These hypotheses 
would support the difference in amino acid preference between the distinct 
superkingdoms, with eukaryotes requiring complex patterning of gene 
expression and precise timing, and prokaryotes requiring a rapid response to 
changes in their extracellular environment.  Phosphorylation however is not 
limited to these four amino acids, arginine (Besant, Attwood, and Piggott 2009), 
lysine (Besant, Attwood, and Piggott 2009), cysteine (McAdams et al. 2008), 
aspartate (Attwood, Besant, and Piggott 2010), glutamate (Attwood, Besant, 
and Piggott 2010) and the already post-translationally modified residue 
hydroxyproline (Kühlberg, Haid, and Metzger 2010) are also potential 
phosphorylation targets.  
Hyperphosphoryation of p53 has been observed in many tumour derived cell 
lines (Minamoto et al. 2001).  The tumour suppressor protein Rb 
(Retinoblastoma protein) has been shown to play an important role in controlling 
the G1-S checkpoint (Harb et al. 2009).  In its unphosphorylated form Rb is 
bound to the transcription factor E2F (Chellappan et al. 1991).  The 
phosphorylation of Rb results in the release of the E2F transcription factor and 
subsequent cell cycle progression (Adams 2001).  Research has been 
published that suggests that Silibinin (available as a dietary supplement) 
promotes the formation of the unphosphorylated form of Rb, which may have 
therapeutic and preventive properties in the treatment of prostate cancer (Tyagi, 
Agarwal, and Agarwal 2002). 
 
 
4 
 
Section 1.1.2  Glycosylation 
Glycosylation is generally split between two main types: N-linked and O-linked, 
defined by the functional group of the amino acid to which the sugar is attached 
(Spiro 2002). N-linked glycosylation is associated with either asparagine or 
arginine, which contain an amide or amino functional group, whereas O-linked 
glycosylation is associated with hydroxyl-containing amino acids, e.g. serine, 
threonine and tyrosine (Spiro 2002). The N-glycosidic bonds are best 
characterised by the β-glycosylamine linkage between asparagines and N-
acetylglucosamine (GlcNAc) (Spiro 2002).  
N-linked glycans are characterised by a core penta-saccharide formed of two 
GlcNAc residues and three mannose (Man) residues.  A series of 
glycosyltransferases and hydrolyases are responsible for both adding and 
removing residues from the core-penta-saccharide (Walsh 2006).  N-linked 
glycans are usually classified into the following groups: high mannose, complex, 
core and truncated (Walsh 2006) (see Table 2 for example structures and 
Section 2.6.4 for further information on N-linked glycan classification).  
Glycosylation was until fairly recently considered to be a PTM that was specific 
to Eukaryotes.  This view was changed with the discovery that Campylobacter 
jejuni (a bacterial species) is able to N-link glycosylate a number of its proteins 
(including flagella) (Szymanski et al. 1999).   Achaea have also been shown to 
glycosylate their proteins – in fact in a recent review on the subject it was 
highlighted that archaeal glycosylation is more prevalent than bacterial (Yurist-
Doutsch et al. 2008). 
In recent years the link between differences in glycosylation patterns and 
disease has become an area of great interest (Hakomori 2002; Jaeken and 
Matthijs 2007). Interestingly all forms of human cancers have glycosylation 
defects, though it is not yet clear whether this is a cause or a symptom 
(Hakomori 2002). Alteration of these modifications is potentially linked to 
metastasis by changing the way in which a cell can interact with those around it, 
as well as inhibiting signalling cascades that would ultimately lead to apoptosis 
(Hakomori 2002). 
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Glycoproteins are an extremely diverse group, which are closely associated 
with cell signalling. Glycosylation is involved in the presentation of self antigens 
to the immune system, via MHC (Parham 1996) and is used to distinguish non-
self (Dziarski 2003). Perhaps one of the most well-known effects of differences 
in the glycosylation of cells is the ABO blood grouping system in humans 
(Takasaki, Yamashita, and Kobata 1978). Erythrocytes from all four blood 
groups: A, B, O and AB, contain the H chain displayed on their cell surface 
(Yamamoto et al. 1990). This can be further extended by glycosyltransferases, 
the precise function of which varies to produce the different groups, e.g. blood 
group A is produced by α1-3 N-acetylgalactosaminyltransferase (A-transferase), 
whereas group B is produced by α1-3 galactosyltransferase (B-transferase) 
(Yamamoto et al. 1990). Blood group O is produced owing to the lack of a 
functional transferase thus contains the H-chain alone (Yamamoto et al. 1990). 
Both functional glycosyltransfereases are the product of the ABO gene on 
chromosome 9. However, the substrate specificity is altered by single 
nucleotide polymorphisms between individuals (Yazer and Olsson 2008). 
 
Figure 2: N-Linked glycan classification examples.  Images created using GlycoWorkbench (Ceroni et al. 2008). 
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Section 1.1.3  Methylation 
Protein methylation involves the transfer of a methyl (CH4) group from the 
substrate S-adenosylmethionine (SAM) onto a number of different amino acid 
side chains (Clarke 1993).  The two most common forms of methylation are the 
methylation of carboxyl groups and nitrogen atoms (Clarke 1993).  N-
methylation is an irreversible reaction (Clarke 1993) that commonly occurs at 
arginine and lysine residues (Grillo and Colombatto 2005).  O-methylation is a 
reversible reaction (Clarke 1993) that has been observed on leucine (Bryant, 
Westphal, and Wadzinski 1999) and asparagine residues (Klotz and Glazer 
1987). 
One of the first examples of O-methylation was observed on the photosynthetic 
accessory Phycobiliproteins (Klotz and Glazer 1987).  S-methylation, the 
methylation of cysteine residues, was first reported from an MS/MS (tandem 
Mass Spectrometry) analysis of the proteins found in the eye lens (Lapko, 
Smith, and Smith 2002).  C-methylation has also been observed at the C-2 
position of glutamine and C-5 position of arginine in the archeal Methyl-
coenzyme M Reductase (Selmer et al. 2000).   
Ha-ras (a key oncogene) is both prenylated (Section 1.1.5(b) and methylated, 
both of which are thought to be required for membrane localisation (Clarke et al. 
1988).  It appears that one of the effects of the chemotherapeutic agent 
Methotrexate is to reduce O-methylation of Ras (Rat Sarcoma) family members 
(Philips 2004). 
Section 1.1.4  Acetylation 
Proteins can either be acetylated at the ε-amino group of lysine residues or α-
amino group of N-terminal methionine (or preceding residue if the methionine 
has been removed) (Soppa 2010).  Acetylation has been observed in all three 
superkingdoms (Soppa 2010).  N-terminal methionine acetylation is a co-
translationally process carried out by N-terminal acetyltransferases (NATs) 
(Polevoda et al. 1999).  N-terminal acetylation may act as a degradation signal 
in the ubiquitin dependent degradation pathway (Hwang, Shemorry, and 
Varshavsky 2010). 
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Acetylation of histone proteins has been known since at least 1976 (Taylor and 
Cook 1981).  Acetylation of lysine residues on Histone tails (by histone 
acetyltransferases, HATs) is associated with the activation of genes and 
deacetylaion (by histone deacetylases, HDACs) with the repression of genes 
(via chromatin remodelling) (Eberharter and Becker 2002).  Histone acetylation 
is associated with a permissive (supporting transcription) chromatin structure 
(Eberharter and Becker 2002).    Histones H3 and H4 located at the 5‟ end of 
FMR1 (fragile X mental retardation 1)  are acetylated in cells derived from 
healthy individuals; in contrast cells from fragile X patients show decreased 
acetylation (Coffee et al. 1999). 
Section 1.1.5  Lipidation 
Section 1.1.5(a)  Glycosylphosphatidylinositolylation 
The glycosylphosphatidylinositol (GPI)-anchors are a way to anchor a protein to 
the cell membrane (Ferguson and Williams 1988).  As the name would indicate 
they are formed of both glycosyl and lipid components, with the hydrophobic 
lipid chains facilitating membrane anchoring and the glycans providing docking 
sites for protein molecules (Ferguson and Williams 1988).  The synthesis of 
GPI-anchored proteins is complex, involving a flippase - required to transport 
the phosphatidylinositol base structure into the lumen of the ER for further 
extension, as well as the Golgi apparatus, which facilitates membrane insertion 
(Almeida, Layton, and Karadimitris 2009).  As with other PTMs, its disruption is 
linked to disease, namely inherited GPI-deficiency and paroxysmal nocturnal 
hemoglobinuria (acquired) that results in thrombosis and haemolytic anaemia, 
respectively (Almeida, Layton, and Karadimitris 2009). 
Section 1.1.5(b)  Prenylation 
Prenylation involves the transfer of either the 15-carbon Farnesyl (C15H25) group 
or 20-carbon (C20H33) GeranylGeranyl group (see Figure 3) to c-terminal 
cysteine residues (Roskoski 2003).  Farnesyl groups are transferred by 
Farnesyl transferases (FTases) and GeranylGeranyl groups by GernaylGernayl 
transferases (GGTases) I and II (Roskoski 2003).  FTase and GGTaseI cleave 
after the cysteine residue in the motif CaaX (where “a” is any aliphatic residue 
and X is any amino acid) and form a thioether bond to the Farnesyl or 
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GeranylGeranyl groups (Maurer-Stroh and Eisenhaber 2005).  GGTaseII 
recognises the motifs CC and CxC (Maurer-Stroh and Eisenhaber 2005).   
Farnesyl 
 
GeranylGeranyl-Monophosphate 
 
Figure 3:  Farnesyl and GeranylGeranyl idealised 3D structures.  PDB coordinates were obtained from the PDB Ligand 
Expo database (Feng et al. 2004). 
Like other lipid modifications prenylation has been shown to be required for the 
membrane association of a number of proteins.  For example the double 
prenylation (GeranylGeranyl) of the GTPase Rab family of proteins (belonging 
to the Ras superfamily) has been shown to be essential for their correct 
localisation (Calero et al. 2003).  Ras family members are key regulators of cell 
proliferation and are frequently mutated in H. sapiens tumours (Downward 
2003).  As the prenylation of Ras family members is essential for their function, 
FTases and GGTases were obvious drug targets (Downward 2003).  In fact 
research has shown that Farnesyltransferase and GeranylGeranyltransferase 
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inhibitors (FTIs and GGTIs) may be relevant as therapeutic agents in the 
treatment of both cancer and viral related diseases.   For example the FTIs 
BZA-5B and FTI-277 have been shown to block the proliferation of Hepatitis 
delta virus (HDV) (a cause of chronic and acute liver disease) (Bordier et al. 
2002).   
Section 1.1.5(c)  Palmitoylation and Myristoylation 
Palmitoylation involves the formation of either an amide (n-linked) or thioester 
bond (s-linked) between a long chain fatty acid (mainly palmitate) and a 
cysteine residue (Linder and Deschenes 2003).  N-myristoylation involves the 
formation of a covalent bond between the n-terminal of a glycine residue and 
the 14 carbon saturated fatty acid, myristate by the enzyme N-
myristoyltransferase (NMT) (Wright et al. 2009).  S-palmitoylation is a reversible 
PTM whereas N-myristoylation is not (Linder and Deschenes 2003).  
S-palmitoylation is required to localise the protease BACE1 (of which the 
Amyloid precursor protein (APP) is a target) to lipid rafts (Vetrivel et al. 2009).  
There is conflicting evidence regarding the importance of S-palmitoylation in the 
eventual deposition of β-amyloid peptides (Aβ) in the brain (formed by the 
cleavage of the APP protein) (Meckler et al. 2010).  Whilst the cleavage of APP 
by BACE1 and γ-secretases into Aβ has been shown to be independent of their 
S-palmitoylation status in vitro, research suggests this may not be the case in 
vivo (Vetrivel et al. 2009; Meckler et al. 2010).  
Many viruses are dependent on the host NMT, including HIV-1, for replication, 
which has led to the development of N-myristoylation inhibitors.  For example, 
N-myristoylation of the Z protein, belonging to Lassa virus (LASV), has been 
shown to be essential for its recruitment to the plasma membrane (Strecker et 
al. 2006).    Treatment of LASV infected cells with N-myristoylation inhibitors 
has been shown to reduce the replication efficiency of the virus (Strecker et al. 
2006).  N-myristoylation has also been implicated in affecting the stability of 
proteins.  For example the catalytic subunit of cAMP-dependent protein kinase 
is stabilised after being N-myristoylated (Yonemoto, McGlone, and Taylor 
1993).  The non-receptor tyrosine kinase family, Src members are key 
regulators of cellular signalling, for which N-myristoylation is essential for their 
10 
 
regulation and membrane association (Patwardhan and Resh 2010).   NMT has 
also been found to be overexpressed in H. sapiens colorectal adenocarcinomas 
(Raju, Moyana, and Sharma 1997).   
Section 1.1.6  Cleavage 
The first protein to have its complete amino acid sequence determined was 
insulin, a discovery that won Frederick Sanger the 1958 Nobel Prize in 
Chemistry  (Sanger and Thompson 1953a; Sanger and Thompson 1953b; 
Sanger and Tuppy 1951a; Sanger and Tuppy 1951b).  Insulin however is 
subject to two forms of post-translational modification: proteolytic cleavage and 
disulphide bond formation, which are required to convert proinsulin, as 
expressed from the INS gene, to the active hormone insulin (Ryle et al. 1955; 
Steiner and Oyer 1967).  Proteolytic cleavage is a frequent occurrence amongst 
secreted proteins, owing to the requirement for removal of the export signal 
peptide, thus it is commonly associated with hormones, e.g. hGH, somatostatin, 
calcitonin, glucagon and parathyroid (Rholam, Nicolas, and Cohen 1986). 
Likewise disulphide-bridges are also regularly linked to exported proteins in 
both eukaryotes and bacteria (Sevier and Kaiser 2002). 
Section 1.1.7  PTM Detection  
It is standard practice for anyone expressing or purifying a protein to analyse 
their samples by PAGE (polyacrylamide gel electrophoresis) to get an indication 
of purity, yield and size of protein (Steinberg 2009).  A polyacrylamide gel is 
formed of a matrix of cross-linked acrylamide monomers.  The cross-linked 
nature of the acrylamide forms pores that serve to separate proteins based on 
size, with pore size dependent on acrylamide concentration.  SDS (sodium 
dodecyl sulphate) is an anionic detergent that is commonly added to PAGE gels 
(SDS-PAGE), which is able to denature proteins and mask their natural charge 
(Wilson 2000).  SDS-polyacrylamide gels are referred to as denaturing gels and 
polyacrylamide gels as native gels (because the protein runs in its native 
conformation in the absence of SDS) (Wilson 2000).  Thus the benefit of each is 
as their names suggest, native gels allow you to study the natural state of the 
protein and denaturing gels allow you to study the peptide chain (Wilson 2000). 
In one dimensional (1D) polyacrylamide gel electrophoresis proteins are 
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separated based on their ability to migrate through the gel, generally resulting in 
a size gradient with larger proteins running more slowly although native gels 
vary in this point due to the different folds and charges like-sized proteins can 
have (Wilson 2000). 
In order to separate by an additional dimension (2D) the 1D gel, or specific lane, 
is rotated 90°C and run again, usually with a pH gradient applied in order to 
separate by the isoelectric point (pI) (Wilson 2000). The benefit of this method is 
that two proteins of equal size are unlikely to share a pI thus a 2D gel could 
distinguish between them when a 1D gel could not.  
These methods are useful for separating unmodified proteins but in order to 
determine whether a PTM has been added additional steps are required.  
Western blots can be performed that make use of PTM specific antibodies that 
act as reporters for particular modifications (Miller, Crawford, and Gianazza 
2006).  In recent years the use of antibodies to detect PTMs has grown in 
popularity with many pharmaceutical companies (e.g. Millipore, Perkin Elmer 
and Sigma-Aldrich) producing a range of products and kits to meet the high 
demand.  As with unmodified proteins many companies also provide an 
antibody generation service when a generic antibody is not appropriate.  PTM-
specific antibodies can be produced that are specific to particular proteins (i.e. 
they recognise part of the modification and other parts of the proteins 3D 
structure).  This allows for protein specific-PTM antibodies to be used with 
mixed population samples. As with all antibodies there can however be cross-
reactivity (Fuchs et al. 2011).  For example a recent study by Fuchs et al. 2011 
demonstrated that antibodies raised against di- and tri-methyl-lysine 
modifications at positions 4 and 79 of histone protein H3, were cross-reactive 
with other di- and tri-methyl-lysine modifications.  The same study also 
demonstrated that adjacent modifications can affect the ability of antibodies to 
recognise the modifications they were raised against. 
A common way of detecting proteins that are modified is to identify spots on 
protein gels that change position in the presence and absence of an inhibitor of 
a particular modification.  For example N-terminal α-amine acetylation has 
traditionally been detected by comparing the position of protein spots on 2D 
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SDS gels in the presence and absence of N-terminal acetyltransferases (Van 
Damme et al. 2009).  Although recently gel-free techniques have been 
developed that both separate and enrich N-terminal α-amine acetylated 
peptides for detection using MS (Van Damme et al. 2009). 
Modified proteins can also be identified on gels through the radiolabelling of 
PTMs.  For instance phosphorylated proteins can be detected by growing cells 
on a medium that contains radiolabelled γ[32P]-ATP (this is only possible 
because no amino acid includes phosphate) (Miller, Crawford, and Gianazza 
2006).  Phosphoserine and phosphotheonine can also be detected on protein 
gels using Methyl green after the phosphates have been hydrolysed with NaOH 
(Miller, Crawford, and Gianazza 2006).  Flourescent stains have also been 
created that can stain proteins with particular modifications (Miller, Crawford, 
and Gianazza 2006). 
MS can be used to identify both the position and type of virtually all PTMs.  
Traditional proteomic experiments start with the digestion of proteins with an 
enzyme such as trypsin.  The resulting mixture of peptides is then usually 
separated using a HPLC (High Performance Liquid Chromatography) system 
that is connected to a mass spectrometer (commonly referred to as on-line LC-
MS).  The mass spectrometer will record a peak for each observed peptide 
fragment with the corresponding mass to charge ratio (m/z).  Software is then 
used that analyses the resulting mass spectrum to identify which proteins were 
present in the sample.  Most algorithms start with a database of protein 
sequences, which are digested in-silico with the same enzyme used in the real 
experiment.  The software then deduces the m/z of each peptide fragment 
based on the conditions of the original experiment (i.e. negative or positive ion 
mode).  This provides the software with a complete list of m/z values for each 
protein.  Algorithms tend to indicate which proteins are present in a sample 
based on the number of expected fragments for a particular protein that were 
actually observed in the MS spectra.  PTMs can be detected by looking for 
peaks that have an m/z shift that is equivalent to an in-silico generated peptide 
fragment having a particular modification.  Even if a modified fragment is 
identified it does not necessarily follow that the software will be able to 
unambiguously tell the user which residue was modified in the fragment.  For 
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example, a phospho-peptide may contain multiple residues that could carry the 
phosphate group.   
The MS analysis of glycoproteins is a particularly challenging area of research 
due to the complex nature of glycan structures.  One simple method of 
identifying glycopeptides in a mixed population is to use lectin affinity 
chromatography (e.g. by using Concanavalin A, which recognises the tri-
mannosyl-core of N-linked glycans) (Fan et al. 2004; Brewer and Bhattacharyya 
1986).  N-linked glycans are commonly removed from the Asn residues of 
glycopeptides using PNGaseF.  This enzyme has the effect of converting the 
modified Asn residues to Asp (Fan et al. 2004).  PNGaseF treatment can 
therefore be used as an indirect method of identifying glycopeptides in a mixed 
sample (by the corresponding m/z shift).  Identifying both the site and 
corresponding glycan structure is a particularly difficult area of research (An, 
Froehlich, and Lebrilla 2009).  One of the problems is that glycans fragment at 
much lower collision energies than peptides (An, Froehlich, and Lebrilla 2009).  
Technologies are however under development that allows for the acquisition of 
glycan and peptide fragments.  For example 157nm light has been shown to 
produce glycan and peptide fragments (including glycan cross-ring cleavages, 
which are required to obtain linkage information) (Zhang and Reilly 2009).  
Deducing which glycan structures produced a particular set of peaks is far from 
a straight forward process.  This, in part, stems from the large number of ways 
in which monosaccharaides can be joined together.  Glycans typically need to 
undergo multiple rounds of fragmentation (e.g. MS/MS, MS/MS/MS, ... MSn) 
before software is able to deduce which structures are present (i.e. fragmenting 
fragments) (Ceroni et al. 2008).  Glycoinformatic tools have been designed that 
attempt to make glycan structure determination a semi-automated process.  For 
instance GlycoWorkbench is able to fragment user supplied structures and 
automatically annotate a given spectra (Ceroni et al. 2008).  Alternatively this 
tool can function in a similar way to general proteomics software, whereby it 
carries out an in silico fragmentation of a database of known glycan structures 
(Ceroni et al. 2008).  Other tools have been designed that reduce the glycan 
structure search space to only those structures that can be produced by known 
biosynthetic pathways (Goldberg et al. 2005). 
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Section 1.2  Bioinformatics resources 
With such a diverse set of post-translational modifications identified to date it 
should come as no surprise that a large number of databases, and associated 
tools, have been created.  Modern proteomics techniques are promising to 
deliver an unprecedented volume of data, including the identification of 
countless new sites of PTM (Prince et al. 2004).  Figure 4 demonstrates the 
explosion that has occurred in published papers associated with keywords 
connected to the analysis and detection of PTMs. 
 
Figure 4: Cumulative number of papers in PubMed that are associated with specific PTM related terms between 
1999 and 2009.  This graph was generated using the class org.drd20.bioinformatics.database.PubMed, which is part 
of the Bioinformatics Basic Perl (BBP) project (created by the author).  More information regarding the BBP project 
can be found in Appendix 2.  The PubMed class utilises the web service API provided for http://ncbi.nlm.nih.gov 
resources called EUtils (http://eutils.ncbi.nlm.nih.gov).   The ESearch command of this API is used by this class to 
obtain counts for the number of papers published between specific dates that are associated with a specific term.  
Usage of the PubMed class can be found here: http://wiki.ptmbrowser.org/index.php/BBP_PubMed_Graph.  The 
PubMed class utilizes the class org.drd20.core.graphing.svg.SVGBarChart2 to produce graphs of the retrieved 
results.  SVGBarChart2 renders graphs using the Cairo vector graphics library. 
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Bioinformaticians have successfully dealt with similar influxes of data from the 
fields of genomics and transcriptomics during the past 10 years (Prince et al. 
2004).  Challenges facing the new field of Proteomic Informatics include: data 
storage and availability, publication standards, and data analysis techniques 
(Prince et al. 2004).  Figure 5 displays the bioinformatics resources that have 
been created to aid in the analysis and storage of PTM annotations – set in the 
context of the experimental techniques that are used to detect them.  The 
experimental and computational techniques that can be used to identify PTMs 
are reviewed in Chapter 4.  Chapter 2 documents the creation of a new 
database of PTMs in detail.  What is now presented is a review of the existing 
databases and interfaces that they provide, which should be used to place this 
new database into context.   
 
Figure 5: Intersection between PTM related tools, databases and experimental determination techniques. 
Databases that store annotations for PTMs can be classified into two groups.  
One group stores annotations for a particular subset of modifications, whilst the 
other stores annotations for the majority of known modification types.  
Phosphorylation and glycosylation are by far the most common modifications 
stored in any of the current databases.  These two types of modification also 
have a large number of databases that are specific to them.   
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Section 1.2.1  Phosphorylation 
Phospho.ELM (<http://phospho.elm.eu.org/>) is a database of experimentally 
determined phosphorylation sites (Diella et al. 2004). Version 7 of this database 
contained 4,078 proteins with 2,083 tyrosine, 12,025 serine and 2,362 threonine 
modification annotations (Diella et al. 2008b).  This database is manually 
curated and contains additional information such as the cellular kinase(s) 
responsible for modifying a particular residue (Diella et al. 2004).  PHOSIDA 
(Phosphorylation Site Database) (<http://www.phosida.de>) is another database 
that contains annotations derived from mass spectrometry experiments (Gnad 
et al. 2007).  In addition Gnad et al. (2007) designed a phosphosite predictor 
using a SVM (Support Vector Machine) trained on the experimentally 
determined sites in PHOSIDA. PhosPhAt (<http://phosphat.mpimp-
golm.mpg.de/>) is a database of phosphorylation sites in Arabidopsis thaliana 
determined by mass spectrometry (Heazlewood et al. 2008).  PhosPhAt also 
contains a plant specific predictor of phosphorylation sites and was updated in 
2010 to include predicted phosphorylation sites in the core database (Durek et 
al. 2010). 
Section 1.2.2  Glycosylation 
The complexity in analysing and representing glycan structures has resulted in 
the creation of a whole field of informatics referred to as glycoinformatics – see 
Frank and Schloissnig 2010 and Perez and Mulloy 2005 for a review of the field.  
The first database created in this field was the Complex Carbohydrate Structure 
Database (CCSD) created at the Complex Carbohydrate Research Centre 
(CCRC) (Doubet et al. 1989).  This database was curated by experts in the field 
of glycobiology from around the world – containing published glycan structures 
and associated information (Doubet et al. 1989).  However, funding for this 
database ran out in 1999 (Loss et al. 2002).  A database of O-linked glycans 
was published in 1995 (Hansen et al. 1996), which was shortly followed by an 
accompanying prediction tool (Julenius et al. 2005).  The first large scale 
database released after the demise of the CCSD was the GlycoSuiteDB 
(Cooper et al. 2001; Cooper et al. 2003).  The GlycoSuiteDB was a commercial 
database that contained N- and O-Linked glycan structures that had been 
extracted from the literature (Cooper et al. 2001).  One of the most useful 
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aspects of this database was their inclusion of attachment site information 
where it was available, as well as links to the UniProtKB (Cooper et al. 2001).  
Although useful, the commercial aspect of this database limited its uptake in the 
scientific community.  In May 2009 the GlycoSuiteDB web interface was made 
public – allowing glycobiologists to access the underlying data 
(<http://glycosuitedb.expasy.org/glycosuite/glycodb>).   Around the same time 
as GlycoSuiteDB was released, a completely free alternative the SWEET-DB 
was released (Loss et al. 2002).  This database was seeded with annotations 
from the CCSD, NCBI PubMed, and NMR data from SugarBase 
(<http://www.boc.chem.uu.nl/sugabase/sugabase.html>).  In the original 
publication the authors explain how they planned to expand this database with 
additional: structures, references, annotations and NMR spectra – using both 
automatic and manual curation.  Lutteke, et al. 2004 created the PDB2LINUCS 
database – that contains all glycans in the PDB as well as their attachment sites 
(Lutteke, Frank, and von der Lieth 2004).  The most recent glycodatabases 
have come from the CFG (Consortium for Functional Glycomics) (Raman et al. 
2006) and EUROCarbDB initiative (<http://eurocarbdb.org/>).  These databases 
focus on storing both glycan structures and the raw experimental data that were 
captured during experiments (for instance MS spectra) (Raman et al. 2006).  
Finally many glycoinformatics resources have been published from groups in 
Japan.  For instance, KEGG/Glycan can be used to analyse the 
glycosyltransferases that are responsible for creating specific glycan structures 
(Hashimoto et al. 2006). 
Section 1.2.3  UniProtKB (http://uniprot.org) 
UniProtKB (UniProt Knowledge Base) contains by far the most PTM 
annotations for multiple PTM classes (Farriol-Mathis et al. 2004).  This 
database is part of UniProt (Universal Protein Resource) that has been created 
to provide the scientific community with resources that can be used to 
interrogate the: structure, function and interactions of proteins (UniProt 
Consortium 2009).   Three additional databases are included in UniProt: UniRef 
(UniProt Reference Clusters), UniMes (UniProt Metagenomic and 
Environmental Sequence database) and the UniParc (UniProt Archive) (UniProt 
Consortium 2009). 
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The UniProtKB is composed of two separate databases: Swiss-Prot and 
TrEMBL (Translated EMBL) (Boeckmann et al. 2003).  The UniProtKB includes 
all CDSs (protein coding sequences) from: EMBL-Bank, GenBank/DDBJ 
Nucleotide Sequence Databases, Arabidopsis Information Resource (TAIR) and 
Ensembl H. sapiens (UniProt Consortium 2009).  
Swiss-Prot contains high-quality curator-maintained annotations for proteins.  
This includes ``curator-evaluated computational analysis'' (UniProt Consortium 
2009).  Proteins that haven't yet been curator-evaluated are placed into the 
TrEMBL database (Boeckmann et al. 2003).  
All PTM annotations are curator reviewed, precluding the PTM annotation of 
TrEMBL entries.  These PTM annotations are derived through the use of 
literature mining and PTM prediction tools.  The PTM prediction tool chain used 
has not been published, although (Farriol-Mathis et al. 2004) states that only 
PTM prediction tools with low false-positive rates have been incorporated.   
In Swiss-Prot release 55.3 there were 185,535 PTM annotations present on 
55,445 proteins from 4,956 taxa.  276 different PTM types and 42 PTM classes 
were represented in this release of the Swiss-Prot database.  Note that only 
58,802 of these PTM annotations were not marked as being predicted. 
Section 1.2.4  dbPTM (http://dbptm.mbc.nctu.edu.tw)  
The other major database with annotations for multiple PTM classes is the 
dbPTM (Database of PTM) (Lee et al. 2006).  The dbPTM aims to enhance the 
annotations from Swiss-Prot, Phospho.ELM, and O-GLYCBASE databases with 
a wide array of information (Lee et al. 2006).  This database predominately 
stores the structural characteristics of modification sites, including: solvent 
accessibility, secondary and tertiary structure, and domain annotations (Lee et 
al. 2006).  The authors of dbPTM had previously published the profile hidden 
markov model prediction tool called KinasePhos (Huang et al. 2005a).  The 
dbPTM contains additional predictions for multiple PTM classes that were made 
with algorithms similar to that published for KinasePhos (Lee et al. 2006).  Note 
that this database hasn‟t been updated since 2007. 
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Section 1.3   Nomenclature 
The analysis of PTMs has been complicated by the use of synonymous and 
ambiguous terms (Montecchi-Palazzi et al. 2008).  A number of attempts have 
been made to create controlled vocabularies (CVs), which remove such 
ambiguities and synonyms.  Such PTM CVs are of interest to researchers in the 
fields of: Proteomics, Bioinformatics and Mass Spectrometry (Montecchi-Palazzi 
et al. 2008).  A controlled vocabulary is simply a list of standard terms, which is 
usually cross-referenced to a list of synonyms for backwards compatibility.  By 
defining relationships between terms, an ontology is formed (Stevens, Rector, 
and Hull 2010).  Probably the best known example of an onology created for the 
biological sciences, is the Gene Ontology (GO) (See Section 3.5.1(b) for further 
information). 
Section 1.3.1  RESID 
The RESID database of protein structure modifications was created in 1993 to 
represent the natural PTM types annotated in the Swiss-Prot and PIR (Protein 
Information Resource) databases (Garavelli 2003).  The creation of the RESID 
database involved the standardisation of the terms used to describe PTMs in 
the Swiss-Prot database, thus creating the first PTM controlled vocabulary 
(Farriol-Mathis et al. 2004).  The Swiss-Prot PTM vocabulary has however not 
been adopted by all researchers. Alternative vocabularies can be found in the 
public databases UNIMOD and DeltaMass as well as some proprietary 
databases (Montecchi-Palazzi et al. 2008).  
The integration of PTM annotations has been hampered by the use of these 
competing vocabularies, a problem that is set to get worse with the advent of 
large scale proteomics initiatives (Montecchi-Palazzi et al. 2008).   The 
Proteomics Standards Initiative, founded by the Human Proteome Organisation 
(HUPO), has started the process of creating a new controlled vocabulary of 
PTMs called PSI-MOD; it is hoped that this will become the standard PTM 
vocabulary (Montecchi-Palazzi et al. 2008). 
The Swiss-Prot database annotates PTM events with one term from a 
controlled vocabulary (Farriol-Mathis et al. 2004).  These will from here-on be 
20 
 
referred to as a PTM type, examples include: 4-aspartylphosphate, 
Phosphothreonine and O-(5'-phospho-DNA)-serine.  Associative keywords are 
used to group together PTMs involving similar chemical changes (Farriol-Mathis 
et al. 2004). For example the three PTM terms listed previously are associated 
with the parent keyword Phosphoprotein.   
PTM events that are derived from multiple PTM processes are associated with 
multiple keywords, for example N6,N6,N6-trimethyl-5-hydroxylysine is 
associated with the keywords Hydroxylation and Methylation.  Keywords can 
also be parents of other keywords.  Take the PTM type "GPI-anchor amidated 
cysteine", involving the transfer of a glycolipid onto a cysteine residue, which 
has the keyword "GPI-anchor". This keyword has the two parent keywords 
"Lipoprotein" and "Glycoprotein". 
It could be argued that by linking PTM types to PTM classes an „is_a‟ 
relationship is being formed; creating a Swiss-Prot PTM ontology (although it is 
never referred to as such). 
Section 1.3.2  PSI-MOD 
The Proteomics Standards Initiative has initiated the construction of an ontology 
of PTMs.  They decided that this was necessary as none of the vocabularies in 
current use fitted the needs of the Proteomic Informatics (PSI-PI) and Molecular 
Interactions (PSI-MI) working groups.  The PSI aims for PSI-MOD to become 
the standard PTM vocabulary both in HUGO and in the wider scientific 
community.  (Montecchi-Palazzi et al. 2008). 
An ontology is the specification of “an abstract, or simplified view of the world 
that we wish to represent for some purpose” (Gruber 1993).  Ontologies contain 
terms or classes that represent abstract views of real world objects; as well as 
containing a representation of the relationships between such objects (Gruber 
1993).  The Gene Ontology (Ashburner et al. 2000) is the canonical ontology in 
the bioinformatics community.   The gene ontology contains three namespaces 
that allow for scientists to annotate the molecular function, biological process, 
and cellular component of gene products (Ashburner et al. 2000).  The gene 
ontology is composed of a DAG (Directed Acylic Graph) where terms are the 
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nodes, and edges represent the relationships between terms (Ashburner et al. 
2000). The presence of an „is_a‟ relationship between two terms indicates that 
one term is a subtype of the other (Smith et al. 2005).  The „part_of‟ relationship 
is used to indicate that a term is contained in the object represented by the 
other/parent term (Smith et al. 2005).  The lack of correctly defined and 
conceived relationship-type definitions has been a particular problem in the 
bioinformatics community and is addressed in detail in Smith et al. 2005. 
PSI-MOD uses the four relationship types as shown in Table 2.  Examples of 
each of these types can be seen in Table 3.  
Relationship Definition 
is_a Indicating membership of a class 
part_of Indicating a child entity is a substructure 
derives_from Indicating a child entity is the result of a chemical process 
has_function_parent Indicating that a child entity derived by functional modification 
shares at least one characteristic group with the parent entity. 
Table 2: PSI-MOD relationships – taken from (Montecchi-Palazzi et al. 2008). 
Child Term Relationship Parent Term 
O-glycosyl-L-threonine is_a O-glycosylated residue 
pentosylated residue part_of complex glycosylation 
N6,N6,N6-trimethyl-L-lysine  
(from L-lysinium residue) 
derives_from protonated L-lysine (L-lysinium) residue 
neddylated lysine Contains N6-glycyl-L-lysine 
Table 3: PSI-MOD relationship examples. 
Section 1.4 Aims of thesis 
The main goal of this body of work was to create the tools and resources 
necessary to allow for the analysis of PTM conservation.  Two different 
conservation analyses were considered to be important at the start of this work.  
The first use-case involves users who wish to analyse PTM conservation for a 
specific list of proteins.  The second use-case involves users who wish to 
analyse PTM conservation between taxonomic groups; for example a user may 
wish to know what percentage of the H. sapiens phosphoproteome is conserved 
in E. coli.  The primary purpose of the majority of the databases previously 
described is to act as a store of experimentally-determined, or computationally-
predicted, modification annotations.  Few provide the interrogation interfaces 
that are required by experimentalists to perform even the simplest of 
conservation analysis.  Of course there are always exceptions and the 
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PHOSIDA is probably the best example.  This database allows users to identify 
conserved phosphorylated residues between orthologous sequences.  However 
there is currently no database that allows for a simple conservation analysis to 
be performed for many different types of PTM classes.   Section 5.3 contains a 
more detailed description of existing resources and how they can be used in 
workflows to analyse PTM conservation. 
Software that is going to perform a conservation analysis for scientists requires 
access to many different pieces of information.  For example to analyse the 
conservation of the phosphoproteome between Eukaryotes and Mammals 
requires access to: taxonomic trees, proteome sets, PTM annotations and some 
form of homology annotation.  The following three chapters of this thesis 
describe the integration of the many different resources required by the tool that 
has been designed to analysis PTM conservation.   
Chapter 2 starts by describing the creation of the PTMDB, a database that 
integrates PTM annotations from Swiss-Prot, Phospho.ELM and the PDB.  This 
chapter highlights the difficulties in analysing the conservation of glycosylation 
caused by incomplete structural datasets. 
Chapter 3 describes the process of adding orthology assignments to the 
PTMDB.  Incorporating these annotations into the PTMDB allows PTM Browser 
to perform a conservation analysis on a choosen protein – without requiring 
users to manually specify proteins they wish to compare (although they still 
can).  In addition these orthology assignments can be used by PTM Browser to 
carry out a high-throughput analysis of the conservation of modifications 
between orthologues of user selected species. 
Chapter 4 describes a process that has been used to transfer existing PTM 
annotations onto homologous sites.  Homologous sites are identified through 
Pfam domain alignments that have been incorporated into the PTMDB.  As well 
as providing the scaffolding for this process, the domain annotations also allow 
for a domain level conservation analysis to be performed by PTM Browser.  The 
cross-annotation procedure combined with the Pfam alignment integration, 
allows PTM Browser to quickly analyse PTM conservation without having to 
carry out a time-consuming multiple sequence alignment step.  The majority of 
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the PTM annotations in the PTMDB were imported from Swiss-Prot.  Therefore 
species whose proteome is predominantly located in the TrEMBL portion of the 
UniProtKB are underrepresented in the PTMDB.  This cross-annotation 
procedure addresses this limitation to an extent by including proteins from the 
TrEMBL database.  Therefore the PTMDB contains the first large scale PTM 
annotation for some species whose genomes have recently been sequenced. 
Chapter 5 describes the development of the PTM Browser tool which allows 
users to analyse the conservation of PTMs.  Included in this chapter is a 
description of a web service that has been created to allow programmatic 
access to both the PTMDB and the PTM Browser conservation analysis 
routines. 
Chapter 6 describes the results of a number of different PTM conservation 
analysis performed with the PTM Browser tool.  This includes an analysis on the 
conservation of modifications between H. sapiens and a number of other 
species.  An example of PTM Browser being used to analysis a protein family is 
presented, via an analysis of the conservation of modifications in the p53 family 
of proteins. 
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Chapter 2  
 
A new database of PTMs 
Section 2.1  Summary 
There are many post-translational modification databases in existence that 
store a variety of information.  These databases, and the tools that accompany 
them, are predominately focused on allowing users to retrieve a list of known 
modification sites for a specific protein.  Some databases, like UniProtKB, also 
provide limited information on the conservation of modifications across 
homologous proteins.  However, using existing resources, it is currently 
impossible for users to ask simple questions such as “What modification sites 
appear in human proteins but not in their mouse counterparts?”.  Before 
software can be designed to answer such questions it is necessary to decide 
where this software is going to obtain its annotations.  None of the currently 
available databases are designed to be used in such a fashion.  Therefore 
presented in this chapter is a description of the creation of a new database of 
PTMs.  This database has been designed with the specific aim of allowing such 
questions to be answered.  The seeding of this database with annotations from 
UniProtKB, Phospho.ELM and the PDB is described.  The extension of this 
database to include additional annotations, and other information, is then 
described in the following two chapters. 
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Section 2.2  Software and conventions 
Throughout this and the following chapters there will be references to many 
classes and scripts that carry out particular tasks required for the work 
presented in this thesis.  The first time a class name is provided it will be written 
in fully qualified form, e.g. <org.drd20.util.MySqlUtil>.  From then on all 
references to the class will appear unqualified and underlined, e.g. <MySqlUtil>.  
Unless otherwise stated all classes reside in the Perl project Bioinformatics 
Base Perl (BBP), information on obtaining and installing the software described 
in this thesis can be found in Appendix 2.  All of the classes described are 
designed for reuse in other pieces of software. However some include a static 
main method implementation similar to that of Java classes, which allows the 
class to be called directly by a Perl interpreter that runs some default task.  
When a particular task being described is accomplished by running the static 
main method of a class its name will be suffixed with a question mark. 
To make it clear that a table, namespace or field from a relational database is 
being referred to they will be underlined, presented in bold font, and enclosed in 
angle brackets, e.g. <vocabulary.PtmDescription>. 
Section 2.3 Design approach 
This section outlines aspects of the schema design process, which might be 
unfamiliar or require justification to the reader.   
The MySQL (<http://mysql.com>) RDBMS (Relational Database Management 
System) was chosen to store the PTMDB primarily because of its ease of use 
and support.  Unless stated otherwise all tables were designed to be stored 
using the InnoDB storage engine (at the time of development the default for 
MySQL was MyISAM, which doesn‟t support foreign key constraints).  
PostgreSQL (<http://www.postgresql.org>) users should be aware that MySQL 
doesn‟t support the notation of separate namespaces in the same database.  
It‟s common practise in the MySQL community to represent each namespace 
with its own separate database, this methodology has been adapted for the 
schemas of the PTMDB. 
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The majority of schemas were designed using the MySQL Workbench (MWB) 
tool (<http://wb.mysql.com/>).  Entity relationship diagrams were produced 
using the SVG (Support Vector Graphic) export functionality of MWB.  Note 
these images have been manually adjusted (using Inkscape 
<http://inkscape.org>) to enable primary, surrogate and business keys to be 
distinguished.  MWB determines the relationship type (identifying or non-
identifying) between two entities based on the primary key of the child table.  
Where a surrogate primary key is used the relationship types determined by 
MWB aren‟t particularly informative.  Therefore the relationship types exported 
by MWB for entities with a surrogate primary key have been manually adjusted 
to reflect the business key.  An identifying relationship indicates that a row in a 
child table cannot be identified without the foreign key constraint to the parent 
table.  In contrast a non-identifying relationship indicates that a row in a child 
table can be identified without the foreign key constraint to the parent table - 
refer to the caption of Figure 10 for examples of each. 
The primary key of a table includes those fields without which an entity cannot 
be uniquely identified.  A surrogate primary key is used where a suitable natural 
primary key doesn‟t exist or it‟s advantageous not to use it.  For instance 
surrogate primary keys are commonly used by ORM (Object Relational 
Mapping) technologies (e.g. Hibernate (<http://www.hibernate.org>) as a fast 
way of uniquely identifying an entity.  Surrogate primary keys have been used 
wherever possible in the PTMDB for both ease of schema design and future 
compatibility with ORM technologies.  Inserting a row into a table that has a 
foreign key dependency on another table‟s surrogate primary key can be 
problematic as it requires an additional query to discover the correct surrogate 
primary key to insert.  To resolve this potential issue a new Perl class 
<org.drd20.util.AbstractERD.WorkBenchParser> has been created that is able 
to create an object model of the schema using SQL that MWB is able to export.  
This object model allows for data to be inserted into a table without having to 
lookup the surrogate primary key manually.  This software has to be able to 
workout which fields represent the business key of a table in order to 
successfully resolve the surrogate primary key.  A business key like a natural 
primary key represents those fields without which an entity cannot be identified.  
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For each table that requires a business key to be defined, a unique index called 
Entry is created, that includes the fields that identify an entity in the 
corresponding table.  These unique indexes can be added to the schema using 
MWB, the <WorkBenchParser> class has been designed to extract the 
business key from unique indexes called Entry. 
Entity relationship diagrams are shown throughout this chapter, refer to Figure 6 
to see what relationships exist between them. 
 
Figure 6: Entity relationship figure connections.  Figure displays the relationships between the different ERD figures 
shown throughout this chapter. 
Section 2.4  Vocabulary 
At the time of writing two popular nomenclatures were being actively developed 
for the purpose of describing PTMs.  The first to be developed was designed for 
use in the Swiss-Prot database, for the purpose of unambiguously annotating 
PTM events (Farriol-Mathis et al. 2004).  The second was published 4 years 
later by the Proteomics Standards Initiative (PSI) for use by the Proteomic 
Informatics (PSI-PI) and Molecular Interactions (PSI-MI) working groups 
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(Montecchi-Palazzi et al. 2008).  The PSI designed their nomenclature as an 
ontology, which they called PSI-MOD.  Further details on PTM nomenclatures 
and the differences between them can be found in Section 1.3. 
In Section 1.2 an overview of existing PTM databases was presented, which 
clearly demonstrated Swiss-Prot as having the most diverse and numerous 
PTM annotation dataset.  The new PTM database that is being described, the 
PTMDB, incorporates the majority of its annotations from the Swiss-Prot 
database.  For this reason the primary PTM nomenclature used in the PTMDB 
has been derived from that which is used in the Swiss-Prot database.  In the 
future it is likely that database curators will annotate PTM events with purposely 
designed ontologies, as has already happened for describing gene products 
and their functions using the Gene Ontology (Ashburner et al. 2000).  Therefore 
support for the PSI-MOD ontology has also been added to the PTMDB. 
The following two sections describe the implementation of both these 
nomenclatures in the PTMDB. 
Section 2.4.1  Swiss-Prot vocabulary 
The following description of the Swiss-Prot PTM vocabulary is based on 
information contained in the original paper by Farriol-Mathis et al., (2004) and 
the UniProtKB manual (<http://www.expasy.ch/sprot/userman.html>).  This 
nomenclature is referred to by the authors as a controlled vocabulary, 
downloadable from the following URL: <http://www.uniprot.org/docs/ptmlist>.  
There are three levels of classification in this vocabulary: (i) Feature key, (ii) 
Feature description and (iii) Keyword.  The most specific of these is the feature 
description; examples include Phosphoserine, N-acetylserine, N-
acetylmethionine, N6-acetyllysine, etc.  The name of this level of classification 
isn‟t particularly descriptive for the purposes of a PTM vocabulary, therefore the 
PTMDB feature description has been renamed to PTM type.   The second layer 
of this vocabulary utilises UniProtKB keywords to group similar PTM types.  For 
example Phosphoserine, Phosphotheronine, Phosphotyrosine, and 
Phosphohistidine all belong to the keyword Phosphoprotein.  For convenience 
these keywords are referred to in the PTMDB as PTM classes.   Note that the 
file that contains this vocabulary also contains an index between PTM types and 
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their associated PTM classes.  The top level of this vocabulary groups PTM 
types by six feature keys, which are shown in Table 4. 
Feature Key Description 
LIPID PTM types with a predominantly lipid constitution. 
CROSSLNK Formation of a covalent bond between two amino acids. 
DISULFIDE Disulphide bonds. 
CARBOHYD PTM types with a predominantly glycan component. 
CHAIN Peptide chain cleavage annotations. 
MOD_RES All PTMs not covered by the previous feature keys. 
Table 4: UniProtKB feature keys associated with PTM types. 
An idealised version of the Swiss-Prot PTM vocabulary schema is shown in 
Figure 7, in summary the figure demonstrates the following points: 
1. All feature keys listed in Table 1 are associated with one-or-more PTM types. 
2. PTM types are associated with zero-or-more PTM classes. 
3. Every PTM class is associated with one-or-more PTM types. 
4. All PTM types are associated with one-or-more PTM classes. 
5. A PTM class can have zero-or-more parents. 
6. A PTM class can have zero-or-more children. 
In order to understand points 4-6 it‟s important to understand the connections 
that can exist between UniProtKB keywords.  It‟s already been stated that a 
PTM class is a UniProtKB keyword; such keywords can be connected to others 
in parent-child fashion.  Note that keyword definitions and the connections that 
exist between them can be downloaded from the following URL: 
<http://www.uniprot.org/docs/keywlist>.  An excellent example of this is 
provided by the GPI-anchor keyword, which has the parents Lipoprotein and 
Glycoprotein; remember that this type of modification includes both a lipid and 
carbohydrate component.  Note that the PTM type-to-PTM class index, provided 
with this vocabulary, doesn‟t explicitly map to parent keywords; for example the 
PTM type GPI-anchor amidated alanine is only associated with the keyword 
GPI-anchor.  Some modifications are the result of two separate processes for 
these multiple keywords are listed in the provided PTM type-to-PTM class 
index.  For example the PTM type 5-hydroxy-3-methylproline is mapped to the 
PTM classes Hydroxylation and Methylation in this mapping. 
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Figure 7: An idealised version of the Swiss-Prot PTM vocabulary schema.  This diagram was designed using MySQL 
Workbench (http://wb.mysql.com/), and exported as an SVG (Support Vector Graphic).  Note that entity names, 
mapping table names, and field names do not directly correlate with the terminology used in either Farriol-Mathis et 
al., (2004) or the UniProtKB manual. 
Table 5 contains a list of the additional information that this vocabulary stores 
for each PTM type.  Although this data isn‟t pertinent to the task of analysing the 
conservation of modifications (the aim of this body of work), for the sake of 
completeness it has been included in the schema that will be discussed below. 
Short identifier Plain Text Description Occurrence 
ID Identifier (FT description) Once 
AC Accession (PTM-xxxx) Once 
FT Feature Key Once 
TG Target Once 
PA Position of the modification on the amino acid Optional, once 
PP Position of the modification in the polypeptide Optional, once. 
CF Correction formula Optional, once 
MM Monoisotopic mass difference Optional, once 
MA Average mass difference Optional, once 
LC Cellular location Optional, one or more 
TR Taxonomic range Optional, one or more 
KW Keyword Optional, one or more 
DR Cross-reference to PTM databases Optional, one or more 
Table 5: UniProtKB PTM vocabulary attributes – list adapted from <http://www.uniprot.org/docs/ptmlist>. 
Section 2.4.2  Primary PTMDB vocabulary 
For reasons previously explained it was decided that the primary PTM 
vocabulary of the PTMDB should be based on that used in the UniProtKB.  
What follows is a brief description of the schema that has been designed to 
house this vocabulary.  Throughout this description the reader is encouraged to 
refer to Figure 10, which contains a schema diagram specific to the vocabulary 
section of the PTMDB.  At the heart of the schema is the <vocabulary> table 
that contains a list of PTM types and their associated feature key.  In addition 
this table also includes all attributes from Table 2, which can occur at most 
once.  The remaining one-or-many attributes from Table 2 have been mapped 
on the tables: <vocabularyLocalisation>, <vocabularyTaxonomicRange>, 
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and <vocabularyKeywords>.  Not all the PTM types and classes stored in the 
primary PTMDB vocabulary will have been imported from the Swiss-Prot PTM 
vocabulary.  For this reason the <vocabulary> table also includes the field 
<vocabulary.FirstObservedSource> to enable a PTM type to be associated 
with the database it was first imported from.   
The terms used to describe PTM types in the Swiss-Prot PTM vocabulary are 
not all amino acid specific.  This shouldn‟t come as a particular surprise as it 
would make the vocabulary incredibly redundant; especially when you consider 
the number of glycan structure/amino acid pairs that could theoretically exist 
(KEGG/Glycan (Hashimoto et al. 2006) currently contains 11,000 structures).  
Early on in the database design process it was decided that it would be useful 
to be able to extract PTM annotations with matching PTM types and attachment 
amino acids.  To meet this requirement PTM annotations are stored in the 
PTMDB using a PTM type identifier that is amino acid specific.  The table 
<vocabularyTargetsSpecific> contains these new identifiers associated with 
their corresponding PTM type and amino acid. PTM types that are clustered 
under the feature keys DISULPHIDE and CROSSLNK involve multiple amino 
acids; it‟s for this reason that the table <vocabularyTargetsSpecific> contains 
two amino acid fields for all other PTM types both fields contain identical values.  
The Swiss-Prot vocabulary flat file that was mentioned earlier doesn‟t include 
any of the Glycosylation PTM types found in the Swiss-Prot database.  Glycan 
structures are by far the most structurally complex of all PTMs, exemplified by 
the numerous encoding languages that have been created (Glyde I (Hellen et 
al. 2008) (Sahoo et al. 2005), Glyde II (York 2011), GlycoCT (Herget et al. 
2008), LINUCS (Bohne-Lang et al. 2001),  etc.).  In Swiss-Prot Glycosylation 
PTM types use a simple encoding scheme that indicates the linkage type, 
terminal reducing-end sugar, and an indicator for whether any sugars are 
attached to the terminal reducing-end sugar. See Figure 8 for further details and 
Glycosylation PTM type examples. 
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REGEXP[OCNS]{1}-linked \(SUGAR(?:…)?(?: or SUGAR(?:…)?)?\) 
SUGAR=(?:HexNAc|GlcNAc|GalNAc|Man|Glc|Gal|Hex|Xyl|Ara|Fuc){1} 
(a) 
N-linked Glycosylation PTM types 
N-linked (GlcNAc…) 
N-linked (Glc…) 
N-linked (GlcNAc) 
N-linked (GlcNAc or GlcNAc…) 
N-linked (Man) 
(b) 
Figure 8: Swiss-Prot Glycosylation PTM type format.  (a) Perl regular expression which conforms to the Swiss-Prot 
Glycosylation PTM type format (documentation regarding the regular expression notation can be found at the 
following URL <http://perldoc.perl.org/perlre.html>). (b) All of the N-linked Glycosylation PTM types in Swiss-Prot. 
The PTMDB vocabulary tables are populated with the Swiss-Prot PTM 
vocabulary using the script <ptmDB/Main/PTMKeywords/ptmVocabularyErd.pl>.  
As the Glycosylation PTM types aren‟t included in the Swiss-Prot PTM 
vocabulary flat file they have to be imported dynamically as PTM annotations 
are parsed from the Swiss-Prot database.  Additional keywords have also had 
to be created for the Glycosylation PTM types.  Its common practise to discuss 
Glycosylation based on the linkage between the protein and the glycan, 
therefore the following new keywords have been created: Glycosylation, 
Glycosylation_O_Linked, Glycosylation_N_Linked, Glycosylation_C_Linked, 
and Glycosylation_S_Linked.  Note that the Swiss-Prot PTM vocabulary flat file 
maps PTM types to the amino acids that they can occur on, therefore for all 
PTM types represented in this file the table <vocabularyTargetsSpecific> can 
be populated.  For Glycosylation PTM types this table is dynamically populated 
as Swiss-Prot PTM annotations are parsed.  Note that in the PTMDB 
vocabulary all PTM types that don‟t have a PTM class in the Swiss-Prot PTM 
vocabulary have been associated with the new PTM class – Other. 
Table 4 contains the six feature keys which represent all PTM types that can be 
stored in the Swiss-Prot database.  Note that it was decided that although the 
PTMDB vocabulary and annotation schemas would be designed to support all 
six; the following three are currently ignored by both the vocabulary import and 
annotation import systems – CROSSLNK, DISULFIDE, and CHAIN. 
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Figure 9 displays the number of PTM types that are grouped under each PTM 
class in the PTMDB vocabulary.  In addition this figure shows the number of 
additional identifiers which had to be generated to create amino acid specific 
PTM types.  Note that this figure was generated after the import of Swiss-Prot 
PTM annotations so that data could be shown for the Glycosylation PTM 
classes.  This figure shows that there are a great many PTM types that have no 
associated PTM class in the Swiss-Prot PTM vocabulary.  A total of 288 PTM 
types grouped by 40 PTM classes are in the current PTMDB vocabulary. 
 
Figure 9: Distribution of PTM types by PTM class in the PTMDB vocabulary.  The number of additional amino acid 
specific PTM types created represents the difference between the number of corresponding rows (for a given PTM 
class) on the tables vocabulary and vocabularyTargetsSpecific. This figure was generated after Swiss-Prot PTM 
annotations had been imported into the PTMDB so that the Glycosylation PTM classes could be included. 
 
 
 
Figure 10: Post-translational modification vocabulary schema diagram.  Identifying and non-identifying relationships: a) field PtmID is included in the business key of vocabularyTargets so the 
relationship between vocabularyTargets and vocabulary has been set to identifying, b) TypeID is not included in the business key of vocabulary so the relationship between vocabulary and 
vocabularyType has been set to non-identifying.  The tables in this figure have been placed in the PTMDB namespace. 
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Section 2.4.3  PSI-MOD incorporation 
PSI-MOD support has been added to the PTMDB for two reasons: a) it is likely 
to become the PTM controlled vocabulary standard, and b) the relationships 
represented in the graph structure will allow for more powerful queries to be 
constructed than are possible with the Swiss-Prot PTM vocabulary.  PSI-MOD 
contains all of the entries from the RESID, Delta Mass and UniMod databases 
(Montecchi-Palazzi et al. 2008).  As stated previously the RESID database 
contains all the PTM types found in the Swiss-Prot PTM vocabulary and hence 
the PTMDB vocabulary, therefore it‟s possible to map PTM types in the PTMDB 
to their PSI-MOD equivalents. 
The PSI-MOD ontology is supported in the PTMDB via the schema shown in 
Figure 12.  Terms in the PSI-MOD have a number of additional attributes 
associated with them; those that can be imported into the PTMDB are shown in 
Table 6.  Note that not all of the terms have all of these attributes.  The table 
<psiModTerms> is used to store a list of all PSI-MOD terms and these 
additional attributes associated with them. 
Short Name Description 
Formula Chemical formula 
MassAvg Monoisotopic mass 
DiffFormula Formula for the difference between observed modified residues and an 
originating residue 
DiffAvg Chemical average mass difference 
DiffMono Monoisotopic mass difference 
Source Residue source, currently with values of 'Natural','Artifact' or 'Hypothetical' 
Origin Residue origin with a value of one IUPAC standard single-letter amino acid 
code or for cross-links, one for each participating residue. 
TermSpec Protein amino or carboxyl terminus specificity, currently with a value of 'C-
term' or 'N-term' or 'none'. 
Table 6: PSI-MOD term attributes supported by the PTMDB. List taken directly from the original specification of PSI-
MOD found in Montecchi-Palazzi, 2008.  
The PSI-MOD schema shown in Figure 12 has the following characteristics. 
1. A term may have zero-or-more synonyms. 
2. A term may represent the modification of zero-or-more amino acids. 
3. A term may have zero-or-more parents and zero-or-more children. 
4. A term may be a part of zero-or-more subsets (a slim). 
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The synonyms of a PSI-MOD term represent the equivalent terms in the RESID, 
Delta Mass and UniMod databases.  PSI-MOD terms that are equivalent to 
PTMDB PTM types can be identified by matching values in the fields 
<vocabulary.PtmDescription> and <psiModTermSynonyms.synonym>.  
The reason not all PSI-MOD terms are associated with target amino acids, 
results from their abstract nature; for example MOD:00001 is the parent of all 
terms which represent the alkylation of residues.  Note that all PSI-MOD terms 
have a parent term except for the root term of the ontology (MOD:00000 protein 
modification).  As has been explained previously a leaf term is one that doesn‟t 
have any children.  The majority of the PTM types in the PTMDB vocabulary 
map to leaf terms.  The PSI-MOD graph is stored in the table 
<psiModTermRelationships>.  To allow for all direct and indirect descendants 
of a specific PSI-MOD term to be obtained, without reparsing the PSI-MOD 
graph, the table <psiModTermToAllParents> has been created.   
The PSI-MOD ontology is available in OBO (Open Biological and Biomedical 
Ontologies) format from the following URL 
<http://psidev.sourceforge.net/mod/data/PSI-MOD.obo>.  The shell script 
<org.drd20.bioinformatics. database.ptmdb.psiModAutomate.sh> (part of the 
BBP project) has been designed to read the PSI-MOD OBO flat file and import 
data into the PTMDB PSI-MOD schema.  Note that this script makes use of a 
number of Perl and Java programs to accomplish this task.  The revision of the 
PSI-MOD ontology incorporated into the PTMDB being reported here contained 
1,409 terms. 
The PSI-MOD ontology contains four main paths that allow for terms to be 
found according to chemical process, target amino acid, isobaric sets and 
uncategorised modifications (Montecchi-Palazzi et al. 2008).  Almost all of the 
direct descendants of the term chemical process have an equivalent PTMDB 
PTM class.   
Figure 9 displays the number of PTM types grouped by PTM class for the 
PTMDB primary vocabulary.  These numbers can be compared with those in 
Figure 11, which shows the number of terms below each direct descendant of 
the chemical process term.   
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Figure 11: PTM type distribution in the PSI-MOD ontology.  The x-axis contains all those terms that are direct 
descendants of the chemical process term (MOD:01157).  This graph shows both the number of terms that can be 
found below each term listed on the x-axis; additionally the number of these terms that are leaf terms is also shown. 
 
  
 
 
 
Figure 12: PSI-MOD ontology schema diagram. 
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Section 2.5  Annotation 
Section 2.5.1  Swiss-Prot annotation format 
The following description of the Swiss-Prot PTM annotation format is based on 
information contained in the original paper by Farriol-Mathis et al., (2004) and 
the UniProtKB manual (<http://www.expasy.ch/sprot/userman.html>).  A more 
general introduction to the Swiss-Prot database and UniProtKB can be found in 
Section 1.2.3. 
In Swiss-Prot each protein is represented as a single entry in the database.  
Each entry is composed of a set of fields that describe the functional and 
structural attributes of the protein.  The feature table component of an entry 
stores the annotations for splice variants, variants, signal sequences, PTMs, 
and many other attributes.  A single annotation is represented as one line in the 
feature table.  The type of annotation present on a line is denoted by a feature 
key.  Feature keys were discussed previously (Section 2.4.1), six of which are 
specific to the PTMs listed in Table 4. 
The vast majority of PTM types are associated with the MOD RES feature key.  
Example PTM annotations taken from the feature tables of Swiss-Prot entries 
are shown in Table 7. 
 Feature key Start Stop  Feature description 
FT MOD_RES 247 247 Phosphothreonine; by PKB (By similarity) 
FT MOD_RES 2 2 N-acetylserine (By similarity) 
FT  MOD_RES 52 52 N6-acetyllysine (By similarity) 
FT MOD_RES 1 1 N-acetylmethionine 
Table 7: Swiss-Prot PTM feature table example entries. 
A PTM feature table entry always includes a feature key, start residue, end 
residue, and a feature description.  As previously described (Section 2.4.1) for 
the majority of PTM types the start and end residue will be the same, the 
exceptions are those PTM types that involve multiple residues e.g. cross-links.  
A feature description always includes a PTM type and an evidence qualifier.  
The evidence qualifier may be followed by variant and/or splice variant 
identifiers, and finally identifiers to indicate enzymes that are responsible.  
Variant or splice-variant identifiers are used to indicate that the PTM being 
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described has an observed sequence that differs from the main sequence listed 
for the entry. 
Swiss-Prot uses four distinct evidence tags for PTM annotations that reflect the 
degree to which experimental evidence supports an annotation.  The tag with 
the highest confidence associated with it is Experimental. However note that 
this qualifier is never actually used, instead the absence of the other three 
implies that the evidence qualifier is experimental.  An annotation must be both 
published and confirmed by experimental means to receive such an annotation. 
Where the experimental evidence supporting the PTM is inconclusive the tag: 
Probable is used instead. 
During the curation process of a Swiss-Prot entry, a PTM annotation may be 
cross-annotated to it from another entry.  The entry must be of a homologue 
from a sufficiently related species; note that this rule is not qualified any further 
in the UniProtKB manual.  There must also be evidence that suggests that the 
protein will be present at the right cellular location to receive the PTM.  PTM 
cross-annotations receive the tag By similarity.  
PTM annotations that are derived from the prediction tool chain used in Swiss-
Prot are given the tag Potential.  Unfortunately neither the prediction program 
nor p-value (or equivalent) is published beside such annotations.  
Section 2.5.2  PTMDB annotation schema 
The PTMDB annotation storage schema which is shown in Figure 14 has been 
designed to incorporate all of the information that can be stored in a Swiss-Prot 
PTM feature table annotation.  The central table <annotationUniProtKB> has 
been designed to store the following attributes of a PTM annotation: UniProtKB 
accession, start position, stop position, amino acid specific PTM type, evidence 
qualifier and source database.  The business key of <annotationUniProtKB> 
may appear slightly strange in that all fields of this table, except for the 
surrogate primary key, are included; this business key allows for the duplication 
of a PTM annotation where all fields are equal except for the <DbId> and/or 
<MethodId>.  This is used by the PTMDB import software to fully replicate a set 
of PTM annotations that are in the original import source, regardless of what is 
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already in the database.  This allows for import sources to be compared with 
simple SQL statements.  It should be noted that there are other obvious 
mechanisms that could be used to remove the requirement to duplicate data; 
such as creating a one-to-many relationship between <annotationUniProtKB> 
and additional mapping tables, i.e. <annotationToDatabase>. 
The tables <variantAnnotations> and <isoformAnnotations>  enable the 
PTMDB to store PTMs that do not apply to the protein primary sequence found 
in UniProtKB entries.  The tables <variants> and <isoforms> are designed to 
store identifiers that can be looked up in the corresponding UniProtKB entry 
feature table, which will contain descriptions for how to transform the protein 
primary sequence into the variant or splice variant for the corresponding 
identifier. 
The tables <enzyme> and <enzymeAnnotation> have also been created so 
PTM annotations can be associated with enzymes that are known to catalyse 
the corresponding PTM type at the corresponding residue. 
The Perl class <org.drd20.bioinformatics.database.ptmdb.PtmDbErd> can be 
used to add PTMs to the PTMDB. 
Section 2.5.2(a)  Sequence space 
To maintain consistency between different PTM annotations a single primary 
protein sequence is considered authoritative in the PTMDB.  An imported PTM 
annotation must therefore be overlaid onto a protein sequence in the PTMDB.  
As most annotation databases can be mapped into UniProtKB this has been 
used to source such authoritative sequences.  Upon update of the PTMDB, the 
latest version of UniProtKB is incorporated in the PTMDB as a series of tables 
in the namespace <UniProtKB>. 
In UniProtKB there are two important attributes of a sequence, both of which the 
PTMDB supports, allowing for the verification of protein sequences. 
1. Sequence version number – every time a sequence is changed in a UniProtKB entry by a 
UniProtKB curator, this number is incremented by one (Bairoch 2009). 
2. Given protein primary sequence. 
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When importing an annotation into the PTMDB, at the very least, one of these 
two attributes should match.  Note that, in addition to entries having a different 
sequence or version number, some may be completely missing.  Missing 
entries may occur through the deletion, addition or merging of UniProtKB 
entries; exactly how this manifests itself depends on whether the PTMDB or the 
external database are using a newer version of UniProtKB.   
Figure 15 shows the simple routine that the PTMDB uses to validate protein 
sequences from external databases. 
Section 2.5.2(b)  Taxonomy support 
Taxonomic trees have been included in the PTMDB to aid in the analysis of 
PTMs at different taxonomic levels.  The NCBI Entrez Taxonomy (NET) project 
distributes taxonomic trees for use by the scientific community (Sayers et al. 
2009; Benson et al. 2009).  These trees include the names of all organisms that 
have a protein or nucleotide in the genetic databases.  Each UniProtKB entry is 
associated with a taxonomic identifier from the NET (Bairoch 2009).  The NET 
taxonomic tree has been incorporated into the PTMDB using the tables shown 
in Figure 13. 
 
Figure 13: NCBI Entrez taxonomy tables in the PTMDB.  These tables are stored in the <ncbiEntrezTaxonomy> 
namespace in the PTMDB. Note that the table tax isn’t actually present in the PTMDB; it’s included in this diagram 
so that relationship cardinality can be shown for the other two tables.  These tables haven’t yet been migrated from 
the MyISAM portion of the PTMDB schema to the InnoDB; therefore these foreign key constraints don’t actually exist 
in the database. 
The table <names> associates NET identifiers with all their synonyms; these 
synonyms are categorised by a class, stored in the field <name_class>.  The 
scientific name associated with a given NET identifier is categorised with the 
class “Scientific name”.  The table <relationships> stores the flattened 
taxonomic tree which can be used to identify all NET identifiers directly or 
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indirectly descended from another; for example to identify all mammalian 
species a search could be performed on this table by settings the field 
<tax_idTaxa> to the NET identifier corresponding to the NET node Mammalia. 
This taxonomic tree can be imported into the PTMDB using the scripts 
<ptmDB/ncbiEntrezTaxonomy/namesToMySQL.pl> and <ptmDB/ncbiEntrez 
Taxonomy/createRelationshipTable.pl>.  The latest version of this tree was 
imported into the PTMDB using the above scripts.  This version contained 
213,942 species in the super-kingdom Eukaryota, 103,800 for Bacteria and 
3,432 for Archaea.  In the taxonomic trees there were 620,000 taxonomic 
nodes.   
No PTM annotation may be included in the PTMDB unless it has an associated 
taxonomic identifier that can be found in the NET. 
 
 
 
Figure 14: PTMDB annotation storage schema. 
 
 
 
Figure 15: PTMDB protein primary sequence validation routine.
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Section 2.5.3  UniProtKB import into the PTMDB 
Software has been written that is able to import PTM annotations from the 
Swiss-Prot database into the PTMDB, using the schema and software library 
previously described.  Additional information, which is not directly related to 
PTM annotations, can also be imported by this software to support other work 
presented in this thesis.  Table 8 contains a list of the additional information that 
is imported into the PTMDB from the UniProtKB. 
Swiss-Prot field ID  Description 
AC UniProtKB Accession 
ID UniProtKB Identifier 
SQ Protein Sequence 
DT Sequence revision number 
OS Taxon Name 
GN Gene Name 
OG Organelle 
KW Keywords 
DR Cross references to other databases 
Table 8: Non-PTM annotation related UniProtKB fields imported into the PTMDB. 
A Perl script has been designed that is able to parse UniProtKB flat files, 
extracting and uploading both the PTM annotations and generic UniProtKB 
fields shown in Table 8.  This script makes use of the SwissKnife Perl API 
(Fleischmann et al. 2007) to parse UniProtKB entries and the Perl library 
<org.drd20.bioinformatics.database.ptmdb.PtmDbErd> to upload PTM 
annotations into the PTMDB.  The upload script can be found here: 
<ptmDB/Main/UniprotUpload/uniprotToDatabaseErd.pl>.  Note that UniProtKB 
is available for download as two flat files - one for Swiss-Prot and another for 
TrEMBL from the following URL <http://www.uniprot.org/downloads>. 
Section 2.5.3(a)  General statistics 
Version 13.3 of the UniProtKB has been imported into the PTMDB to support 
the work presented in this thesis, this version consists of versions 55.3 and 38.3 
of Swiss-Prot and TrEMBL respectively.  
Swiss-Prot version 55.3 contains 366,226 entries.  Table 9 shows that 15% of 
these entries have at least one PTM annotation.  282,200 residues are 
annotated with PTMs.  The five most abundant PTM classes, ranked by number 
of proteins, are: Phosphorylation, N-linked Glycosylation, Lipidation, Acetylation 
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and Palmitation.  Phosphorylation and Glycosylation account for 80% of the 
PTMs in Swiss-Prot, with 36.9% and 43.31%, respectively. 
The distribution of PTM annotations by evidence qualifier, for the most 
abundant modifications is shown in Table 10 and Table 11.  Table 10 shows the 
distribution based on the number of modified residues and Table 11 by the 
number of modified proteins.  The values in Table 10 and Table 11 appear very 
similar; this occurs because most proteins only have one modification 
annotation for a given PTM class.  The same results are shown graphically in 
Figure 16 and Figure 17.  The majority of annotations either have the potential 
(predicted) or By similarity (cross-annotated) evidence types.  The two most 
abundant PTMs, Phosphorylation and Glycosylation, show remarkably different 
evidence qualifier profiles.  41% of phosphorylation sites are backed up by 
experimental evidence; with the vast majority of remaining sites 56%, having 
been cross-annotated.  In contrast, almost all glycosylation sites (94%) have 
been predicted using computational tools.  The five PTM classes having the 
highest percentage of sites with experimental evidence are: Amidation (65%), 
Hydroxylation (57%), Pyrrolidone carboxylic acid (50%), Phosphorylation (41%) 
and O-linked glycosylation (33%).  Note however that the number of actual 
annotations for some of these is quite low.  For example there are only 995 O-
linked glycosylation sites in contrast to 27,042 phosphorylation sites.   It must 
also be pointed out that the Swiss-Prot curators do not transfer predicted 
annotations between protein entries (Farriol-Mathis et al. 2004); if they did the 
fraction of N-linked glycosylation annotations would most likely increase. 
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PTM Class Proteins Positions 
 Observed Percentage Observed Percentage 
  PTMDB SP   
Swiss-Prot 56074  15.31 186408  
Phosphoprotein 23679 42.23 6.47 70360 36.99 
Glycosylation 21844 38.96 5.96 85483 44.94 
Glycosylation_N_Linked 21354 38.08 5.83 82381 43.31 
Lipoprotein 5884 10.49 1.61 9132 4.80 
Acetylation 5385 9.6 1.47 8319 4.37 
Palmitate 3240 5.78 0.88 4411 2.32 
Other 2409 4.3 0.66 2547 1.34 
Methylation 2140 3.82 0.58 4559 2.40 
Amidation 1966 3.51 0.54 2659 1.40 
Pyrrolidone carboxylic acid 1120 2 0.31 1234 0.65 
Myristate 1097 1.96 0.3 1099 0.58 
Prenylation 931 1.66 0.25 1248 0.66 
Glycosylation_O_Linked 866 1.54 0.24 2990 1.57 
Pyruvate 759 1.35 0.21 759 0.40 
Glycoprotein 757 1.35 0.21 757 0.40 
GPI-anchor 756 1.35 0.21 756 0.40 
Hydroxylation 390 0.7 0.11 2184 1.15 
Sulfation 336 0.6 0.09 860 0.45 
Flavoprotein 205 0.37 0.06 207 0.11 
Peptidoglycan-anchor 197 0.35 0.05 197 0.10 
FAD 139 0.25 0.04 139 0.07 
Formylation 135 0.24 0.04 139 0.07 
Covalent protein-RNA linkage 134 0.24 0.04 142 0.07 
Gamma-carboxyglutamic acid 128 0.23 0.03 736 0.39 
ADP-ribosylation 105 0.19 0.03 205 0.11 
Nucleotide-binding 95 0.17 0.03 95 0.05 
Hypusine 87 0.16 0.02 87 0.05 
Citrullination 68 0.12 0.02 125 0.07 
FMN 66 0.12 0.02 68 0.04 
D-amino acid 58 0.1 0.02 81 0.04 
Nitration 49 0.09 0.01 57 0.03 
Organic radical 46 0.08 0.01 46 0.02 
TPQ 42 0.07 0.01 43 0.02 
Glycosylation_C_Linked 32 0.06 0.01 104 0.05 
Oxidation 32 0.06 0.01 37 0.02 
Bromination 21 0.04 0.01 24 0.01 
S-nitrosylation 17 0.03 0 20 0.01 
Glutathionylation 17 0.03 0 21 0.01 
Covalent protein-DNA linkage 15 0.03 0 15 0.01 
Glycosylation_S_Linked 8 0.01 0 8 0.00 
Iodination 4 0.01 0 17 0.01 
Selenium 4 0.01 0 4 0.00 
Table 9: Distributions of PTM annotations imported from Swiss-Prot grouped by PTM class. Observed proteins: 
number of proteins in Swiss-Prot with at least one PTM annotation of the corresponding PTM class. Percentage 
protein: percentage of proteins in Swiss-Prot with at least one PTM annotation of the corresponding PTM class.  
Observed positions: Number of residues that are modified in Swiss-Prot database with the corresponding PTM class.  
Percentage positions: Percentage of modified sites which are of the corresponding PTM class.  Note that a protein 
may receive Glycosylation PTMs of different linkage types; therefore the totals for the PTM class Glycosylation will 
not necessarily be the sum of the totals for the PTM classes, Glycosylation_[NCOS]_Linked. 
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PTM Class Experimental Probable By similarity Potential 
Amidation 65.1 3.65 22.41 8.84 
Hydroxylation 57.03 4.21 36.88 1.88 
Pyrrolidone carboxylic acid 50.16 4.62 42.54 2.67 
Phosphoprotein 41.19 0.73 56.5 1.58 
Glycosylation_O_Linked 33.28 6.89 30.2 29.63 
Acetylation 26.69 1.68 71.33 0.30 
Sulfation 22.09 3.95 30.7 43.26 
Methylation 19.34 2.15 76.34 2.18 
Other 11.63 0.55 87.31 0.51 
Myristate 10.92 2.18 59.05 27.84 
Prenylation 9.08 1.53 83.28 6.11 
Lipoprotein 6.81 6.26 53.59 33.34 
Palmitate 5.33 8.91 50.12 35.64 
Glycosylation 5.08 0.74 2.2 91.97 
Glycosylation_N_Linked 4 0.5 1.14 94.36 
Glycoprotein 3.83 3.04 15.72 77.41 
Total 16.09 1.18 23.27 59.46 
Table 10: Percentage of PTM sites imported from Swiss-Prot grouped by PTM class and evidence qualifier. 
PTM Class Experimental Probable By similarity Potential 
Amidation 66.22 4.55 24.09 5.15 
Hydroxylation 54.05 2.7 38.82 4.42 
Pyrrolidone carboxylic acid 52.22 4.63 41.19 1.96 
Phosphoprotein 37.96 1 59.14 1.90 
Sulfation 30.24 3.41 38.54 27.80 
Acetylation 29.68 2.38 67.49 0.45 
Glycosylation_O_Linked 25.48 7.82 46.14 20.56 
Methylation 16.54 2.66 76.96 3.85 
Myristate 10.76 2.19 59.16 27.89 
Prenylation 9.88 2.04 80.67 7.41 
Other 9.83 0.41 89.22 0.54 
Glycosylation 7.85 1.57 4.22 86.37 
Glycosylation_N_Linked 7.41 1.27 2.47 88.85 
Lipoprotein 6.65 7.02 45.78 40.56 
Palmitate 4.64 10.38 38.73 46.25 
Glycoprotein 3.83 3.04 15.72 77.41 
Total 19.02 2.21 33 45.77 
Table 11: Percentage of PTM proteins imported from Swiss-Prot grouped by PTM class and evidence qualifier. 
 
 
 
Figure 16: Number of modified residues grouped by PTM class and evidence qualifier 
 
 
 
Figure 17: Number of modified proteins grouped by PTM class and evidence qualifier
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Section 2.5.4  Phospho.ELM 
Phospho.ELM is a database of experimentally determined phosphorylation 
sites, detected by both HTPs and LTPs (High/Low Throughput Protocols).  This 
database is maintained as part of the ELM (Eukaryotic Linear Motif) (Puntervoll 
et al. 2003) project; ELM contains a collection of small protein functional motifs.  
Although the PTMDB imports a vast number of phosphorylation sites from 
UniProtKB it should not be considered the authoritative resource for PTM data.  
Indeed UniProtKB, as previously discussed, only annotates PTMs to proteins 
that are in Swiss-Prot.  In contrast, Phospho.ELM contains annotations on 
proteins in both Swiss-Prot and TrEMBL. 
Phospho.ELM is available for download as a flat file from the following URL: 
<http://phospho.elm.eu.org/dataset.html>.  The Perl class <org.drd20. 
bioinformatics.database.ptmdb.Phospho.ELM> has been created that is able to 
parse Phospho.ELM flat files and upload the extracted PTM annotations into the 
PTMDB using the previously described Perl class 
<org.drd20.bioinformatics.database.ptmdb.PtmDbErd>.  This software is able to 
extract the following information from a Phospho.ELM flat file: UniProtKB 
accession, sequence version number, PTM type (Phospho.ELM uses the 
Swiss-Prot PTM vocabulary), residue number, evidence qualifier and enzymes 
that are responsible.   
Not all Phospho.ELM annotations include the UniProtKB sequence version 
number; however all include the protein primary sequence.  The sequence 
validation procedure shown in Figure 15 is used to verify that Phospho.ELM 
annotations have been made on identical sequences to those stored in the 
PTMDB (from UniProtKB version 13.3).   
Phospho.ELM uses two evidence qualifiers, HTP and LTP, all PTM annotations 
in Phospho.ELM would qualify for the Swiss-Prot evidence qualifier 
Experimental.  However it was decided that it might at some point became 
useful to be able to differentiate between those annotations determined by high 
versus low throughput techniques; therefore two new evidence qualifiers have 
been added to the PTMDB – Phospho.ELM_HTP and Phospho.ELM_LTP.  
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Section 2.5.4(a)  General statistics 
Version 7 of the Phospho.ELM database was parsed and uploaded into the 
PTMDB.  It‟s important to note how many annotations were rejected by the 
PTMDB upload software because of sequence differences or UniProtKB entries 
simply being missing from the PTMDB; summary statistics are shown in Table 
12.  879 Phospho.ELM instances were rejected by this procedure: 422 
sequence mismatches, 426 missing UniProtKB accessions in the PTMDB and 
31 UniProtKB sequence version mismatches.  
 No Phospho.ELM instances 
Sequences do not match 422 
UniProtKB accession missing 426 
Sequence versions do not match 31 
Total 879 
Table 12: Breakdown of the reasons for Phospho.ELM annotation rejection.  Not all Phospho.ELM annotations 
contain the UniProtKB sequence version number; where these are missing the listed protein primary sequence (in the 
Phospho.ELM flat file) are compared with that in the PTMDB (taken from UniProtKB version 13.3). There are two 
possible reasons that UniProtKB accessions annotated in Phospho.ELM may be missing from the PTMDB; a) The 
PTMDB uses a newer version of UniProtKB than Phospho.ELM in which the missing accessions have been removed, 
or b) Phospho.ELM uses a newer version of UniProtKB than the PTMDB, which contains new accessions not found in 
the older version.  
A detailed breakdown of the phosphorylation sites which were imported into the 
PTMDB from Phospho.ELM are show in Table 13.  Separate statistics are 
displayed in Table 13 (a) and Table 13 (b) for proteins from Swiss-Prot and 
TrEMBL respectively.  15,590 instances of phosphorylation sites were imported, 
10,902 of which match instances in the UniProtKB. 2,036 new phosphoproteins 
have also been imported into the PTMDB. 
Section 2.5.5Negative PTM annotations 
In science a negative conclusion or result should be given equal weight to a 
positive one.  It is therefore important that bioinformatics databases record, and 
tools report, such negative experimental results.  A negative PTM annotation 
results from experimental evidence that a predicted PTM cannot be detected 
(Farriol-Mathis et al. 2004).  Farriol-Mathis et al., (2004) emphasize that 
negative PTM events should be plausible; the example quoted is that the 
protein to be modified should be present within the same cellular compartment 
as the necessary PTM enzyme(s).  To date the only database that maintains a 
list of negative PTM annotations is Swiss-Prot; they were originally intended to 
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be used as a negative dataset to train/benchmark PTM prediction tools (Farriol-
Mathis et al. 2004).  
Swiss-Prot records negative PTM annotations in the feature table of an entry 
using the feature key SITE; this key is used for any single amino acid feature 
which doesn't have a dedicated key of its own (Bairoch 2009).  Negative PTM 
annotation lines can be detected by the presence of the word Not in field five of 
a feature table SITE line.   The Perl class <org.drd20.bioinformatics. 
database.NotPtm> has been created that can extract such negative PTM 
annotations from Swiss-Prot flat files.  
Phospho.ELM SwissProt results 
Type New sites New proteins  Matching sites Matching proteins 
Phosphoserine 2606 351 8196 3623 
Phosphothreonine 656 147 1518 1284 
Phosphotyrosine 777 124 1180 875 
Phosphohistidine 1 1 0 0 
Total 4040 510 10894 4407 
(a) 
     
Phospho.ELM TrEMBL results 
Type New sites New proteins   
Phosphoserine 533 259   
Phosphothreonine 82 68   
Phosphotyrosine 41 28   
Total 656 292   
(b) 
Table 13:  Phospho.ELM import statistics.  These tables show the number of phosphorylation sites and 
phosphorylated proteins imported into the PTMDB from version 7 of the Phospho.ELM database.  (a) shows import 
statistics for those proteins which are in the Swiss-Prot section of the UniProtKB; Matching sites and Matching 
proteins shows the intersect between the Swiss-Prot and Phospho.ELM datasets in the PTMDB.  (b) shows import 
statistics for proteins in the TrEMBL database (obviously there’s no intersect counts). 
Section 2.5.5(a)  General statistics 
Negative PTM annotations from version 55.3 of the Swiss-Prot database have 
been uploaded into the PTMDB; using the previously mentioned class.  During 
the development of this class it was noted that not all of the PTM types listed for 
negative annotations conform to the previously described Swiss-Prot PTM 
vocabulary.   Table 14 contains a list of these additional PTM types, along with 
the corresponding PTM type that has been registered with the PTMDB 
vocabulary.  All of these annotations have been given the value Swiss-Prot-Not 
for the database name attribute in the PTMDB; so that these annotations can 
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easily be differentiated from all others.  Some of these negative annotations 
were specific to particular variants; these have been given the value Swiss-Prot-
Not-Var for the database name attribute.  
PTM Listed PTM registered in the SP-PTM-CV 
Glycosylation Glycosylation_Generic 
Hydroxylation Hydroxylation_Generic 
N6-methyalted Methylation_Generic 
Methylated Methylation_Generic 
Acetylated Acetylation_Generic 
Phosphorylated Phosphoprotein_Generic 
N-palmitoylation Palmitate_Generic 
S-palmitoylated Palmitate_Generic 
N-formylated Formylation_Generic 
Sulphated Sulfation_Generic 
Table 14: Additional PTM types created for the Swiss-Prot negative annotations. 
Figure 18 displays the distribution of negative PTM annotations in the Swiss-
Prot database grouped by PTM class.  The current dataset is extremely small 
consisting of 135 experimentally verified negative PTM events.  The largest 
negative datasets are those for Glycosylation (54) and Methylation (24). 
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Figure 18: Distribution of negative PTM sites by PTM class. 
Section 2.6  Glycan structure import using the 
PDB2LINUCS tool 
UniProtKB provides the following information regarding Glycosylation: modified 
residue, linkage type, terminal reducing sugar residue (where known) and mark-
up to indicate if the glycan has additional sugars attached (see Figure 8 for 
further details).  Therefore in the PTMDB none of the glycosylation site 
annotations have associated glycan structures.  It was considered possible that 
glycan structures might vary between orthologues; thus being important to the 
study presented in this thesis. 
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There are currently only two databases that contain both glycan primary 
sequence and associated attachment points: GlycoSuiteDB and the PDB 
(Protein Data Bank).  At the time this work was carried out, GlycoSuiteDB was a 
commercial product, thus precluding the inclusion of data from this database in 
the PTMDB.    The PDB contains some protein structures with covalently bound 
glycans; as such both the identity and connectivity of sugar residues can be 
extracted from such PDB entries.  An overview of two bioinformatic resources, 
GDB::Structures (Nakahara et al. 2008) and PDB2LINUCS (Lutteke, Frank, and 
von der Lieth 2004), which can extract glycan structures from the PDB, is 
shown in Table 15.   
 GDB::Structures PDB2LINUCS 
Verifies glycan structures Yes Yes 
Corrects glycan structures No Yes 
Database of glycan structures Yes Yes 
Accepts PDB formatted files Yes Yes 
Displays glycan structure IUPAC LINUCS 
Displays attachment position No Yes 
Links to other databases KEGG CFG 
Table 15: Comparison of tools that can extract glycan structures from the PDB. 
GDB::Structures doesn‟t indicate which residue the extracted glycan structures 
are attached to; therefore PDB2LINUCS has been chosen to incorporate glycan 
structures into the PTMDB.  Note that this resource is so named because it 
outputs glycan structures in the LINUCS (Linear notation for unique description 
of carbohydrate structures) format (Bohne-Lang et al. 2001); see Figure 19 for 
an example glycan structure in LINUCS format. 
  
(a) 
 
[][ASN]{[(4+1)][a-D-GlcpNAc]{[(4+1)][b-D-GlcpNAc]{[(4+1)][b-D-Manp]{[(3+1)][a-D-Manp]{}[(6+1)][a-D-Manp]{}}}}} 
(b) 
Figure 19: Core N-linked glycan in CFG symbolic nomenclature and LINUCS format.  (a) The GlycoWorkbench tool has 
been used to produce a graphical representation of the LINUCS code shown in (b). 
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Section 2.6.1  Annotation extraction 
The PDB2LINUCS web site (<http://www.glycosciences.de/tools/pdb2linucs/>) 
allows users to browse glycan structures and their attachment sites using a 
mirror of the PDB created in 2003.  Two issues are caused by the 
PDB2LINUCS web site using a relatively old version of the PDB: a) new 
structures deposited since 2003 can‟t be found with this tool, and b) it‟s time 
consuming to map a residue in a PDB structure from an old version of the PDB 
into a much newer version of UniProtKB (for reasons that will become clear 
shortly).  Fortunately the PDB2LINUCS web site allows for glycan structures to 
be searched for in a PDB file that the user uploads.  Note that the 
PDB2LINUCS resource doesn‟t explicitly provide a web service for 
Bioinformatic tools, however one of the original authors of the tool made it clear 
that they didn‟t mind their tool being used automatically by scripts. 
Unless stated otherwise all of the following scripts and classes required to 
import PDB2LINUCS Glycosylation annotations into the PTMDB can be found 
in the directory/namespace <org.drd20.bioinformatics.database.ptmdb.GlycoSci 
ences>.  A number of scripts and classes will be described that carry out the 
process of importing and classifying these Glycosylation annotations; note that 
the single wrapper script <importPDB2LINUCS.pl> has been created which can 
carry out the whole import process. 
The Perl script <batchRetrievalRemediatedFiles.pl> has been designed to 
submit PDB files from a local archive to the PDB2LINUCS web page; extracting 
the LINUCS ID (numeric identifier for the LINUCS code), LINUCS code, PDB 
ID, chain ID, and attached residue number.  The appropriate command to send 
to the PDB2LINUCS web site was reverse engineered by analysing the source 
code of the corresponding user input pages; for reference the URL used by this 
script is <http://www.glycosciences.de/tools/pdb2linucs/pdb2linucs.php> with 
the parameters: notation=”linucs”, usechime=”off” and userfile=”encoded PDB 
file”. 
When this script was originally designed the PDB2LINUCS tool only outputted 
the residue number for amino acid residues with attached glycans; as will be 
shown below the chain ID is required to map residues from the PDB to 
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UniProtKB.  At the time the only available solution to obtain the chain ID was to 
make use of information stored in a log file that PDB2LINUCS automatically 
generates on PDB file upload.  The location of the log file has to be extracted 
from the HTML that the tool initially returns to the script.  This log file contains 
the residue number and chain ID corresponding to the terminal-reducing end 
sugar (i.e. the sugar residue attached to the amino acid residue).  Each 
glycosylation annotation, which is extracted from the raw PDB2LINUCS output, 
therefore consists of the following fields: terminal-reducing end sugar residue 
number and associated chain ID, and the residue number for the amino acid 
residue the corresponding terminal-reducing end sugar is attached to.  LINK 
records in a PDB entry indicate linkages between residues that aren‟t implied by 
the primary sequence; this includes linkages between terminal-reducing end 
sugars and the amino acid residues they are attached to.  The triplet of fields 
previously described can be searched for in the LINK records of the 
corresponding PDB file to identify the missing chain ID.  This issue has since 
been brought to the attention of one of the authors of the PDB2LINUCS tool; the 
latest version of PDB2LINUCS includes chain identifiers for amino acid residues 
with attached glycans (note that the above script has since been adjusted to 
support this new information). 
Section 2.6.2  PTMDB import process 
The script <batchRetrievalRemediatedFiles.pl> produces a list of residues 
(identified by PDB ID, Chain ID and residue number) and the glycan structures 
(in LINUCS format along with a LINUCS ID) that they are attached to.  These 
residues must be mapped onto the protein primary sequences stored in the 
PTMDB for each corresponding UniProtKB entry.  A database called PDBSWS 
has been published which contains a map between residues in the PDB and 
their equivalent residue numbers in the UniProtKB (Martin 2005).  Note that a 
single PDB file may contain multiple chains; these chains may represent 
different protein/polypeptide chains.  It‟s for this reason that it‟s necessary to 
know the chain ID in addition to the residue number (of glycosylated residues in 
a PDB file) to identify the correct UniProtKB entry.  The PDBSWS database is 
available for download as a CSV file from the following URL: 
<http://www.bioinf.org.uk/pdbsws/pdbsws_res.txt>.  A simple SQL script has 
60 
 
been created that incorporates this mapping directly into the PTMDB; 
<createMySQLMapping.sql>.  The output from the script 
<batchRetrievalRemediatedFiles.pl> can be directly fed into the script 
<dumpResultsToDatabaseErd.pl>; this additional script maps the PDB 
glycosylation sites into the UniProtKB (using the PDBSWS) and uploads the 
new annotations into the PTMDB using the <PtmDbErd> class.  The PTM type 
is set to the LINUCS ID returned by the PDB2LINUCS tool; in the vocabulary 
schema this means that the field <vocabulary.PtmDescription> is being used 
to store LINUCS IDs; see Section 2.6.4(c)for further details on how LINUCS 
structures are supported in the PTMDB vocabulary. 
Section 2.6.3  Import into the PTMDB 
A snapshot of the PDB was downloaded and archived on the 23rd May 2008; 
this version contained 50,830 structures compared to 22,448 in the version of 
the PDB used to generate the default PDB2LINUCS dataset (available on their 
web site).  The script <batchRetrievalRemediatedFiles.pl> was used to upload 
all of the 50,830 PDB files to the PDB2LINUCS tool; note that this script 
includes sleep code, so not to overload the PDB2LINUCS web server.  The 
script <dumpResultsToDatabaseErd.pl> was then used to upload the results 
into the PTMDB.   
The original PDB2LINUCS dataset contained 5,647 glycan chains in 1,663 PDB 
entries.  1,457 of the 50,380 entries in the new dataset contained protein-glycan 
covalent linkages.  The PDB2LINUCS tool returned 422 glycosylation sites 
without a LINUCS ID; these structures have been removed from the results 
returned by the tool.  Manual inspection of the structures without a LINUCS ID 
suggested that the tool was unfamiliar with some of the sugars they contained.  
6,371 unique quadruplets (PDB ID, chain ID, residue number, LINUCS ID) were 
returned by the PDB2LINUCS tool.  Mapping these sites into the UniProtKB 
(with the PDBSWS database) revealed that 3,755 of them mapped to the same 
triplet formed of: UniProtKB accession, residue number, and LINUCS ID.  In 
total 1,363 glycosylation sites (unique pairs formed of a UniProtKB accession 
and residue position) have had annotations imported for them from the PDB.  
These sites are distributed amongst 540 UniProtKB accessions.  271 different 
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LINUCS encoded structures were represented in the results returned by the 
PDB2LINUCS software. 
Section 2.6.4  Glycan classification 
A manual inspection of the glycan structures found by the PDB2LINUCS tool 
appeared to reveal that the vast majority were short truncated structures.  In 
order to investigate this further it was decided that it would useful to cluster 
glycan structures in some way.  The first step in this process involved splitting 
the structures into those which were n-linked and those which were o-linked; 
this can be done using the script <generateUniqueGlycanList.pl> 
Section 2.6.4(a)  N-linked 
N-linked glycan structures are usually classified as being of one of the following 
types: high mannose, complex, hybrid, or core (Walsh 2006).    The glycan 
structure database which can be found at the following URL: 
<http://www.glycosciences.de/sweetdb/start.php?action=form_class_nglycan> 
includes class designations for n-linked glycans; these designations have been 
used to manually derive the simple rules used to cluster them.  The first class 
core is formed of the core n-linked penta-saccharide (formed of two GlcNAc and 
three Man residues); see the glycan in Figure 20 labelled core3. 
 
Figure 20: N-linked glycan core types used in the classification of structures from the PDB. 
An example of each of the remaining three classes can be seen in Figure 2.  A 
structure is classed as high mannose if the only residues present in the 
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branches initiated by the two antenna residues of the core penta-saccharide are 
mannose.  A hybrid structure is one that has a mixture of mannose and non-
mannose residues in its branches.  Finally if all residues in the branches are 
non-mannose residue types the structure is considered to be complex.  During 
the maturation process of an n-linked glycan the core penta-saccharide is 
trimmed back and elaborated upon with other sugars (Walsh 2006).  A brief 
check of the structures imported into the PTMDB from the PDB revealed that 
many lacked the core penta-saccharide.  To enable these structures to also be 
assigned a meaningful class the following classification system has been 
implemented.  First the classification system identifiers which one of the four 
core structures shown in Figure 20 are present; core3 is the core penta-
saccharide, the remaining cores 2-0 have one successively less mannose 
residue.  The system then uses the same rules previously outlined to identify 
which residues are present in the branch(s) that extend from the antenna 
terminal mannose residue(s); the traditional glycan class names are preceded 
by the core type found (e.g. n-linked-core3-high mannose).  
This classification scheme can be carried out using the Perl class 
<GlycoSciencesNClassifier>.   
Section 2.6.4(b)  O-linked 
As the number of o-linked glycans identified by the PDB2LINUCS tool was 
relatively low; no attempt has been made to classify them.  For consistency all 
o-linked structures have been associated with the PTM class o-linked (specific 
to LINUCS o-linked PTM types).  These PTM types have also been associated 
with the PTM classes Glycosylation and Glycosylation_O_Linked.  The script 
<GlycanOLinkedTempClassifier.pl> attaches the o-linked PTM class to the o-
linked structures output by the <generateUniqueGlycanList.pl> script. 
Section 2.6.4(c)  Incorporation into the PTMDB vocabulary 
Both the o-linked and n-linked classifiers output their classification results in the 
same format.  The script <insertLinucsIntoVocabulary.pl> is able to read these 
classification results and upload them into the PTMDB vocabulary (using the 
class <VocabErd>).  Figure 21 contains those tables of the PTMDB vocabulary 
that are relevant to the following discussion on how this was achieved.  First 
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note that the field <vocabulary.PtmDescription> has an upper size limit of 200 
characters (this length was chosen based on the field and index size limits 
imposed by the InnoDB storage engine); this isn‟t enough characters to store 
many of the LINUCS patterns returned by the PDB2LINUCS tool.  It was 
therefore decided that the glycan structures would be represented in the 
PTMDB vocabulary by their LINUCS IDs (stored in the 
<vocabulary.PtmDescription> field); these thus become new PTM types in 
the vocabulary.  The LINUCS patterns are connected to their corresponding 
PTM types using the table <vocabularyToGlycanStructure>.  The classes 
created by the n-linked and o-linked classifiers are added to the table 
<keywords> and associated with their corresponding PTM types using the 
table <vocabularyToKeywords>. 
 
Figure 21: Glycan classification support in the PTMDB vocabulary 
Section 2.6.4(d)  Classification summary 
Table 16 summaries the number of PDB and UniProtKB entries and individual 
glycosylation sites by the glycan classifications previously described.  N-linked 
glycans were the most abundant accounting for 86% of those structures 
imported.  Of the 235 n-linked glycan structures 41 were core0, 24 core1, 82 
core2 and 88 core3.  123 (52%) of the structures did not have extensions to the 
core structure that was present.  The largest single class of structures was 
core0 with 41 entries; note that other categories had a similar number of 
structures (e.g. core2 35, core3 High mannose 33).  Of the extended classes 
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High mannose was associated with the most structures (61 structures).  509 
UniProtKB entries were found to be represented in the Glycosylated PDB entry 
set.  466 of these had core0 structures associated with them (not necessarily 
exclusively though).  1,236 residues in the UniProtKB were found to correspond 
to the 5,483 residues glycosylated in the PDB dataset.   79% of the glycosylated 
residues were associated with core0 class structures (again not necessarily 
exclusively). 
  PDB UniProtKB 
 Structures Entries Sites Entries Sites 
n-linked[core0] 41 1260 4480 466 1081 
n-linked[core1] 22 238 463 116 174 
n-linked[core1] Complex 2 19 22 3 4 
n-linked[core2] 35 94 129 51 62 
n-linked[core2] Complex 19 24 25 14 15 
n-linked[core2] High mannose 28 69 82 26 27 
n-linked[core3] 25 82 123 44 51 
n-linked[core3] Complex 29 49 72 19 20 
n-linked[core3] High mannose 33 69 86 32 37 
n-linked[core3] Hybrid 1 1 1 1 1 
o-linked 36 128 688 48 127 
Glycosylation_N_Linked 235 1383 5483 509 1236 
Glycosylation_O_Linked 36 128 688 48 127 
Glycosylation 271 1457 6171 540 1363 
Table 16:  Glycan classification in the PDB2LINUCS dataset imported into the PTMDB.  Note that the counts for n-
linked[core0], n-linked[core1], n-linked[core2], and n-linked[core3] are not inclusive of the extended classes with the 
same core type; i.e. the counts for n-linked[core1] do not include the counts for n-linked[core1] complex.  In addition 
note that the counts for PDB entries, PDB sites, UniProtKB entries and UniProtKB sites for the class Glycosylation will 
not necessarily be equal to the totals for the values for the classes n-linked*, and o-linked.  
36 o-linked structures have been imported which mapped to 48 UniProtKB 
entries and 127 residues. 
The PTMDB of course already contains a large number of Glycosylation sites 
imported from the Swiss-Prot database.  Table 17 displays the intersect 
between the Swiss-Prot glycosylation annotations and those in the 
PDB2LINUCS dataset.  Of the 509 UniProtKB entries in the PDB2LINUCS 
dataset which have n-linked Glycosylation annotations; 386 have corresponding 
entries in the Swiss-Prot database which are also annotated with n-linked 
glycans.  Of the 1,236 n-linked residues in the PDB2LINUCS dataset 936 
correspond to n-linked residues in the Swiss-Prot database 
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    New         Matching 
Type Sites Entries Sites Entries 
n-linked[core0] 45 13 824 358 
n-linked[core1] 5 3 136 87 
n-linked[core1] Complex 0 0 3 2 
n-linked[core2] 2 0 46 38 
n-linked[core2] Complex 0 0 12 11 
n-linked[core2] High mannose 0 0 22 21 
n-linked[core3] 1 0 45 39 
n-linked[core3] Complex 0 0 15 14 
n-linked[core3] High mannose 2 1 28 26 
n-linked[core3] Hybrid 0 0 1 1 
o-linked 54 28 67 15 
Glycosylation_N_Linked 51 14 936 386 
Glycosylation 105 31 1003 395 
Table 17:  Intersect between the Swiss-Prot and PDB2LINUCS imported Glycosylation annotations.  Note that the 
same rules regarding the inclusivity of the counts in this table as explained in the caption of Table 16 apply. 
Protein chains in a PDB file are not limited to being mapped to Swiss-Prot 
entries; the PDBSWS database also maps chains to residues in the TrEMBL 
database.  As the only source of Glycosylation annotations imported into the 
PTMDB (other than from the PDB) is the Swiss-Prot database; all sites imported 
using the PDB2LINUCS tool which map to residues in TrEMBL entries are new.  
Table 18 displays the number of TrEMBL entries and residues which have had 
Glycosylation annotations imported into the PTMDB from the PDB2LINUCS 
dataset.  255 residues in TrEMBL entries are annotated with Glycosylation sites 
in the PDB2LINUCS dataset imported into the PTMDB; these map to 114 
TrEMBL entries.  
 New 
Type Sites Entries 
n-linked[core0] 212 95 
n-linked[core1] 33 26 
n-linked[core1] Complex 1 1 
n-linked[core2] 14 13 
n-linked[core2] Complex 3 3 
n-linked[core2] High mannose 5 5 
n-linked[core3] 5 5 
n-linked[core3] Complex 5 5 
n-linked[core3] High mannose 7 5 
o-linked 6 5 
Glycosylation_N_Linked 249 109 
Glycosylation 255 114 
Table 18: Breakdown of the Glycosylation annotations for TrEMBL entries in the PDB2LINUCS imported dataset.  
Note that the same rules regarding the inclusivity of the counts in this table as explained in the caption of Table 16 
apply. 
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Chapter 3  
 
Incorporation of homology assignments into 
the PTMDB  
Section 3.1  Summary 
One of the main aims of creating the PTMDB was to create a resource that 
could be used to allow users to ask questions about the conservation of 
modifications between homologous proteins.  Publically available databases 
such as KEGG and InParanoid contain orthologue and paralogue assignments 
between large numbers of species.  Orthologue annotations from both these 
projects were not suitable for inclusion in the PTMDB as the protein sequence 
space analysed did not match that of the PTMDB.  The software used to build 
the InParanoid dataset was obtained from the authors, but failed to produce any 
orthologue assignments.  A new implementation of the InParanoid algorithm 
has therefore been created to populate the PTMDB with orthologue 
assignments – called CoPaO (Clusters of Paralogues and Orthologues).  
CoPaO has been designed to distribute orthologue detection around a 
compute-cluster running the SunGrid engine software. 
This chapter begins with a short overview of protein evolution and the correct 
use of the terms orthologue and paralogue.  Following on from these definitions 
is a brief overview of the three classes of orthologue detection algorithm: tree-
based, graph-based and a hybrid of the previous two.  A comparison of two 
graph-based algorithms, InParanoid and COG, is then presented.  The CoPaO 
algorithm is then described along with the process used to remove redundancy 
from the PTMDB sequence space.    The orthologue assignments detected by 
the CoPaO program between H. sapiens and Mus musculus are then compared 
to those in the original InParanoid dataset.  As an additional validation step the 
gene ontology annotations associated with Orthologues have been compared.  
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Finally a brief discussion is presented on the conservation of the H. sapiens 
proteome in a selection species. 
Section 3.2  Protein evolution 
John Maynard Smith originally defined protein evolution as a walk around 
sequence space that doesn‟t pass through non-functional intermediates (Smith 
1970).  He also postulated that an increase in the number of genes in an 
organism‟s genome may occur by gene duplication (Smith 1970).  Such a gene 
duplication event results in two identical copies of a gene in a genome – a 
condition that is unsustainable without an appropriate selection pressure to 
maintain the copy (He and Zhang 2005). As a result, the two genes naturally 
diverge.  Two theories have been put forward to explain the divergence: 
neofunctionalisation and subfunctionalisation. Neofunctionalisation maintains 
that one gene alone is required to meet the demands of the organism, whereas 
the other is free to acquire mutations, leading to novel functions in the resultant 
protein (He and Zhang 2005). Subfunctionalisation is where the combination of 
the two genes lessens the selective pressure on either one alone, allowing both 
to diverge to a point where both are now required for the original function (He 
and Zhang 2005). 
Two nucleotide sequences that have been produced by a duplication event 
share the same ancestor (Fitch 1970).  Two sequences that share a single 
common ancestral form are referred to as being homologous (Fitch 1970).  
Such sequences are referred to as having undergone divergent evolution (Fitch 
1970).  Sequences that don‟t share a single common ancestor, but are 
nevertheless similar, are referred to as having undergone convergent evolution 
– such sequences are said to be analogous (Fitch 1970). 
Section 3.2.1  Defining Homology 
Homologous relationships between genes can be subdivided based on when 
the gene duplication occurred relative to the LCA (Last Common Ancestor) 
(Fitch 2000).   Genes that originate from a single ancestral gene in the LCA are 
referred to as orthologues (Koonin 2005).  Those related by gene duplication 
rather than speciation are referred to as paralogues (Koonin 2005).  Paralogues 
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can be further categorised as in-paralogues, when the duplication occurred after 
speciation, and out-paralogues, when it occurred before (Koonin 2005). 
An example is shown in Figure 22 of a single gene that undergoes duplication 
and subsequent speciation.  In the first species gene “X” has been duplicated to 
produce X1 and X2 – these are in-paralogues.  A subsequent speciation event 
produces two species “A” and “B”, which have copies of each of these genes.  
The relationship between the genes Ax1, Bx2 and Ax2 is out-paralogous – as their 
ancestry can be traced back to the original gene duplication event in species 
“X”.  The inverse is also true – the genes Ax2, Bx1 and Ax1 are also out-
paralogous to each other.  Finally the ancestry of Ax1 and Bx1 can be traced 
back to the single ancestor protein X1 (likewise Bx2 and Ax2 to X2). These are 
therefore orthologues. 
 
 
Figure 22: Simple model of a gene undergoing duplication and subsequent speciation.  Gene X has been duplicated 
to produce X1 and X2 these two genes are in-paralogous to each other.  A subsequent speciation event produces two 
species “A” and “B”, which both have copies of the X1 and X2.  AX1 and Bx1 are orthologous to each other, as are Bx2 
and Ax2.  Ax1, Bx2 and Ax2 are out-paralogues, as are Ax2, Bx1 and Ax1 
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Section 3.2.2  Horizontal Gene Transfer (HGT) 
So far homologous genes have been referred to as being either orthologous or 
paralogous.  It has been reported that a large number of bacterial genes appear 
to have been transferred between species (Daubin, Moran, and Ochman 2003).  
These genes can neither be referred to as orthologues nor paralogues.  They 
are instead referred to as xenologues (Koonin 2005).  It has recently been 
suggested that a bacterial species is defined as a collection of organisms that 
can frequently exchange genetic material by HGT (Daubin, Moran, and Ochman 
2003). 
Section 3.2.3  Mixed ancestry 
A number of processes have been proposed that allow for gene duplication to 
occur, including unequal cross-over, non-homologous driven repair and retro 
transposition (Hurles 2004).  Most of these processes have a degree to which 
they randomly pick start and end positions of a duplication.  Therefore the 
likelihood of creating non-functional (at best) and lethal (at worst) new 
sequences is highly likely (Hurles 2004).   
During evolution some genes may acquire new domains from other genes by 
duplication.  Note that it is in this situation that one may refer to one gene as 
being a percentage homologous to another.  Walter Fitch has been at pains to 
point out that homology only refers to a common ancestry and not to the degree 
of similarity between two sequences (Fitch 2000).  Therefore if 40% of a gene 
resulted from the duplication of part of another gene – these two genes can be 
referred to as being 40% homologous (Fitch 2000). 
Section 3.2.4  Detection algorithms 
Orthologue detection techniques can be classified as being: tree-based, graph-
based or hybrid (Kuzniar et al. 2008) – see Table 19 for some examples of each 
of these. 
Tree based methods start by constructing a multiple sequence alignment of 
homologous sequences.  A phylogenetic tree is then constructed from this 
multiple sequence alignment. This “gene tree” is then reconciled with the 
“species tree”, which may have a different topology.  The differences between 
70 
 
these two trees can be accounted for by gene loss, gene gain (by HGT) and 
gene duplication.  This method is susceptible to errors in any of the following: 
gene tree, species tree and multiple sequence alignment.  There is not always a 
“species tree” available, and although methods have been created that do not 
require one, such methods are considered difficult to automate.  (Kuzniar et al. 
2008) 
Graph-based methods start by defining “an operational definition of orthology” 
(Kuzniar et al. 2008).  Most graph-based techniques assume that two 
orthologous sequences should be more similar to each other than to any other 
sequence in either the other genome or their own (Kuzniar et al. 2008).  This is 
normally expressed in terms of detecting reciprocal BLAST best hit pairs 
(Kuzniar et al. 2008).  Graph-based methods therefore detect orthologues by 
performing all-against-all BLASTs of their respective genomes (Kuzniar et al. 
2008).  Not all graph-based methods have the same ability to differentiate 
between orthologous and the two types of paralogous relationship (Kuzniar et 
al. 2008).  Further methods usually differ in their ability correctly to label 
sequences in the presence of gene deletion and horizontal gene transfer 
(Kuzniar et al. 2008).  
Method classification Examples 
Tree based COCO-CL, HOPS 
Graph based COGs, InParanoid 
Hybrid Ensembl compara, PHOGs 
Table 19: Example orthologue detection techniques classified as: tree-based, graph-based and hybrid (adapted from 
(Kuzniar et al. 2008). 
Graph-based methods are generally considered to be computationally less 
intensive than tree-based methods as they do not require the construction of 
phylogenetic trees (Remm, Storm, and Sonnhammer 2001).  For this reason it 
was decided that the PTMDB would incorporate annotations from a graph-
based method.  A brief overview of two graph-based methods and one hybrid is 
now presented. 
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Section 3.2.4(a)  COG (Tatusov, Koonin, and Lipman 1997)   
The orthologue detection algorithm created by Tatusov, et al. for the COG 
(Clusters of Orthologous Groups of proteins) database is described in this 
section (Tatusov, Koonin, and Lipman 1997; Tatusov et al. 2000).  Orthologues 
are detected using a graph-based technique, which clusters proteins together 
based on Blast Best Hits (BBHs).  The authors of COG decided that it was best 
only to cluster proteins together based on BBHs formed between 
phylogenetically distant species.  The first step in generating the COG database 
was to perform an all-against-all sequence comparison using BLAST.    
Paralogues are detected first as those proteins whose highest similarity score 
was obtained from a protein which was part of the same genome.   Symmetrical 
and asymmetrical BBHs form edges between the compared proteins.  Triangles 
of proteins are formed when three proteins from phylogenetically distant taxa 
are all connected by BBHs. Triangles that have a common edge are merged 
recursively  
The first version of COG required the comparison of 17,967 prokaryote proteins.   
COG was last updated in 2003 when a Eukaryote companion database KOG 
was published (Tatusov et al. 2003). 
Section 3.2.4(b)  Inparanoid (Remm, Storm, and Sonnhammer 
2001) 
The work of Remm et al. describes the construction of a new algorithm, which 
attempts to address some of the short-comings they had identified with the 
COG database (Remm, Storm, and Sonnhammer 2001).   As previously stated, 
by definition a COG can only exist where orthologues are shared between three 
phylogenetically distant taxa.  They argued that this precludes the 
representation of lineage specific functions in the COG database.  InParanoid 
was also created because COG lacked support for Eukaryotes – although this 
was obviously addressed with the later release of KOG. 
Dessimoz et al. also criticise COG for allowing asymmetrical BBHs to form 
orthologous relationships (Dessimoz et al. 2006).  This has made COG 
susceptible to clustering out-paralogues in a COG (Dessimoz et al. 2006).  
Remm et al. state that a pair-wise comparison between two individual species 
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will provide different orthologous assignments to one carried out between many 
species all at once (Remm, Storm, and Sonnhammer 2001). 
The InParanoid algorithm has been designed to allow users to enquire as to the 
conservation of proteins between two species.  The central aim of this new 
algorithm was to prevent out-paralogues from being clustered into orthologous 
groups. 
The InParanoid algorithm detects symmetrical BBHs from the results of all-
against-all BLAST comparisons, implemented as four separate BLAST runs.  
First the proteome of species A is queried against the proteome of species B 
followed by the reverse.  This process must be repeated in both orientations to 
correctly detect orthologues – consider the following example.  The BBH of 
Protein A1 from species A is protein B2 of species B; however the true 
orthologue of A1 has been lost from species B – which is evident as the BBH of 
protein B2 is protein A2.  Without running the comparison in both orientations the 
algorithm would incorrectly conclude that the orthologue of A1 is B2; if the only 
query performed was species A against the proteome of species B.  Note that 
requiring symmetrical BBHs does not guarantee that correct orthologue 
assignments will be made, as the algorithm is still easily thrown off by the 
multitude of gene deletion events that can occur (both symmetrical and 
asymmetrical, with regards to the event occurring in both or one species).  All-
against-all BLAST comparisons are performed between the same proteomes 
(i.e. proteome A against A and proteome B against B) to identify in-paralogues.  
In-paralogues can be detected from the results of these comparisons as 
proteins that are more similar to a protein from the same species than to one in 
a different species.  The fullset of comparisons that must be performed for the 
InParanoid algorithm are shown below. 
   Query     Hit 
 Proteome A – Proteome A 
 Proteome A – Proteome B 
 Proteome B – Proteome A 
 Proteome B – Proteome B  
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Briefly the InParanoid clustering routine works as follows – see the original 
paper by Remm, et al., for further details. Insignificant BLAST hits are excluded 
using a bit score cut-off of >=50 and an overlap threshold of >=50% of the 
longest sequence (hit or query).   Symmetrical BBHs are idenfied and placed 
into descending bit score order (so that the most similar are processed first), 
these form the initial homologous seed clusters.  In-paralogues are identified 
and added to each seed cluster in-turn; note that this process involves the 
merging, separating, and destruction of seed clusters with a lower bit score.   
The InParanoid algorithm makes the assumption that orthologues are more 
distantly related to each other than they are to their respective in-paralogues.  
This is implemented as only allowing in-paralogues to be clustered if their bit-
score to the iso-orthologue is >= that between the orthologues.  If an inter-
genomic BBH pair contains a protein that has already been clustered as an in-
paralogue, in another cluster, then rules are applied to decide what action to 
take (i.e. seed cluster deletion, merging, etc.).   
InParanoid also generates a confidence value for each in-paralogue, which 
indicates the degree of similarity compared to that shown between the main 
orthologues.  This confidence value is calculated using the equation shown in 
Figure 23.  The most similar proteins in an InParanoid cluster are the main 
orthologues – this equation assigns these a score of 1.  In-paralogues are 
assigned a score that is > 0 and < 1.  
Confidence equation:  
    (                                              )                                            
   (                                              )                                            
 
 
Main orthologue self against self    (                                              ) 
Main orthologue against in-paralogue.    (                                              ) 
Distance between main Orthologues                                            
Figure 23: InParanoid confidence value equation for in-paralogues.  Main orthologues receive a score of 1 and in-
paralogues receive a score that is > 0 and < 1. 
The InParanoid program is available on request and datasets are periodically 
made available on the InParanoid web site.  The InParanoid algorithm has also 
been used to create the OrthoDisease database, which connects genes from 
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model organisms to their H. sapiens orthologues and overlays OMIM (Online 
Mendelian Inheritance in Man) annotations onto these orthologous pairs 
(O‟Brien, Westerlund, and Sonnhammer 2004). 
Section 3.2.4(c)  PHOG (Merkeev, Novichkov, and Mironov 
2006) 
Hybrid methods use phylogenetic trees to guide graph based clustering 
techniques (Kuzniar et al. 2008).  The PHOG (Phylogenetic Orthologous 
Groups) technique is an interesting hybrid method that produces orthologous 
groups at each node of the taxonomy tree (Merkeev, Novichkov, and Mironov 
2006).  Briefly this technique starts with the creation of orthologous clusters, 
using a graph-based approach, between species at the same taxonomic node.  
These clusters are merged into what is termed a supergenome.   
Supergenomes, which are at the same taxonomic node, then undergo the same 
orthologous clustering procedure.  This process is repeated until the root of the 
taxonomic tree has been reached. 
Section 3.2.5  Summary 
None of the existing databases of orthologues are particularly well suited for 
inclusion in the PTMDB because most have either been abandoned or are 
updated very infrequently.   Infrequent updates are a problem because it: a) 
excludes newly sequenced genomes and b) increases the probability of 
sequences being present in one database but missing in the other.  For 
example the COG database hasn‟t received an update since 2003, and the 
InParanoid database was last updated in 2006.  It was therefore decided that 
new orthologue assignments would need to be made specifically for the 
PTMDB.  With limited computational resources it was decided that a graph-
based technique should be used for the detection of orthologues in the PTMDB.  
The advantages of the InParanoid algorithm over that used to create COG have 
already been discussed.   The InParanoid authors‟ implementation of their 
algorithm was obtained, but failed to produce any orthologue assignments.  
Rather than attempt to fix their software it was decided that a new 
implementation of the InParanoid algorithm would be created.  This new 
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implementation has been designed to be able to take advantage of clusters 
running the SunGrid engine software, if available.   
Section 3.3  CoPaO An implementation of the 
InParanoid algorithm 
The new implementation of the InParanoid algorithm was designed to take 
advantage of new multi-core systems and the HPC that was available.  It is 
important to take advantage of such systems as even for a small number of 
species the number of comparisons that need to be performed can become 
quite large – consider the following.  If n is the number of species to compare 
(all-against-all) then there are (n2-n)/2 comparisons that must be performed and 
(n2-n)+n BLAST runs.  Note that to-date the InParanoid algorithm has only been 
implemented and extended by one other group.  Kim and colleagues created a 
new InParanoid based algorithm to create “COG” like clusters (Kim, Jung, and 
Ryu 2006). 
This new implementation of the InParanoid algorithm has been called CoPaO 
(Clusters of Paralogues and Orthologues).  Note that all programs are listed 
relative to the package <org.drd20.bioinformatics>.   The CoPaO software suite 
is composed of the following three core programs: i) a program to distribute 
CoPaO jobs across an HPC running the Sun Grid engine software 
<database.copao.CoPaORun>, ii) a program to detect orthologues and 
paralogues <alignment.copao.CoPaO>, and iii) software to upload the results 
into an RDBMS <database.copao.CoPaODatabase>.  The second program that 
actually detects orthologues and paralogues can be run standalone – where it is 
responsible for carrying out the all-by-all BLAST comparisons required by the 
InParanoid algorithm.  This program can only be run on pairs of proteomes.  
Alternatively the CoPaO HPC software can be used, which accepts a list of 
species pairs whose proteomes are to be compared.  This software distributes 
the all-against-all BLAST jobs across the HPC before farming out the actual 
cluster detection to the HPC.  The script 
<database.copao.runOnSelectSpecies.pl> can be used to automate orthologue 
detection and upload to an RDBMS for a list of species. 
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Given the large number of comparisons being performed it was decided that the 
cluster detection program (run after the four BLAST runs) would be threaded 
(using Perl Interpretor threads).  The following tasks carried out by the cluster 
program have been threaded: i) Running all-against-all BLAST comparisons – 
only activated when running in standalone mode ii) Sorting of results for each 
protein into descending order, iii) detection of reciprocal BBHs.  The discussion 
at the end of this chapter addresses the merit of threading the cluster detection 
program.  Note that CoPaO uses a modified version of the BLAST parsing script 
obtained from the InParanoid authors – which creates a simple table structure 
of the all-against-all BLAST results. 
The InParanoid algorithm has been designed with the assumption that in-
paralogues will not diverge from each other at a rate faster than the main 
orthologues (Remm, Storm, and Sonnhammer 2001).  When this assumption is 
violated in-paralogues will be detected as out-paralogues and thus will not be 
clustered.  This assumption is obviously used to prevent real out-paralogues 
from being detected as in-paralogues (Remm, Storm, and Sonnhammer 2001). 
The theories of neofunctionalization and sub-functionalization have already 
been discussed.  Both methods of in-paralogue divergence may result in two in-
paralogues appearing to be more distantly related than a recent gene 
duplication might suggest.  A neofunctionalized in-paralogue is by definition 
much more likely to have a greater distance to the main orthologue than there is 
between the two main orthologues. 
CoPaO has been designed to attempt to capture such in-paralogues that are 
further away from the main orthologue than the main orthologues are to each 
other.  They are detected using the following algorithm, which is run after 
orthologue and in-paralogue detection.  For each protein that hasn‟t been 
clustered, its intra-genomic BBHs are placed into descending bit score order.  If 
the protein it is most similar to has been clustered it is placed into the same 
cluster.  This process is repeated until no more proteins are added to a cluster.  
Note that the same BLAST score thresholds are applied to these BBHs as are 
applied to those used in the previous orthologue/in-paralogue detection routine. 
Finally the third program is used to import the CoPaO results into a RDMS. 
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Section 3.3.1 Confidence value complications 
During the first round of in-paralogue detection proteins are only placed into a 
cluster if they are as close as or closer to the orthologue from the same species 
than the two orthologues are (one from each species) to each other.  Therefore 
if two orthologues share 100% SI during the first round of paralogue clustering 
only identical proteins can be clustered with such proteins.  The confidence 
value equation shown in Figure 23 can‟t be used when two orthologues are 
identical – because the denominator becomes zero.  Note that this occurs 
because the self-BLAST score of either orthologue will equal the BLAST score 
between them.  Under this situation the confidence value is simply set to 1. 
The additional paralogue clustering step incorporates proteins that are, by 
definition, further away from the main orthologue of the same species than the 
two orthologues are to each other.  Confidence values for these paralogues are 
always negative.  In the rare circumstance that paralogues clustered at this step 
are placed into a cluster with orthologues that are identical to each other, it is 
unclear how a confidence value can be assigned.  The current version of 
CoPaO uses the following equation under such circumstances. 
   (                                              )                                            
                                          
 
Figure 24: Confidence value equation used for paralogues which are further away from the main orthologue than 
the orthologues are from each other – when the orthologues are identical. 
Section 3.4  Orthologue detection in the PTMDB 
In this section a brief description is given of the process used to select species 
that were to be compared using the CoPaO software.  In addition the 
complication of protein sequence redundancy in the PTMDB is discussed, 
which complicates the creation of proteome sets for use by the CoPaO 
software.  The method used to remove redundancy from proteome sets is then 
described along with a brief overview of the estimated completeness of the 
generated proteome sets. 
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Section 3.4.1  Species selection 
CoPaO uses the graph-based InParanoid algorithm for orthologue/in-paralogue 
detection.  In general graph-based methods are considered faster and easier to 
automate than tree-based ones (Remm, Storm, and Sonnhammer 2001).  That 
being said the all-against-all BLAST step of the InParanoid algorithm is still 
quite computationally intensive.  The CoPaO software was to be run on a small 
shared HPC composed of 8 nodes with 16 cores.  It was therefore decided that 
it would only be possible to run the CoPaO software on a limited number of 
species.  As an example of how long it takes to run the CoPaO software on a 
typical higher Eukaryote, a test was performed running CoPaO in standalone 
mode on an Amazon EC2 (Elastic Compute Cloud) instance 
(http://aws.amazon.com/ec2). The instance had 7GB of RAM and 8 virtual cores 
– it took just under 5 hrs to compare the H. sapiens and M. musculus proteome 
sets.   
Species from each of the three superkingdoms were ordered separately 
according to the percentage of their proteome that had modification 
annotations.  The top 10 ten species from each superkingdom were then 
selected from the ordered list.  This produced a list of 30 species and 420 
comparisons – in comparison version 6.1 of the InParanoid database contained 
35 species and 595 comparisons.  In addition it was decided that the following 
recently sequenced species, which were not selected with the above routine, 
would be compared with H. sapiens: Tetraodon nigroviridis; Nematostella 
vectensis, and A. thaliana.  Table 20 shows the full list of species that were 
selected. 
Eukaryotes Bacteria Archaea 
Mus musculus Pseudomonas aeruginosa Sulfolobus acidocaldarius 
Tetraodon nigroviridis Escherichia coli K12 Sulfolobus solfataricus 
Bos Taurus Salmonella typhimurium Halobacterium salinarum 
Rattus norvegicus Escherichia coli O157:H7 Pyrococcus furiosus 
Nematostella vectensis Escherichia coli O6 Pyrococcus horikoshii 
Drosophila melanogaster Shigella flexneri Methanothermobacter 
thermautotrophicus str. Delta H 
Gallus gallus Mycobacterium tuberculosis Methanocaldococcus jannaschii 
Caenorhabditis elegans Mycobacterium bovis Mycoplasma pneumonia 
Pongo pygmaeus Bacillus subtilis Haloferax volcanii 
Arabidopsis thaliana   
Schizosaccharomyces pombe   
Saccharomyces cerevisiae   
Homo sapiens   
Table 20: Species selected for orthologue detection using the CoPaO program. 
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Section 3.4.2  Redundancy in the UniProtKB 
The PTMDB contains 72,420 UniProtKB entries for H. sapiens which far 
exceeds the latest estimates regarding the number of protein coding genes of 
20,500 (Clamp et al. 2007).  53,127 of the H. sapiens entries are present in the 
automatically annotated part of the UniProtKB – TrEMBL.  Clamp et al. 
discovered that a great deal of the predicted H. sapiens protein coding genes 
are not evolutionary conserved and suggest that many of these annotations are 
therefore incorrect (Clamp et al. 2007).  Note that the TrEMBL database 
contains all coding sequences from the nucleotide sequence databases 
EMBL/GenBank/DDBJ.  It is therefore likely that some of the annotations that 
Clamp et al. identified as being incorrect have been incorporated into the 
TrEMBL database and hence the PTMDB.  Obviously this problem will extend 
to other species in TrEMBL. 
In addition some entries may contain duplicate sequences, which have 
accidently been incorporated into either the Swiss-Prot or TrEMBL databases.  
Although it is stated that Swiss-Prot entries with the same protein sequence are 
meant to be merged into a single Swiss-Prot entry (Boeckmann et al. 2003).  
Note that identical sequences from different genes from the same organism are 
also merged into a single Swiss-Prot entry (UniProtKB 2010).  In addition a 
redundancy removal pipeline is used during the preparation of the TrEMBL 
database to keep redundancy down to a minimum (O‟Donovan et al. 1999).   
Therefore, before orthologues can be detected between the previously selected 
species, redundant and erroneous sequences must first be removed from their 
respective sequence sets in the PTMDB.   
Note that the PTMDB contains 6,074,524 UniProtKB entries - 366,226 Swiss-
Prot and 5,708,298 from TrEMBL.   
Section 3.4.3  Removing redundancy from the PTMDB 
UniProtKB is annotated with what are called „complete proteome sets‟, currently 
for 1,380 species.  In addition the Integr8 (Pruess, Kersey, and Apweiler 2005) 
project provides similar proteome sets, currently for 1,515 species.  At the time 
these sets were being constructed there were discrepancies between the sizes 
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of some of the proteomes and their respective protein encoding-gene counts.  
For example the H. sapiens Integr8 set contained 40,639 UniProtKB accessions 
– far more than the 20,500 protein encoding genes predicted by Clamp et al. 
(Clamp et al. 2007).  Additionally note that some proteins that are present in the 
PTMDB may be missing from Integr8 dataset (and visa-versa); note that this 
point does not apply to the „complete proteome sets‟ as these annotations are 
taken from the same version of UniProtKB that the PTMDB was populated with.  
It was therefore decided that, where available, these proteome sets would 
provide a starting point for further redundancy removal. 
The protocol that is described next, to create proteome sets for the PTMDB, is 
in-part based on that used by the Integr8 project to create their H. sapiens 
proteome set (see Pruess et al., 2005) (see Figure 25 for an overview of this 
protocol).  
Section 3.4.3(a) Step one – Initial selection of proteins 
Step one of this protocol creates an initial set of proteins for each species – 
according to the following two rules: 
I. All Swiss-Prot and TrEMBL entries are extracted for a species that isn‟t 
in either the UniProtKB Complete Proteomes or Integr8 project 
II. Alternatively only those entries that are included in the proteome set are 
extracted.  Note that when a species is present in both projects the 
UniProtKB Complete Proteomes set is taken, as this has been expertly 
curated. 
Section 3.4.3(b) Step two – UniRef  clusters are overlaid 
Step two involves the use of UniRef (Suzek et al. 2007) clusters to identify 
redundant sequences.  The UniRef project provides non-redundant UniProt 
protein reference clusters at the predefined sequence identity thresholds of 100, 
90 and 50 PSI (Percentage Sequence Identity) (Suzek et al. 2007).  The UniRef 
database is seeded with the primary protein sequences listed for each 
UniProtKB entry as well as those splice variant sequences represented in the 
feature table of each entry (Suzek et al. 2007).   
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Figure 25:  Redundancy removal protocol. 
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Proteins present in each proteome were clustered by their corresponding 
UniRef cluster accessions (thereby grouping similar proteins together).  It is 
possible for proteins to be present in multiple clusters by virtue of the differential 
clustering of their corresponding splice-variants; such overlapping clusters are 
automatically merged.  
It was assumed that there would be more duplicate and/or sub-fragment 
sequences present in TrEMBL for Eukaryote species compared with Prokaryote 
ones.  For this reason, protein sets for Eukaryote species were clustered at the 
more restrictive 90 PSI compared with 100 PSI used for Prokaryotes.  
Obviously the use of the 90 PSI threshold for Eukaryote species increases the 
likelihood of excluding sequences that arise from unique genes. 
Section 3.4.3(c) Step three – redundancy removal 
Now that the proteins in each proteome have been clustered, redundant 
sequences are identified as follows, and subsequently removed from the 
corresponding proteome.  All proteins present in the Swiss-Prot section of 
UniProtKB are protected and never deleted.  All TrEMBL entries that have been 
clustered with at least one Swiss-Prot entry are first removed from the proteome 
(because the gene they represent has presumably already been accounted for 
by the Swiss-Prot entry).  Finally the longest TrEMBL entry is kept (and all 
others removed) from clusters which do not contain any entries from the Swiss-
Prot database. 
Section 3.4.3(d)  Species selection 
As will become apparent in the next chapter, proteome sets were required for 
more than just orthologue detection.  Therefore proteome sets have been 
created for all species in the PTMDB that have an Integr8 or UniProtKB 
Complete Proteomes set.  In addition, species present in UniProtKB were 
grouped by super-kingdom and ranked in descending order according to how 
many entries they had – those in the top 10 of each list were also added to the 
list of species for which proteomes should be generated.  This same process 
was carried out for the PTMDB – ranking species by the number of PTM 
annotations they had.  Table 21 provides a breakdown of the number and 
source of species that had been selected for proteome generation.  In total 
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1472 species were selected for proteome generation: 72 Eukaryotes, 54 
Archaea, 582 Bacteria and 763 taxa that do not belong to any of the super-
kingdoms. 
Database Total Eukaryotes Archaea Bacteria Other 
UniProtKB CP 947 42 48 543 314 
Integr8 551 2 5 60 461 
PTMDB 4 1 3  - - 
Swiss-Prot 1 1 - - - 
UniProtKB 9 3 1 5 - 
Sub-Total 1512 72 57 608 775 
Not in UniRef 40 - 2 26 12 
Final-Total 1472 72 55 582 763 
Table 21: Number of species for which proteome sets have been generated subdivided by super-kingdom (note that 
other contains taxa that don’t belong to a super-kingdom – e.g. Viruses).   The number of proteomes imported from 
the UniProtKB Complete Proteomes and Integr8 projects are shown. In addition the number of species selected for 
proteome generation, by being in the top 10 most abundant species (in their corresponding super-kingdom) in the 
PTMDB, Swiss-Prot, and UniProtKB, are shown (note this excludes those already selected by being present in the 
UniProtKB Complete Proteomes or Integr8 project).  The number of species that had to be removed because they 
didn’t have any entries in the UniRef database is also shown. 
Section 3.4.3(e)  Redundancy removal summary 
Table 22 displays the number of proteins present after each stage of the 
proteome construction process.  At the start of the process, for the 1,472 
species - there were 3,236,891 UniProtKB entries.  All UniProtKB entries 
belonging to species which were not present in their corresponding UniProtKB 
Complete Proteome Integr8 proteome set were removed (obviously this doesn‟t 
apply to species that don‟t have an entry in either).  This step removed 3,636 
Swiss-Prot and 340,923 TrEMBL entries – 80% of these were assigned to 
Eukaryote species.  Proteins were next removed that did not have UniRef 
annotations – a requirement for the final step.  This step removed 344,559 
proteins in total – 86% of these were removed from bacterial species.  Only 72 
of these entries were contributed from the Swiss-Prot database.  The final step 
was designed to remove any remaining redundancy that existed in the 
proteomes constructed so far.   This procedure involved the removal of proteins 
contributed from TrEMBL, which clustered with those from Swiss-Prot.  In 
addition, only the longest TrEMBL entry was retained from a cluster of TrEMBL-
only proteins.  90,605 TrEMBL entries were removed.  84,511 of these were 
from Eukaryote species – proteins of which were clustered at 90% SI.  Only 
5,655 proteins were removed at this step for bacterial species.   
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The final set of proteomes contained 2,768,148 proteins; 68% from Bacteria, 
27% from Eukaryotes and the remaining 5% is distributed between Archaea 
and those species that do not belong to any of the superkingdoms. 
UniProtKB ( A )  
 Swiss-Prot TrEMBL Total 
Eukaryotes 92695 1010650 1103345 
Bacteria 191438 1794545 1985983 
Archaea 13601 97960 111561 
Other 3314 32688 36002 
Total 301048 2935843 3236891 
    
Overlay of Integr8 and UniProtKB CP (B)  Reduction 
 Swiss-Prot TrEMBL Total Swiss-Prot TrEMBL Total 
Eukaryotes 90065 736585 826650 2630 274065 276695 
Bacteria 190583 1732452 1923035 855 62093 62948 
Archaea 13589 97390 110979 12 570 582 
Other 3175 28493 31668 139 4195 4334 
Total 297412 2594920 2892332 3636 340923 344559 
        
UniRef constraint overlay( C )  Reduction 
 Swiss-Prot TrEMBL Total Swiss-Prot TrEMBL Total 
Eukaryotes 92695 1010650 1103345 37 4407 4444 
Bacteria 191438 1794545 1985983 26 29051 29077 
Archaea 13601 97960 111561 0 0 0 
Other 3314 32688 36002 9 4 13 
Total 301048 2935843 3236891 72 33462 33534 
   
Final Proteomes ( D )  Reduction 
 Swiss-Prot TrEMBL Total Swiss-Prot TrEMBL Total 
Eukaryotes 90028 647667 737695 0 84511 84511 
Bacteria 190557 1697746 1888303 0 5655 5655 
Archaea 13589 97265 110854 0 125 125 
None 3166 28130 31296 0 359 359 
Total 297340 2470808 2768148 0 90650 90650 
Table 22: Number of proteins removed at each step of the redundancy removal protocol. 
Section 3.4.3(f)  Estimated proteome completeness 
In order to estimate the completeness of the proteome sets just created - 
proteome sizes for selected model organisms have been compared with the 
number of protein-coding genes listed in the Ensembl (Flicek et al. 2010) and 
CMR (Comprehensive Microbial Resource) (Davidsen et al. 2010) databases 
for Eukaryotes and Prokaryotes, respectively. 
Eukaryotes 
Table 23 shows the estimated proteome coverage for selected model 
eukaryotes. The proteome for T. nigroviridis appears at the top of Table 23 as 
its percentage coverage value is the highest.  This proteome contains 75% 
more proteins than there are protein coding genes in Ensembl for this species.  
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For simpler eukaryotes, such as Caenorhabditis elegans, it is therefore almost 
certain that the Ensembl dataset is far from complete.  The H. sapiens 
proteome contains 28,457 proteins – higher than the number of Ensembl 
protein coding genes (23,438).   
Table 23 shows that there is high proteome coverage for the following other 
eukaryotes: Drosophila melanogaster, M. musculus, N. vectensis, 
Saccharomyces cerevisiae, C. elegans, Schizosaccharomyces pombe.  There 
is also greater than 50% coverage for: Danio rerio; Bos taurus, Rattus 
norvegicus.  The two plants in this table: A. thaliana; Oryza sativa Indic aGroup, 
also have high proteome coverage. 
 PTMDB  
  Swiss-
Prot 
Proteome 
size 
Genome sequence statistics 
Species UniProtKB rel. 13.3 Number of 
protein 
coding 
genes 
Source PTMDB 
coverage 
Tetraodon nigroviridis 46 26,234 15,204 Ensembl 172.55% 
Homo sapiens 19,293 28,457 23,438 Ensembl 121.41% 
Drosophila melanogaster 2,784 15,303 14,076 Ensembl 108.72% 
Arabidopsis thaliana 6,582 26,723 25,498 1 104.80% 
Mus musculus 15,447 24,038 22,974 Ensembl 104.63% 
Nematostella vectensis 28 22,007 22,000 2 100.03% 
Saccharomyces 
cerevisiae 
6,555 6,526 6,532 Ensembl 99.91% 
Caenorhabditis elegans 3,178 20,002 20158 Ensembl 99.23% 
Schizosaccharomyces 
pombe 
4,217 4,942 4,985 Ensembl 99.14% 
Oryza sativa Indica 
Group 
423 36,988 46,022-
55,615 
3 80.37% 
Danio rerio 2,078 16,102 24,147 Ensembl 66.68% 
Bos Taurus 5,180 11,483 20,118 Ensembl 57.08% 
Rattus norvegicus 6,979 11,167 21,107 Ensembl 52.91% 
     26,835-
22,000 
4 50.76% 
Table 23: Example estimated proteome coverage in the PTMDB proteome sets. The resources that the number of 
protein coding genes was obtained from 1^(Initiative 2000), 2^(Putnam et al. 2007), 3^(Yu et al. 2002), 4^(Elsik, 
Tellam, Worley, et al., with Sequencing et al., Analysis Consortium 2009). 
Prokaryotes 
Estimated proteome coverage in the PTMDB for selected model Eubacteria and 
Archaea is shown in Table 24.  For most of the selected species, the majority of 
their proteomes appear to be in the TrEMBL database.  The size of almost all of 
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the shown proteomes is very close to the number of protein coding genes listed 
in the CMR database. 
  PTMDB Estimators 
  Swiss
-Prot 
Proteome 
size 
Genome sequence statistics 
Species UniProtKB rel. 
13.3 
Number of 
protein 
 coding genes 
Source PTMDB 
coverag
e 
Eubacteria      
Streptococcus pneumonia 504 2106 2,047 CMR 102.88% 
Streptomyces coelicolor 698 8029 7,897 CMR 101.67% 
Escherichia coli K12 4343 4339 4,289 CMR 101.17% 
Helicobacter pylori 578 1553 1,544 CMR 100.58% 
Bacillus subtilis 2871 4105 4100 CMR 100.12% 
Mycoplasma pneumoniae 687 687 688 CMR 99.85% 
Corynebacterium 
diphtheria 
311 2265 2,320 CMR 97.63% 
Clostridium difficile 630 223 3704 3,804 CMR 97.37% 
Enterococcus faecalis 442 3235 3,337 CMR 96.94% 
Mycobacterium 
tuberculosis 
1439 3943 4,246 CMR 92.86% 
Escherichia coli 616 7943     
Archaea      
Pyrococcus horikoshii 452 2076 2,064 CMR 100.58% 
Sulfolobus tokodaii 343 2816 2,826 CMR 99.65% 
Sulfolobus acidocaldarius 299 2206 2223 CMR 99.24% 
Pyrococcus furiosus 429 2043 2,065 CMR 98.93% 
Methanosarcina mazei 443 3298 3,381 CMR 97.55% 
Haloquadratum walsbyi 
DSM 16790 
153 2637 2,862 CMR 92.14% 
Table 24: Example proteome coverage in the PTMDB for selected model species and species of special interest. 
Section 3.5  Results 
Section 3.5.1  Cluster Validation 
Section 3.5.1(a)  Indirect cluster comparison 
The orthologue assignments created by the InParanoid 6.1 software between H. 
sapiens and M. musculus were downloaded from the InParanoid web site.  In 
addition a FASTA file for each species was also downloaded from the same 
website.  These files identified protein sequences with identifiers from Ensembl 
for H. sapiens and MGI (Mouse Genomics Initiative) for M. musculus.  To 
compare the two assignments, the Ensembl and MGI identifiers needed to be 
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mapped to their corresponding UniProtKB identifiers in the PTMDB.  This was 
accomplished by simply creating one table that contained the checksum of all 
UniProtKB sequences in the PTMDB and another, which contained the 
checksum of those in the two FASTA files obtained from the InParanoid web 
site.  An intersection of these two tables was then obtained – using the 
checksum field.  This method is of course susceptible to minor differences in the 
protein sequences stored in these two different datasets.   Table 25 shows that 
only 65% of H. sapiens and 75% of M. musculus proteins from the InParanoid 
dataset could be mapped into the PTMDB. 
Species Number of proteins 
 InParanoid  PTMDB 
Homo sapiens 22983 15055 
Mus musculus 23132 17498 
Total 46115 32553 
Table 25: The number of Homo sapiens and Mus musculus proteins in the InParanoid 6.1 dataset and the 
corresponding number that could be mapped to UniProtKB entries in the PTMDB. 
The orthologue assignments were then compared between the CoPaO and 
InParanoid datasets.  A new dataset was first created that contained all the 
clusters from the InParanoid dataset, but excluded any proteins that had not 
been mapped to the PTMDB.  Next any cluster that did not contain at least one 
protein from H. sapiens and M. musculus was also thrown away.  Finally the 
percentage of proteins that had been placed into the same cluster of both 
datasets was deduced – according to the following process.  A protein was said 
to be in the same cluster in the CoPaO dataset as in the InParanoid dataset – if 
its CoPaO cluster ID had been assigned to the majority of the other members of 
the same InParanoid cluster (note that the cluster ID was set to -1 for proteins 
not in a CoPaO cluster).  Of the 32,523 proteins from the InParanoid dataset 
that were mapped into the PTMDB – 18,146 were present in the constrained 
InParanoid cluster set.  16,745 of these were determined to be in the same 
cluster in both the InParanoid and CoPaO datasets. 
Section 3.5.1(b)  Gene Ontology Analysis 
Homology refers only to common ancestry and not to the degree of 
conservation between two sequences (Koonin 2005).  Also note that orthology 
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detected between proteins does not imply that they share the same function; 
although they commonly do (Koonin 2005).  Therefore one method of validating 
the correct detection of orthologous proteins is to determine whether the 
orthologues share the same function, noting the caveat above.  Such a 
technique will inevitably be dependent on the quality and completeness of the 
underlying functional annotations.    
The Gene Ontology (GO) is the gold standard of protein function annotation 
(Ashburner et al. 2000). The GO was created to standardise the vocabulary that 
is used to describe the product(s) of a gene.  The Gene Ontology is composed 
of three namespaces: Molecular Function; Cellular Component and Biological 
Process.  The process to which a gene product contributes to is described by 
using the Biological Process ontology, e.g Cell Growth, Translation, DNA 
Replication etc.  The role that a gene product plays in a biological process is 
more precisely described by the Molecular Function ontology, e.g catalyses 
binding, protein binding, GTPase activating protein binding, transporter etc.  
The location of the active gene product within the cell is described using the 
Cellular Component ontology, e.g Nucleus, Mitochondria etc.   
The Gene Ontology allows a single term to be connected to many parents.  This 
structure is referred to as a DAG (Directed Acyclic Graph).  In the Gene 
Ontology there are two different types of edges that can be used to connect 
terms together, these are: is_a and part_of.  An is_a connection defines an 
abstract relationship between the parent and child term.  This relationship 
resembles that from Object Orientated programming where a subclass inherits 
all attributes and methods from its parent class.  A part_of relationship defines 
that when the child term is present it is always part of the parent term.  Both 
types of relationship follow the „true path‟ rule.  This rule states that not only 
should a specific annotation apply to a gene, but also that all parents of this 
annotation should apply to the gene as well. 
The simplest validation procedure would only compare whether proteins in the 
same cluster shared identical functional annotations.  However the possibility of 
subfunctionalization and neofunctionalization having occurred to proteins in a 
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cluster makes it less than desirable to assume that functional annotations 
should be identical.  
A validation procedure is now presented which scores the functional distance 
observed between orthologues and in-paralogues in the same cluster.  This 
procedure uses a metric, which provides a score indicating the semantic 
similarity of two GO terms.  Note that GO semantic similarity measures have 
previously been shown to have good correlation with sequence similarity (Lord 
et al. 2003).   The RSS (Relative Specificity Similarity) semantic metric 
published by Wu et al. 2006 was chosen as it scores GO term pairs according 
to both the distance between the terms and the specificity of each term (Wu et 
al. 2006).   GO terms that represent general abstractions of a gene function are 
found higher up in the DAG (Ashburner et al. 2000).   
The RSS metric assigns a value of one to GO terms that are identical and are 
the most specific in the whole of the DAG.  The most specific terms in the DAG 
are taken as those that are the maximum distance from the root of node of the 
ontology (i.e. the deepest).  The remaining possible GO term pairs are assigned 
a value less than one and greater than or equal to zero.  A pair of GO terms is 
assigned a score of zero if their most recent common ancestor is the root node 
of the DAG.   
Lord et al., 2003 previously demonstrated that the correlation between GO 
semantic similarity measures and sequence similarity was greatest when using 
the molecular function namespace.  The validation routine was therefore setup 
to use this namespace – although initial results produced by this routine were 
similar regardless of which namespace was used (data not shown). 
To utilise the RSS metric in the validation routine, GO annotations were first 
obtained from the GOA (Gene Ontology Annotation) resource (Barrell et al. 
2009).  The gene ontology is available for download in OBO (Open Biomedical 
Ontology) format – a Java parser and object representation was created for 
version 1.2 of the OBO specification (See <http://www.geneontology. 
org/GO.format.obo-1_2.shtml> for the specification).  Next the RSS metric was 
implemented in the same software package as the new parser. 
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It was decided that only species comparisons that involved H. sapiens as one of 
the two species would be validated with the RSS metric. For each cluster an 
average RSS value was first calculated.  An all-by-all comparison was 
performed between proteins in the same cluster which have at least one GO 
term.  As originally published by Wu et al., (2006), when multiple GO term 
annotations are present for either, or both, proteins being compared an all-by-all 
comparison of the GO terms is performed.  The maximum RSS value is taken to 
represent the semantic similarity of the two proteins.  An average is then 
calculated for all RSS values that have been calculated.   Note that this process 
does not take into account the percentage of the Proteins in the clusters that 
actually had GO annotations. 
To provide a context for the intra-cluster average RSS values, inter-cluster 
average RSS values have been calculated.  These were produced by randomly 
selecting 1000 clusters, or the maximum number of clusters present, whichever 
was greater.  Each selected cluster was then compared to all others.  Not all 
clusters have one protein from each species being compared annotated with a 
GO term.  Since such clusters have not been compared; the percentage of 
clusters that could be compared has been recorded and is shown in Table 26. 
The validation procedure shows that proteins in the same CoPaO cluster have 
on average a smaller functional distance than proteins in different clusters.  The 
intra-cluster average value varies from 1 – 0.75 between the H. sapiens 
proteome and those of the listed species.  Whereas the inter-cluster value 
ranges from 0.73-0.45, with a value of 1 associated with two annotations at the 
root of the gene ontology graph. 
The average intra-cluster distance between H. sapiens and the prokaryotes 
listed in Table 26 is slightly smaller than that observed for the eukaryote 
comparisons.  Presumably this has occurred because the only proteins retained 
in both eukaryotes and prokaryotes have essential functions, which are unlikely 
to change over the course of evolution.  
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 Average RSS  
Species Intra-cluster Inter-cluster 
Percentage of 
clusters compared 
Tetraodon nigroviridis 1.00 0.44 33.00% 
Pyrococcus horikoshii 0.99 0.65 100.00% 
Methanocaldococcus 
jannaschii 
0.98 0.63 100.00% 
Salmonella 
typhimurium 
0.97 0.62 100.00% 
Mycobacterium 
tuberculosis 
0.96 0.67 100.00% 
Mycobacterium bovis 0.96 0.65 100.00% 
Shigella flexneri 0.96 0.61 89.00% 
Arabidopsis thaliana 0.96 0.55 89.00% 
Methanothermobacter 
thermautotrophicus 
str. Delta H 
0.95 0.71 89.00% 
Pyrococcus furiosus 0.95 0.52 100.00% 
Saccharomyces 
cerevisiae 
0.95 0.55 89.00% 
Mycoplasma 
pneumoniae 
0.94 0.65 89.00% 
Pseudomonas 
aeruginosa 
0.94 0.70 67.00% 
Escherichia coli K12 0.94 0.69 100.00% 
Sulfolobus solfataricus 0.94 0.69 100.00% 
Escherichia coli 
O157:H7 
0.93 0.61 100.00% 
Schizosaccharomyces 
pombe 
0.93 0.52 78.00% 
Pongo pygmaeus 0.92 0.51 78.00% 
Drosophila 
melanogaster 
0.92 0.46 44.00% 
Bacillus subtilis 0.91 0.67 100.00% 
Halobacterium 
salinarum 
0.91 0.73 100.00% 
Escherichia coli O6 0.90 0.65 100.00% 
Rattus norvegicus 0.89 0.56 89.00% 
Mus musculus 0.87 0.54 67.00% 
Bos Taurus 0.85 0.51 33.00% 
Gallus gallus 0.84 0.50 78.00% 
Sulfolobus 
acidocaldarius 
0.83 0.68 100.00% 
Caenorhabditis 
elegans 
0.82 0.49 89.00% 
Nematostella 
vectensis 
0.75 0.45 78.00% 
Table 26: RSS validation of orthologue clusters detected between Homo sapiens and a select list of other species. 
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The percentage of CoPaO clusters for which a functional distance could be 
calculated was on average higher for H. sapiens/prokaryote comparisons than 
H. sapiens/eukaryote ones.  It is likely that this results from a combination of: a) 
better annotation of prokaryote proteomes, which tend to be smaller, and b) that 
those orthologues detected carry out essential functions, which may be more 
likely to be annotated with a GO term. 
Section 3.5.2  Proteome conservation 
One implicit assumption, which is formed from the definition of homology, is that 
species that diverged from each other more recently should be more 
homologous to each other than those that diverged more distantly.   Table 27 
shows the degree of homology detected between H. sapiens and a collection of 
model organisms – using the CoPaO software.   In this table species have been 
ordered according to the percentage of the H. sapiens proteome which has 
been annotated as an orthologue in each comparison.     
Note that “percentage orthology” can be expressed from the point of view of 
either species being compared.  Given a comparison between two species the 
number of orthology assignments must be equal for both species by definition; 
the same is not true for the proteome size of the two species being compared. 
This statement is only violated when multiple in-paralogues are 100% identical 
and thus are all assigned as iso-orthologues.  Table 27 shows “percentage 
orthology” from the point of view of H. sapiens and the species with which its 
proteome is being compared to. 
This table also shows the percentage of each proteome that has been assigned 
as either an orthologue or in-paralogue.  Species that have an incomplete 
proteome are highlighted. 
This table shows that the most orthologous species to H. sapiens is M. 
musculus.  57% of the H. sapiens proteome is orthologous to the M. musculus 
proteome (which is 68% orthologous to the H. sapiens proteome).  ~5% of the 
H. sapiens proteome has been assigned as an in-paralogue. T. nigroviridis 
follows M. musculus.  34% of the H. sapiens proteome is orthologous to the T. 
nigroviridis proteome (which is 36% orthologous).   These values suggest that 
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H. sapiens and T. nigroviridis have undergone significant proteome evolution 
since they diverged.   
B. taurus, R. norvegicus, Gallus gallus, and Pong pygmaeus all diverged from 
H. sapiens later than T. nigroviridis but appear below it in the table.  These have 
all been highlighted in this table – because their proteomes are currently 
incomplete in the PTMDB.  A higher percentage than for M. musculus of each of 
these species‟ proteomes has been assigned an orthologous relationship. 
These results can probably be attributed to a combination of the following: a) 
essential or genes with disease links are given sequencing/annotation priority, 
and b) genes that share a high percentage identity are annotated first as their 
assignments are relatively unambiguous. 
The next species with complete proteomes in this table are N. vectensis and D. 
melanogaster.  Note that although the H. sapiens proteome appears closer to 
N. vectensis, the percentage of the D. melanogaster proteome that is assigned 
an orthologous relationship is higher.  The C. elegans proteome is 20% 
orthologous to that of H. sapiens.  Of all the Eukaryote species shown in this 
table, the H. sapiens proteome is least orthologous to that of the two yeast 
species shown.  However, the percentage of the yeast species proteomes that 
are orthologous to that of H. sapiens is relatively high.  For example 41% of the 
S. pombe proteome has been assigned an orthologous relationship.  This may 
suggest that approximately half of the yeast proteome is essential in higher 
Eukaryotes such as H. sapiens. 
This table shows that only ~1% of the H. sapiens proteome is assigned as 
being orthologous to proteomes from bacteria.  However ~10% of each 
bacterial proteome has been found to be orthologous to the H. sapiens 
proteome.   Again the most plausible explanation is that the proteins 
represented in the 10% are essential across both super-kingdoms. 
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 Percentage of 
proteome with an 
orthologous partner 
Percentage of 
proteome clustered 
 Homo 
sapiens 
Species X Homo 
sapiens 
Species 
X 
Mus musculus 57.47 68.05 62.48 72.57 
Tetraodon nigroviridis 34.01 36.82 45.97 39.47 
Bos Taurus 33.29 82.73 36.96 84.87 
Rattus norvegicus 31.36 79.79 36.08 83.14 
Nematostella vectensis 19.8 25.38 33.74 31.5 
Drosophila 
melanogaster 
17.16 31.8 31.2 39.85 
Gallus gallus 14.91 76.92 19.25 80.67 
Caenorhabditis elegans 14.18 20.04 28.82 25.33 
Pongo Pygmaeus 12.74 83.46 14.69 84.03 
Arabidopsis thaliana 9.78 10.58 19.33 27.02 
Schizosaccharomyces 
pombe 
7.27 41.3 12.71 45.29 
Saccharomyces 
cerevisiae 
6.44 27.9 13.57 32.72 
Pseudomonas 
aeruginosa 
2 10.16 4.47 13.75 
Escherichia coli K12 1.76 11.27 3.65 14.31 
Salmonella typhimurium 1.73 10.74 3.94 13.46 
Escherichia coli 
O157:H7 
1.71 9.12 3.95 11.61 
Escherichia coli O6 1.71 9.03 3.75 11.58 
Shigella flexneri 1.61 11.09 3.43 13.51 
Mycobacterium 
tuberculosis 
1.55 11.06 3.72 14.58 
Mycobacterium bovis 1.55 11.24 3.66 14.98 
Bacillus subtilis 1.54 10.6 3.94 14.64 
Sulfolobus 
acidocaldarius 
1.34 16.55 3.2 20.44 
Sulfolobus solfataricus 1.31 12.58 2.69 16.44 
Halobacterium salinarum 1.24 14.34 2.82 17.53 
Pyrococcus furiosus 1.2 16.4 2.39 19.97 
Pyrococcus horikoshii 1.14 15.17 2.34 18.11 
Methanothermobacter 
thermautotrophicus str. 
Delta H 
1.08 16.21 2.12 18.78 
Methanocaldococcus 
jannaschii 
0.94 14.65 1.99 16.61 
Mycoplasma pneumonia 0.46 19.07 1.27 21.25 
Haloferax volcanii 0.11 28.57 0.83 32.14 
Table 27: Percentage of the Homo sapiens proteome which has been clustered with a selected group of species. 
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Section 3.6  Discussion 
Orthologue annotations have successfully been added to the PTMDB with a 
new implementation of the InParanoid algorithm.  420 pairs of species were 
analysed – composed of 30 individual species.  Orthologue assignments 
between H. sapiens and M. musculus stored in the InParanoid database 
(version 6.1) have been compared with those produced by the CoPaO software.  
65% of the H. sapiens and 75% M. musculus proteins in the original InParanoid 
dataset were mapped into the PTMDB.  The same sequence was identified in 
each dataset by an MD5 checksum.  This precludes the detection of sequences 
which represent the same gene in each database that have any differences at 
all in their sequence.  The alternatives would have been to either: 1) run an 
exhaustive all-against-all sequence comparison between the two datasets, or 2) 
attempt to use an ID mapping service to between the MGI/Ensembl and the 
UniProtKB.  Regardless the majority of the InParanoid dataset was mapped into 
the PTMDB.  It was discovered that 92% of the orthologue assignments in the 
InParanoid dataset (which could be compared) matched those produced by the 
CoPaO software.  Additionally further validation of the orthologous clusters has 
been provided through the use of the GO semantic similarity measure. 
An error was discovered in the CoPaO implementation of the InParanoid 
algorithm that resulted in a small number of orthologues also being assigned to 
different clusters as in-paralogues.  79,751 paralogues (including both first and 
second pass detection) of these 2,617 were found to be incorrectly annotated; 
they were in fact correctly annotated as orthologues in different clusters.  These 
entries have been removed from the clusters in which they were present.  
After the redundancy-removal step, the H. sapiens proteome size far exceeded 
that of the number of protein coding genes predicted by Clamp et al., (2007).  
Although it was suspected that redundant sequences of some form existed in 
this set, nothing was done to attempt to reduce this protein set any further.  An 
analysis has now been performed on the H. sapiens and M. musculus proteome 
set with an interesting finding.  A checksum was created for all sequences 
present in the PTMDB for both of these species.  Identical checksums were 
then identified.  Surprisingly 3,784 Swiss-Prot and 723 TrEMBL entries were 
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found to have duplicate sequences for H. sapiens.  A similar number was seen 
for M. musculus with 4,068 Swiss-Prot and 40 TrEMBL entries identified.  
Unfortunately Swiss-Prot entries were explicitly excluded from being removable 
during the redundancy removal pipeline.  It is interesting to note that two of the 
duplicate entries A8K5L3 and P05109 have been merged into a single entry in 
Swiss-Prot version 56.7.  In the future when the PTMDB is updated, Swiss-Prot 
entries identified as being identical will have their PTM annotations merged into 
a single entry. 
The program <org.drd20.bioinformatics.alignment.CoPaO> makes use of Perl 
interpreter threads in an attempt to speed up the detection of orthologues and 
paralogues from the BLAST all-by-all comparisons.  The design of this Perl 
program made it difficult to test the merits of threading the cluster detection; 
therefore a Java version of this program has been created 
<org.drd20.bioinformatics.alignment.CoPaO.java>.  On an Intel Core II 
(2.4GHZ) with 4GB RAM the cluster routine completed its detection of 
orthologues between H. sapiens and M. musculus 16% faster when running two 
threads compared to one (a thread count greater than two became 
progressively slower).  Note that the Perl program never actually completed this 
process on the benchmark machine – due to an unidentified bug (which 
appeared to be related to Perl itself), not releasing memory after a thread had 
finished (this behaviour was observed regardless of whether Perl was compiled 
against the system malloc or its own).  The Java program was able to carry out 
all 420 comparisons (minus the BLAST all-by-all comparisons) in ~30mins; 
therefore it appears that there is little to gain by distributing the orthologue 
detection around a compute-cluster (obviously this still depends on the number 
of species being compared.); however it is still very much advisable to distribute 
the BLAST all-by-all comparisons on such a cluster.  With only 30 species and 
few with large proteomes it also appears that there is little to gain by threading 
the orthologue detection; although it should be pointed out that for the Java 
program this was a trivial process.  
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Chapter 4  
 
Cross annotation of PTMs 
Section 4.1  Summary 
To obtain accurate conclusions regarding the conservation of post-translational 
modifications between species, and specifically between orthologues and 
paralogues, requires that the modification dataset used must be as complete as 
possible.  A preliminary analysis suggested that numerous plausible 
modification sites had not yet been annotated.  In addition, many of the 
proteome sets that were created in the last chapter contained a significant 
number of TrEMBL entries for which no annotations existed in the PTMDB.  
Hence the aim of the work presented in this chapter was to develop a method to 
transfer annotated acceptor sites between homologous sites. With particular 
emphasis placed on extending the PTMDB into the sequence space occupied 
by entries in the TrEMBL database. 
This chapter begins with an explanation of why there has been a massive 
explosion in the number of proteins for which their modification states need to 
be identified.   A brief description then follows on the high and low throughput 
experimental techniques that can be used to identify PTMs.  This is followed by 
an overview of the computational techniques that are used to support and 
extend the data that is produced by experimentalists.  Particular emphasis is 
placed on the continued requirement to design tools that can predict PTMs and 
transfer annotations between homologous sites.  A protocol is then described 
that has been used to cross-annotate PTM annotations between proteins in 
Swiss-Prot and TrEMBL.  Finally a summary of the cross-annotations that have 
been made is provided. 
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Section 4.2  Introduction 
Next generation sequencing technologies (Metzker 2010) and the knowledge 
and expertise gained from sequencing the Human genome (Lander et al. 2001; 
Venter et al. 2001) have resulted in an explosion in the number of genome 
sequences that have become available.  The Genomes OnLine Database 
(GOLD) (Liolios et al. 2010), which documents active and on-going genome 
sequencing projects, has seen an explosion in the number of projects 
referenced.  The authors of GOLD noted that in September 2005 there were 
1,575 projects referenced, which had expanded to 5,843 in September of 2009. 
At the same time as the publication of the draft Human genome sequence, the 
HUPO (Human Proteomics Organisation) was announced, with the goal of 
supporting researchers in the exploration of the Human proteome (seen as the 
next target) (Abbott 2001).  A major component of the process of defining and 
analysing a proteome is to discover when (i.e. specific biological context) and 
where (defined at either the protein or residue level) PTMs occur. 
Section 4.2.1  Experimental determination 
An overview of the methods that can be used to identify PTMs can be seen in 
Figure 5.  With so many genomes now sequenced (and many more to follow) 
the sheer number of proteins whose modification patterns (i.e. when and where) 
need to be discovered quickly overwhelms the traditional low-throughput PTM 
discovery techniques (Gupta et al. 2007).    
One such low-throughput technique involves identifying a protein of interest that 
appears to shift position on 1D and 2D SDS PAGE gels – where one gel 
contains proteins extracted from a sample where an inhibitor for a specific 
modification has been added indicating a gain/loss, or rearrangement, of the 
chemical structure of the protein.  Modifications may be prevented by specific 
enzyme inhibitors (Davis et al. 2006), or by the removal of a gene which is 
required for the modification to take place. In addition, modifications can be 
mapped to specific residues using site directed mutagenesis in combination 
with an identification technique such as 2D SDS PAGE (Robinson and Michel 
1995).   This technique is considered low-throughput because of a) the 
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requirement to be able to identify the protein represented by a gel band (i.e. 
requires an antibody that recognises a protein of interest or the use of Edman 
sequencing), and b) if the modified residue needs to be identified – this may 
require repeated site-directed mutagenesis experiments. 
The inability rapidly to identify the proteins that are present in each gel band has 
recently been overcome by the development of advanced analysis pipelines 
that use mass spectrometers for protein identification.  Not only do they allow 
for protein identification but they can also be used to elucidate the position and 
nature of any PTMs that may be present, removing the requirement for site-
directed mutagenesis (Claverol et al. 2003).  Even with the availability of high-
throughput techniques, those that are low-throughput are still routinely used to 
validate results from the aforementioned techniques. 
Section 4.2.2  Computational determination 
Figure 5 shows that a significant number of databases and tools have been 
designed to aid in the identification of PTMs.  These bioinformatics resources 
can be broken down into three groups: i) databases, ii) tools used to aid in the 
interpretation of mass spectrometry results, and iii) those that are used to 
predict PTM sites. Databases that contain both experimentally determined and 
predicted PTM annotations have many uses during the process of proteome 
characterisation.  One example is their use in identifying sites that should be 
mutated for PTM mapping – via annotated homologous sites.  Tools that are 
used to detect PTMs in mass spectrometry results also make use of PTM 
databases.  For example, in the process of annotating mass spectra with glycan 
structures, the GlycoWorkbench tool allows users to browse known structures in 
the CarbBank and CFG (Consortium for Functional Glycomics) databases 
(Ceroni et al. 2008).   
The design of tools to predict PTM sites predates the use of high-throughput 
experimental proteomic techniques.  However such tools present many useful 
attributes leading to their continued development.  Most PTM prediction tools do 
not attempt to deduce the biological context that is required for a PTM to occur.  
This can be seen as both a positive and negative aspect of prediction tools; 
although most cannot tell experimentalists the conditions they require to 
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observe a PTM, they can at least tell them that conditions may exist that will 
trigger the modification of a particular residue.  This is in sharp contrast to 
experimental approaches that can only be used to identify PTMs which are 
actually present in their system under very precise conditions.  Some PTM 
prediction tools attempt to predict some aspects of the biological context that is 
required for a particular modification to occur.  For example the KinasePhos 
(Huang et al. 2005a) tool predicts kinase-specific phosphorylation sites.  Finally 
prediction tools are of course also useful in annotating potential modification 
sites for organisms that are scientifically interesting but unlikely to attract the 
funding required for large-scale proteomic analysis.   
In addition to traditional prediction algorithms (which are briefly discussed 
below) there is also the notion of cross-annotation (Farriol-Mathis et al. 2004).  
Cross-annotation is the process of transferring feature annotations between 
proteins.  Swiss-Prot curators carry out this process when new entries are 
added to the database (Farriol-Mathis et al. 2004).  Of those PTM annotations 
imported into the PTMDB from Swiss-Prot, 23% have the evidence qualifier “By 
similarity” (which indicates a cross-annotation).  Figure 26 shows a brief 
comparison between traditional prediction software and the process of cross-
annotation. 
To predict a protein feature de novo – requires the construction of rules that 
determine when a feature annotation applies and when it does not.  Machine 
learning algorithms are now frequently being used, which are able to ascertain 
the rules that determine the designation of a particular residue as an acceptor 
or non-acceptor of a particular modification type. 
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Figure 26: Comparison of model-based prediction with cross-annotation. 
Section 4.2.2(a)  Examples of prediction programs 
The most widely used machine learning algorithms that have been used to date 
include: Support Vector Machines (SVMs) (EnsemblGly (Caragea et al. 2007), 
Profile Hidden Markov Models (KinasePhos (Huang et al. 2005b) and Neural 
networks (NetPhosK (Blom et al. 2004), (Senger and Karim 2008).  In addition 
both rule based and PSSMs (Position Specific Scoring Matrices) have been 
utilised. 
The Prosite database contains two different types of protein feature model (See 
Sigrist et al. 2010 and Sigrist et al. 2002a). This database includes models for 
predicting many different protein features including: binding motifs, modification 
sites, catalytic sites, etc.  The two model types found in Prosite are termed 
patterns and profiles.  Patterns are akin to regular expressions, which are 
frequently used in text mining; see Figure 27 for an example.  They are 
composed of individual rules, which state what residues can and cannot occur 
at specific positions in a sequence motif.  Patterns are constructed from multiple 
sequence alignments that aid in identifing conserved residues.  Sequences 
either contain a match to a particulary pattern or they don‟t; therefore they are 
qualitative.  The prosite database is tightly coupled with the release of new 
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versions of the Swiss-Prot database.  Swiss-Prot is scanned with the patterns 
present in Prosite to help identify those which occur often. 
[ R K ] - x ( 2 ) - [ D E ] - x ( 3 ) - Y o r [ R K ] - x ( 3 ) - [ D E ] - x ( 2 ) - Y  
Figure 27: Prosite, tyrosine kinase phosphorylation site pattern (PDOC00007).  Pattern format is documentated at 
the following URL <http://expasy.org/prosite/prosuser.html>; the tryosine that is modified in this pattern is 
underlined and presented in a larger font. 
Unlike patterns, that are specific to small highly conserved motifs, profiles are 
designed to match sequences across entire domains (which obviously includes 
regions of differing conservation).  Like patterns they are constructed from an 
initial multiple sequence alignment (guided by 3D structures where these are 
available), which is converted into a profile hidden Markov model.  Briefly these 
models are used to deduce the probability of a particular residue being present 
at a particulary position in the domain; based on both a substitituion matrix and 
the frequency of residues at each position in the original multiple sequence 
alignment.  These individual probabilities are converted into a score for the 
whole aligned region – similar to a BLAST e-value; profiles are therefore 
quantitive. 
ProRule (Sigrist et al. 2005) is a database of rules in UniRule format 
(<http://www.expasy.org/sprot/hamap/unirule_manual_short.html>) that are 
designed to aid in the annotation of genomes.  The rules have been designed to 
overlay information from patterns and other biological resources onto profiles.  
Note that profiles do not include a facility to make the presence of certain 
residues mandatory for a domain to be matched against a query sequence; this 
limitation of profiles is addressed with ProRules.  For example a ProRule can be 
created for a profile that represents a domain with a catalytic activity that makes 
the presence of residues key to this activity (dervived from Prosite patterns and 
additional biological information) mandatory.   
Profiles and ProRules are not directly related to the annotation of PTMs; 
however it is important to understand their use, as PTM sites can be made a 
mandatory requirement of a ProRule. 
The dbPTM prediction tool chain (Lee et al. 2006) combines a number of 
different techniques to create models of PTM sequence motifs, which can be 
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seen as an evolution of the models found in Prosite.  Like Prosite, the first stage 
is the construction of multiple sequence alignments for each motif.  Next the tool 
utilises a technique called MDD (Maximal Dependence Decomposition), which 
clusters individual sequences that share the same dependencies between 
specific motif positions.  Dependent positions can only be calculated when there 
is sufficient data to satisfy the statistical test that is used.  The multiple 
sequence alignments from each MDD/raw cluster are then converted into a 
profile hidden Markov model.  Profile hidden Markov models are more powerful 
than PSSMs as they are able to incorporate a model of how protein sequences 
evolve. 
Section 4.2.2(b)  Positive and negative datasets 
The prediction of a protein feature usually starts with the acquisition of 
experimentally determined annotations for the feature of interest.  When the 
protein feature is the presence of a specific PTM, this so called „positive 
dataset‟ is composed of the known acceptor sites for this modification. 
The Swiss-Prot database is commonly used to source the positive dataset used 
to train a PTM prediction model (Lee et al. 2006).  In addition some databases, 
which are specific to a particular class of PTM, have also been used.  For 
example the dbPTM prediction tool chain also includes annotations from the 
Phospho.ELM ((Diella et al. 2008a) - phosphorylation resource) and O-
GLYCBASE ((Gupta et al. 1999) - O-linked glycosylation) databases (Lee et al. 
2006). 
Prediction methodologies also require a set of negative annotations – which are 
used in conjunction with the positive dataset to train the model on.  Such 
datasets are much harder to generate for the prediction of PTMs owing to a lack 
of experimentally determined non-acceptor sites (Farriol-Mathis et al. 2004). 
The Swiss-Prot database allows for the annotation of a non-acceptor site.  The 
incorporation of such sites from the Swiss-Prot database into the PTMDB has 
already been discussed.  In the PTMDB, there are only 135 such annotations 
compared with the 186,408 acceptors sites imported from the Swiss-Prot 
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database.  Clearly there are not enough experimentally determined non-
acceptor sites to form a negative dataset. 
Previously published PTM prediction tools have been forced to attempt 
computationally to define non-acceptor sites.  Farriol-Mathis et al., 2004 warned 
the community that a predicted non-acceptor site must be “plausible” – it is no 
good including non-acceptor sites that would never be within the same 
compartment as the required enzyme(s) for example. 
The negative dataset constructed by Lee et al. 2006 only utilises predicted non-
acceptor sites from proteins that have experimentally determined acceptor sites 
at different positions; they created one negative dataset for each PTM class 
they were interested in.  By only including such non-acceptor sites in this 
context, they guaranteed that the sites would be available to the necessary 
enzymes.  Lee et al. 2006 state that they are making the assumption that all 
acceptor sites on such proteins have been characterised.  They are also making 
the implicit assumption that the sites are surface accessible to the necessary 
enzymes at some point during their lifetime. 
The authors of the PHOSIDA phosphorylation prediction SVM constructed a 
much simpler negative dataset.  This dataset was composed of randomly 
chosen sites which were not in their positive acceptor site list (Gnad et al. 
2007).  Obviously this method doesn‟t take into account the plausibility of the 
sites they have chosen. 
Section 4.3  Cross-annotation protocol 
The first step in cross-annotating modification annotations between homologous 
proteins is to create a pairwise sequence alignment.  To increase the likelihood 
of cross-annotated sites being correct, Swiss-Prot curators have decided only to 
transfer annotations between proteins from closely related species (Farriol-
Mathis et al. 2004).  This policy could have been directly applied to this 
procedure using the orthology annotations incorporated into the PTMDB.  
However as orthology assignments have only been made between 30 species, 
this would rather limit the scope of the cross-annotation process.  On the 
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assumption that PTMs are more likely to be conserved in conserved domains, it 
was decided to transfer annotations based on domain annotations instead. 
Section 4.3.1(a)  Domain constraints 
The Pfam project (Finn et al. 2008) contains protein domain annotations for 
UniProtKB, which are produced by the HMMER tool 
(<http://hmmer.janelia.org/>). Pfam is composed of two datasets.  PfamA is the 
gold standard protein domain dataset derived from manually aligned seed 
sequences.  PfamB supplements the PfamA database providing automatically 
detected domains not present in PfamA.  The PfamA domain annotations have 
been incorporated into the PTMDB as well as the provided domain alignments 
provided by this project.  These domain alignments are used to identify 
homologous residues between proteins during the cross-annotation process.  
The PfamB dataset was not incorporated into the PTMDB for two reasons: i) it 
was undergoing extensive revision at the time of incorporation and ii) the 
domain annotations are, by definition, less reliable than those in PfamA. 
Section 4.3.1(b)  Positive dataset 
The positive dataset represents all those modification annotations that are going 
to be available for cross-annotation to homologous sites.  PTMs from the 
PTMDB, which had been extracted from the Swiss-Prot or Phospho.ELM 
databases, were used as the positive dataset.  In the future support will be 
added for the PDB2Linucs dataset.  It was decided only to cross-annotate sites 
that were annotated on the protein sequence listed for each UniProtKB entry.  
Therefore all those modifications annotated on splice variants were removed 
from this positive dataset. 
Section 4.3.1(c)  Query dataset 
The use of pre-computed sequence alignments from the PfamA project 
significantly reduces the computational requirements of this cross-annotation 
process.  However some aspects of the cross-annotation process are still quite 
computationally intensive.  Performing a cross-annotation of all sequences in 
the PTMDB was determined to be an unattainable goal given the available 
hardware.   It was also considered unnecessary to compare all 6,074,524 
sequences in the PTMDB – as it has already been shown that a great deal of 
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redundancy exists.  It was therefore decided that TrEMBL entries in the PTMDB 
proteome sets, and all those Swiss-Prot entries in the PTMDB, would be 
included in the positive set.  In total the dataset contained 2,768,148 UniProtKB 
entries. 
Section 4.3.1(d)  Cross annotation procedure 
PTM sites are first overlaid onto the PfamA alignments, which have been 
imported into the PTMDB.  The alignment column, to which a site maps, is used 
to identify homologous sites in other proteins.    Modifications that align to the 
same PfamA domain are analysed together.  For each domain all proteins in the 
positive set are selected that are annotated with this domain.  For every 
combination of annotation and protein, the algorithm checks if the target 
annotation is compatible with the residue found in the query sequence.  A 
compatible site is identified by checking in the PTMDB vocabulary whether the 
given modification can occur on the query residue.  It seemed logical that 
modified residues may be constrained during evolution only to be mutable to 
other residues that are compatible with the same modification.  As an initial test 
of this idea the algorithm was set up so that all phosphorylated residue 
annotations could be interchanged.  For example a phosphotheronine 
annotation mapped to a serine residue on a query would produce a 
phosphoserine annotation. 
The cross-annotated Swiss-Prot annotations are considered to be somewhat 
reliable because they are manually checked for their suitability for the new 
protein.  Without such manual checking an automatic method must have some 
way of scoring cross-annotations.  An obvious method would be to run 
prediction programs on the same sequences and compare the cross-
annotations to the predictions.  Although this would be the best method it would 
be both: a) limited to modification classes for which prediction tools exist (and 
are not biased to particular organisms), and b) would be extremely 
computationally intensive.  The cross-annotation algorithm has been designed 
to generate sequence windows around cross-annotated sites – between the 
target and query sequence.  Sequence windows are created that extend left 
and right from the modified residue by 1, 2, 4 and 6 residues.  In these 
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sequence windows a PSI is calculated and recorded for the match.  Where a 
modification is closer than the extension length to the C/N terminal of the 
protein the window is extended by the missing amount in the opposite direction 
– this matches the technique used in dbPTM (not the PTMDB being discussed 
here). 
The cross-annotation procedure was implemented on a relatively small HPC – 
with 9 nodes each equipped with two AMD 64bit Opteron processors and 2GB 
RAM.  The procedure took 7½hrs to cross-annotate proteins in the Swiss-Prot 
database and 17hrs for those in TrEMBL. 
Section 4.4  Results 
Section 4.4.1  Incorporation of Pfam 
Pfam annotations were only imported for Swiss-Prot entries and those TrEMBL 
entries included in the proteome sets, which have been incorporated into the 
PTMDB.  Table 28 displays the number of proteins that had at least one Pfam 
domain annotation as well as the total number of annotations imported.  Import 
statistics are shown in tables a) and b) in Table 28 for all UniProtKB entries 
referred to in the PTMDB proteome sets.  Tables c) and d) show the same 
statistics for all Swiss-Prot entries, and table e) shows totals for these four 
tables.   
The proteomes in the PTMDB are composed of 297,340 Swiss-Prot entries and 
2,470,808 TrEMBL.  91% of the Swiss-Prot entries have at least one Pfam 
domain annotation compared with 62% of those from TrEMBL.  The Pfam 
database used was not based on the same version of UniProtKB that was used 
to populate the PTMDB.  It was therefore necessary to check that the 
UniProtKB entry sequence versions did not differ.  A change to the protein 
sequence makes it impossible to know in which alignment column a modified 
residue is present. The Pfam annotations for 2,931 Swiss-Prot and 6,041 
TrEMBL entries from the proteome were discarded because of a sequence 
version mismatch. 
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457,178 domain annotations have been imported for Swiss-Prot entries and 
2,362,164 for TrEMBL entries.  71% of the proteins that have imported Pfam 
domains are from bacterial species.  An additional 60,662 Swiss-Prot entries, 
not part of the proteome sets, have imported Pfam annotations. 
In total, 1,878,940 proteins have had Pfam annotations imported and thus have 
the potential for PTM cross-annotations to be made onto them.   Note that only 
~0.5% of proteins and Pfam annotations have been lost because of sequence 
version mismatches. 
Section 4.4.2  Target PTM set 
The PTMDB contains 190,231 unique post-translational events. 52% (98,884) 
of these events have been overlaid onto Pfam domains.  7,834 Pfam domains 
have at least one acceptor site in the PTMDB.  Table 29  displays the 
percentage of modified proteins in the PTMDB that have at least one of their 
annotations overlaid onto a Pfam domain, subdivided by PTM class.  By protein 
abundance, phosphorylation and glycosylation are the most common 
modifications present in the PTMDB.  For example; 66% of phosphoproteins 
and 81% of glycoproteins from the PTMDB are present in the target cross-
annotation set. Many of the modification classes, which have a higher 
percentage inclusion than these two modifications, have extremely low 
abundance in the PTMDB. 
Table 30 displays the percentage of modification sites specific to each PTM 
class which are annotated in Pfam domains.    54% of phosphorylation and 69% 
of glycosylation sites have been annotated to Pfam domains.  Both tables show 
a similar distribution of numbers, most likely because most proteins only have 
one example of each modification. 
Some modifications are specific to the C and N termini of protein sequences.  
These regions of a protein are less likely to be found in a PfamA domain – as 
shown in Figure 28. 
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Figure 28: Limited conservation of N and C termini of proteins.  Each position in an individual protein sequence has 
been converted into the percentage distance it is in the protein.  The percentage of percentage-corrected positions 
found in Pfam domains – has then been plotted above. 
Only 7% of prenylated proteins in the PTMDB are found in the target dataset.  
Figure 29 shows that prenylation sites are predominantly found in the c-
terminus of proteins and that a very low fraction of these c-terminal sites are 
annotated on Pfam domains. 
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Figure 29: Distribution and annotation of Prenylation acceptor sites in the Pfam database. 
In comparison Figure 30 shows that the GPI-anchor acceptor sites are similarly 
C-terminally distributed, although 41% of proteins with GPI-anchor modifications 
are included in the target set.  Most modifications have a sequence distribution 
profile similar to that shown in Figure 30  for phosphorylation acceptor sites, 
which are evenly distributed throughout protein sequences. 
111 
 
 
 
Figure 30: Comparison between the likelihoods of a residue at each position in a protein that is either (A) GPI-
anchored or (B) phosphorylated, being annotated in a Pfam domain. 
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(a) Number of Pfam annotations imported and excluded for the query/target 
sets 
 Kept Excluded Percentage 
removed 
Superkingdom Swiss-
Prot 
TrEMBL Swiss-
Prot 
TrEMBL Swiss-
Prot 
TrEMBL 
Eukaryota 154834 640427 3744 7385 2.36% 1.14% 
Bacteria 280440 1626428 2073 2265 0.73% 0.14% 
Archaea 17431 86552 114 74 0.65% 0.09% 
None 4473 8757 21 18 0.47% 0.21% 
Total 457178 2362164 5952 9742 1.29% 0.41% 
       
       
(b) Number of proteins excluded  
 Kept Excluded Percentage 
removed 
Superkingdom Swiss-
Prot 
TrEMBL Swiss-
Prot 
TrEMBL Swiss-
Prot 
TrEMBL 
Eukaryota 75290 353521 1628 4490 2.12% 1.25% 
Bacteria 182161 1115798 1208 1508 0.66% 0.13% 
Archaea 12324 60817 80 31 0.64% 0.05% 
None 1753 7392 15 12 0.85% 0.16% 
Total 271528 1537528 2931 6041 1.07% 0.39% 
 
       
      (c) Number of annotations excluded (Swiss-Prot) 
Superkingdom 
Kept Excluded 
Percentage 
removed 
Eukaryotes 221898 4034 1.79% 
Bacteria 297803 2107 0.70% 
Archaea 18130 122 0.67% 
None 16109 64 0.40% 
Total 553940 6327 1.13% 
    
    (d) Number of Proteins (Swiss-Prot) 
Superkingdom Kept Excluded 
Percentage 
removed 
Eukaryotes 117053 1812 1.52% 
Bacteria 192871 1234 0.64% 
Archaea 12790 88 0.68% 
None 9476 47 0.49% 
Total 332190 3181 0.95% 
 
 
(e) Cross annotation  (Total) 
 
Removed Total 
Percentage 
removed 
Proteins 9222 1878940 0.49% 
Annotations 16069 2932173 0.55% 
Table 28: Comparison between the likelihoods of a residue, at each position in a protein, being either (A) GPI-
anchored or (B) phosphorylated, being annotated in a Pfam domain. 
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PTM Class % of proteins with at least one known 
acceptor site in a Pfam domain 
Iodination 100.00% 
Selenium 100.00% 
ADP-ribosylation 100.00% 
Organic radical 100.00% 
Covalent protein-DNA linkage 100.00% 
Pyruvate 99.08% 
FAD 98.56% 
Flavoprotein 96.10% 
TPQ 95.24% 
Oxidation 93.75% 
Other 91.49% 
FMN 90.91% 
Glycosylation_C_Linked 90.63% 
S-nitrosylation 88.24% 
Glutathionylation 88.24% 
Gamma-carboxyglutamic acid 87.50% 
Glycosylation_N_Linked 81.27% 
Glycosylation 81.03% 
Peptidoglycan-anchor 79.70% 
Nitration 75.51% 
Hydroxylation 70.00% 
Formylation 65.93% 
Phosphoprotein 65.72% 
Glycosylation_O_Linked 63.16% 
Glycosylation_S_Linked 62.50% 
Bromination 61.90% 
Amidation 48.42% 
Sulfation 47.02% 
Palmitate 45.43% 
Methylation 42.01% 
GPI-anchor 41.67% 
Glycoprotein 41.61% 
Lipoprotein 40.23% 
Nucleotide-binding 38.95% 
Myristate 38.92% 
D-amino acid 37.93% 
Pyrrolidone carboxylic acid 37.86% 
Hypusine 33.33% 
Acetylation 30.88% 
Citrullination 16.18% 
Prenylation 9.45% 
Covalent protein-RNA linkage 5.97% 
Table 29: The percentage of proteins that have at least one of their known acceptor sites, for the given PTM class, in 
a Pfam domain. 
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PTM Class Percentage of acceptor sites 
in a Pfam domain 
Selenium 100.00% 
Organic radical 100.00% 
Covalent protein-DNA linkage 100.00% 
Pyruvate 99.08% 
FAD 98.56% 
Flavoprotein 96.14% 
Oxidation 94.59% 
TPQ 93.02% 
Gamma-carboxyglutamic acid 92.12% 
FMN 91.18% 
Other 89.47% 
S-nitrosylation 85.00% 
Peptidoglycan-anchor 79.70% 
Nitration 77.19% 
ADP-ribosylation 77.07% 
Glycosylation_C_Linked 74.04% 
Glutathionylation 71.43% 
Glycosylation_N_Linked 69.69% 
Glycosylation 69.09% 
Formylation 65.47% 
Glycosylation_S_Linked 62.50% 
Hydroxylation 60.97% 
Bromination 54.17% 
Phosphoprotein 53.65% 
Amidation 52.88% 
Glycosylation_O_Linked 52.47% 
Palmitate 48.61% 
Iodination 47.06% 
D-amino acid 44.30% 
Sulfation 42.21% 
GPI-anchor 41.67% 
Glycoprotein 41.61% 
Pyrrolidone carboxylic acid 40.84% 
Lipoprotein 40.39% 
Nucleotide-binding 38.95% 
Myristate 38.94% 
Methylation 37.51% 
Hypusine 33.33% 
Acetylation 32.07% 
Citrullination 30.40% 
Prenylation 7.15% 
Covalent protein-RNA linkage 5.63% 
Table 30: Percentage of acceptor sites in a Pfam domain. 
Section 4.4.3  Cross-annotation results 
Cross-annotations have been made between proteins regardless of how 
taxonomically close their parent species are.  Cross-annotations have been 
made between, for instance, bacterial and eukaryotic species. Initially only 
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cross-annotations that have been made between species of the same super-
kingdom will be described.   A brief overview of the cross-annotations made 
between species of different super-kingdoms – including those taxa not 
annotated to any super-kingdom (e.g. viruses) – will then follow. 
Section 4.4.3(a)  Window analysis 
As previously stated the cross-annotation protocol calculates the sequence 
identity in sequence windows of various lengths centred on sites of cross-
annotation.  These have been calculated to provide two parameters to which 
thresholds can be used to constrain the cross-annotation set.  The annotation 
protocol also calculates sequence windows around homologous sites that 
already contained identical annotations before this cross-annotation procedure 
was carried out.  Figure 31 plots the percentage of these sites that are lost as 
the PSI threshold is increased.  This figure also shows the effect of varying the 
sequence window length. 
 
Figure 31: Conservation of the regions surrounding homologous PTM sites in the target dataset.  Each line 
represents a different extension length to the left and right of the PTM site; the number of amino acids compared is 
twice the extension length.  The y-axis represents the percentage of target PTM sites with at least one homologous 
partner in the target dataset; for each such site the highest observed PSI between it and all homologues is recorded 
for each extension length.  The x-axis represents a >= PSI threshold which is used to show what percentage of PTM 
sites in the target dataset with at least one homologue had a recorded PSI >= a given value. For example ~50% of 
target sites (that had at least one homologous partner) had a recorded PSI of 100 in a sequence window of 12 amino 
acids. 
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Such a plot provides only a rough guide as to the sequence similarity which is 
observed around currently annotated PTMs in the PTMDB.  Plots were also 
produced for specific PTM classes.  Those for glycosylation and 
phosphorylation looked very similar to that in Figure 31.  This plot shows that a 
large percentage of sites are still present even with quite a high PSI threshold – 
this suggests that the dataset being compared contains a high proportion of 
closely related sequences.  As you might expect; as the PSI threshold is 
increased, the number of sequences lost increases quite dramatically. 
This plot can be compared with that in Figure 32 which shows the same 
information for all those cross-annotations made for proteins in the Swiss-Prot 
database (note that the plot for TrEMBL was extremely similar). 
 
Figure 32: Sequence window analysis of the Swiss-Prot cross-annotation set. 
This plot shows a much steeper loss of cross-annotations as the PSI is 
increased.  As would be expected the cross-annotation protocol appears to be 
comparing sequences with a much greater degree of diversity compared to the 
117 
 
target set.  This emphasises the need to apply a threshold to both the sequence 
window length and PSI.  
Section 4.4.3(b)  Intra-super-kingdom predictions 
Table 31 shows the total number of cross-annotations that have been made.  In 
total 54,453 Swiss-Prot and 262,265 TrEMBL entries now have PTM 
annotations that did not before.  Between both databases 2,301,107 individual 
annotations have been added.  These numbers drop significantly when a 70 
PSI cut-off is applied to the new annotations with a sequence length of 12 aa 
(extension length 6).  After applying these thresholds, 15,961 Swiss-Prot and 
62,450 TrEMBL entries still have cross-annotations that did not have any 
modification annotations before this process was carried out. The total number 
of individual modification sites dropped to 163,763. Unless otherwise stated, all 
remaining statistics have been used after a 70 PSI cut-off was applied to a 
sequence window of 12aa. 
  Number of Proteins Number of 
modifications 
Number of acceptor 
sites 
 
  On existing New    
 Complete      
 Swiss-Prot 20,340 54,453 620,042 576,632  
 TrEMBL 24 262,265 1,139,179 1,113,662  
 Total 20,364 316,718 2,301,107 1,690,294  
 70% SI 12aa      
 Swiss-Prot  7,811 15,961 60,610 57,400  
 TrEMBL (70|6) 8 62,450 103,153 100,827  
 Total 7,819 78,411 163,763 158,227  
Table 31: Gross number of cross-annotations made in the Swiss-Prot and TrEMBL database.  The top three rows 
represent the whole cross-annotation dataset before any constraints are applied.  The final three rows represent 
those annotations with > 70 PSI in a window of 12 aa. 
A breakdown of the number of proteins that received cross-annotations for each 
PTM class is shown in Table 32.  The PTM classes that were most abundant in 
the target annotation set are also the most abundant in the predicted set.  
Phosphorylation and Glycosylation were the most abundant cross-annotations 
when ranked according to the number of proteins with a new annotation.  Of the 
78,411 proteins that received a cross-annotation, 55,466 (70%) had at least one 
phosphorylation annotation and 16,407 (20%) received a glycosylation 
annotation. 
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PTM Class 
Swiss-Prot TrEMBL 
 On Existing New On Existing New 
Phosphoprotein 2742 12795 7 39922 
Glycosylation 2987 1863 0 11557 
Glycosylation_N_Linked 2785 1818 0 11335 
Methylation 185 2947 0 4046 
ADP-ribosylation 0 274 0 3213 
Acetylation 231 1512 0 1823 
Other 0 489 0 1212 
Lipoprotein 2 269 0 957 
Palmitate 2 109 0 844 
Flavoprotein 0 0 0 753 
FAD 0 0 0 587 
Nitration 4 849 0 541 
Hydroxylation 57 875 0 465 
Nucleotide-binding 0 0 0 442 
Organic radical 0 0 0 370 
Pyruvate 0 2 0 339 
Oxidation 0 33 0 311 
S-nitrosylation 0 709 0 274 
Glycosylation_O_Linked 32 302 0 269 
Table 32: Number of proteins with cross-annotations for each PTM class. 
A breakdown is now provided of the cross-annotations made for species in the 
three different super-kingdoms. 
Bacteria 
Before cross-annotation, 799 species/strains had at least one PTM annotation 
in the PTMDB.  This number increased slightly to 884 after this process.  Table 
33 shows the number of proteins that have been annotated with each PTM 
class for all bacterial species in the query protein set.  The most abundant 
modification cross-annotation was for phosphorylation with 20,236 proteins 
being annotated with at least one new acceptor site (note that 40% of the 
original bacterial annotations were for this modification).  The number of 
phosphorylated proteins for bacteria has increased almost 9-fold.  A significant 
increase in the number of methylation and ADP-ribosylation sites was also 
observed. 
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PTM Class 
Swiss-Prot TrEMBL 
 On Existing New New 
Phosphoprotein 122 1844 18270 
Methylation 0 1612 3085 
ADP-ribosylation 0 1 2836 
Other 0 270 920 
Palmitate 0 25 612 
Lipoprotein 0 25 612 
Flavoprotein 0 0 570 
Nucleotide-binding 0 0 430 
FAD 0 0 416 
Organic radical 0 0 368 
Oxidation 0 31 278 
Acetylation 0 16 255 
Pyruvate 0 2 217 
FMN 0 0 154 
Hydroxylation 0 4 137 
Peptidoglycan-anchor 0 0 118 
S-nitrosylation 0 3 78 
Glutathionylation 0 3 78 
Table 33: Bacteria cross-annotation statistics – some PTM classes have been excluded. 
Archaea 
Before the cross-annotation process the PTMDB contained 666 modifications to 
sites in archaeal species – 385 of which mapped to positions in PfamA 
domains.  Of the three super-kingdoms; archaeal species have by far the fewest 
modifications in the PTMDB.  As previously noted; 86,230 proteins received 
new annotations from the cross-annotation procedure – 196 of these were 
archaeal proteins.   
Eukaryotes 
Eukaryotes account for 95% of the annotations present in the target set of 
PTMs used for the cross-annotation process.  This contained annotations for 
2,047 species – the cross-annotation has resulted in an additional 713 species 
having at least one annotation.  Table 34 shows that 35,203 eukaryote proteins 
have received new phosphorylation annotations and 16,374 new glycosylation 
annotations. 
As already stated, phosphorylation and glycosylation are the most abundant 
cross-annotations.  Figure 33 shows the distribution of these cross-annotations 
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between Eukaryote species.  It is interesting to note that a few species that did 
not prominently feature in the PTMDB before this process now have a 
significant number of their proteins annotated with at least one annotation. For 
example, the PTMDB contained annotations for seven T. nigroviridis proteins; 
this cross-annotation process has increased this number to 3,702.  Another fish, 
D. rerio, had no annotations in the target set; after cross-annotation, 2,853 
proteins had at least one annotation.  In addition this figure shows that a lot of 
cross-annotations have been made for H. sapiens, M. musculus, and Xenopus 
laevis. 
The distribution of phosphorylation cross-annotations between the different 
types of phosphorylation between eukaryote species is shown in Figure 34.   
 
Figure 33: Distribution of predicted Glycosylated, N-linked Glycosylated and Phosphorylated proteins between 
different Eukaryote species.  Note that all species with less than 500 proteins that have been cross-annotated have 
been excluded from this figure. 
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Figure 34: Distribution of phosphorylation cross-annotations between the different types of phosphorylation, 
grouped by species.  The number of residues that have been modified is also displayed.  Note that species with less 
than 1000 phosphorylation cross-annotations are not shown 
PTM Class 
Swiss-Prot TrEMBL 
 On Existing New On Existing New 
Phosphoprotein 2620 10951 7 21625 
Glycosylation 2987 1862 0 11525 
Glycosylation_N_Linked 2785 1817 0 11307 
Acetylation 231 1495 0 1551 
Methylation 175 1335 0 940 
Nitration 4 849 0 541 
ADP-ribosylation 0 273 0 347 
Lipoprotein 2 244 0 342 
Hydroxylation 57 871 0 328 
Glycosylation_O_Linked 32 302 0 265 
Table 34: Eukaryote cross-annotation statistics.  Note that for brevity not all keywords are shown in this table. 
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Section 4.4.3(c)  Inter-super-kingdom cross-annotations 
Some PTM classes are thought to be exclusive to particular lineages; for 
example glycosylation is almost exclusively associated with Eukaryotes.  This is 
one reason why cross-annotating modifications between species that belong to 
different super-kingdoms might not be a valid procedure.  However it should be 
pointed out that some modification sites have been identified that are conserved 
across super-kingdoms (Macek et al. 2008).  In the target annotation set, 7% of 
the PfamA alignment positions annotated with a modification in Bacteria shared 
the same annotations with Eukaryote proteins.   
In addition it is important to note that many Prokaryotes have now been 
recorded as being able to glycosylate some of their proteins (Hitchen and Dell 
2006).  It is important to stress again at this point that the PTMDB does not 
contain detailed glycan structures; therefore glycosylation cross-annotations do 
not imply anything about the conservation of glycan structures.  
Although some conservation of modification sites between species belonging to 
different super-kingdoms has been experimentally confirmed; the majority of 
sites appear unlikely to be conserved.  Therefore the inter-super-kingdom 
cross-annotations should be treated as a dataset that can be further 
interrogated and refined. 
Table 35 summarise the inter-super-kingdom cross-annotations that were 
performed and the direction of the transfer.  This table includes all inter-super-
kingdom cross-annotations and not just those that could satisfy the thresholds 
applied to the intra-super-kingdom annotations – previously described.   Whilst 
the results of this table are interesting they are also a warning.  This table 
shows that without applying any thresholds an extremely large number of cross-
annotations are selected for inter-super-kingdom matches.  Note that this table 
shows the number of alignments that generated a cross-annotation and not the 
number of unique sites for which an intra-superkingdom cross-annotation was 
performed. 
 
 
123 
 
 
Donor->recipient 
PTM Class e->b b->e e->a a->e a->b b->a 
Phosphoprotein 205,924 12,758 12,519 137 11 1,320 
Glycosylation_N_Linked 161,509 38 7,506 19 47 30 
Acetylation 26,101 477 1,295 20 0 327 
Nitration 4,906 0 275 0 0 0 
Methylation 3,237 199 276 990 1,797 156 
Hydroxylation 1,616 248 31 0 0 42 
Glycosylation_O_Linked 1,280 14 23 0 0 0 
Table 35: Inter-super-kingdom predictions. The number of acceptor sites that only have evidence from a species of a 
different super-kingdom are shown above.  The direction of annotation is shown in the form donor->acceptor – 
where; a=Archaea, b=Bacteria and e=Eukaryote.  For example the first cell contains the number 205,924, which 
indicates the number of phosphoprotein annotations that have been transferred from Eukaryotic species to bacterial 
ones. 
Section 4.4.4  Comparison to UniProtKB release 2010_12 
The target PTM dataset was derived from annotations released as part of 
Swiss-Prot release 55.3 (published in August 2008) and Phospho.ELM release 
7 (published in July 2007).  At publication the most recent release of the 
UniProtKB was the December 2010 version (release tagged as 2010_12).  The 
2010_12 version has been used to create an updated version of the PTMDB – 
which has been searched for the previously discussed cross-annotations.   
The PTM Browser web services API was used to retrieve cross-annotation sets 
that were specific to Eukaryotes, Mammals, Bacteria and Archaea.  The web 
service was asked to exclude annotations that didn‟t match any in the target set 
(all those annotations imported from Swiss-Prot and Phospho.ELM) for the 
same taxonomic group.  For example the returned Mammalian dataset didn‟t 
contain any cross-annotations derived entirely from non-Mammalian proteins. 
Table 36 provides a breakdown of the number of proteins present in each 
taxonomic-specific cross-annotation dataset (extracted as described above).  In 
order to understand how many of the cross-annotations are present in the 
2010_12 release of Swiss-Prot – it is important to remember that some Swiss-
Prot entries may have been removed, and some TrEMBL entries added, to 
Swiss-Prot; this table records such events.  Furthermore it‟s important to only 
compare annotations where the sequence version number is unchanged; again 
the same table records this information.  Across all four datasets very few of the 
TrEMBL proteins with cross-annotations have been incorporated into the latest 
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release of the Swiss-Prot database.  This appears to indicate that although the 
PTMDB is based on an older version of Swiss-Prot its cross-annotations to 
TrEMBL proteins may still represent a useful resource for scientists.  Note that a 
relatively small number of the Swiss-Prot entries, that had cross-annotations, 
appear to have been removed from Swiss-Prot (196 for Eukaryotes).  Some 
proteins have been excluded because of sequence version mismatches; for 
example 13% of TrEMBL and 5% of Swiss-Prot entries belonging to Eukaryotes 
were excluded.  A very small number of cross-annotations had corresponding 
PTM sites (defined as a unique triplet of UniProtKB accession, residue number, 
and PTM class) in the 2010_12 Swiss-Prot release.  For example of the 65,567 
Eukaryote Swiss-Prot proteins there were only 1,891 matches; which is 0.028 
matching sites per protein.  It is not particularly surprising that so few sites 
match between the two datasets, especially when you consider that new 
annotations are added manually by curators. 
Taxa Database No Proteins 
  Total 
Present 2010_12 
Swiss-Prot 
Sequence version 
matches 
Matching annotations 
Eukaryotes TrEMBL 189161 5590 4870 863 
Eukaryotes Swiss-Prot 68780 68584 65567 1891 
Mammalia TrEMBL 12248 920 720 228 
Mammalia Swiss-prot 32861 32753 30550 1403 
Bacteria TrEMBL 73168 1805 1680 393 
Bacteria Swiss-Prot 10513 10504 10456 12 
Table 36: Number of Cross-annotations present in PTMDB that are also present in UniProtKB release 2010_12. 
Section 4.5 Discussion 
The primary aim of performing the cross-annotation procedure was to expand 
the PTMDB to include proteins that are in the TrEMBL database.  A secondary 
objective was to identify and add any annotations that appeared to be missing 
in homologous sites between Swiss-Prot entries.  These new annotations are of 
course not of the same high-quality associated with those in the Swiss-Prot 
(excluding those annotated as potential or probable) and Phospho.ELM 
databases.  The assumption was made that the higher the local sequence 
identity between the target and query site, the more likely the query residue is to 
be modified.  Therefore the PSI between the target and query sites in windows 
of various lengths was calculated for each cross-annotation.  A PSI threshold 
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can therefore be used to compensate for the fact that these cross-annotations 
have not been manually curated like those in the two previously-mentioned 
databases.  It is important to point out that when a cross-annotation takes place 
it is guaranteed to take place between homologous sites; assuming that the 
Pfam domain alignment is correct.  Therefore there is no need for any type of 
alignment scoring metric to indicate if two regions are homologous.   
It would be beneficial to know which sites match known recognition sites for 
corresponding enzymes.  This could be accomplished by scanning the regions 
surrounding the cross-annotation sites with the recognition patterns from Prosite 
of such enzymes.  Note that such patterns either match or don‟t match (e-
values are only calculated for Prosite profiles); although Prosite does indicate if 
a pattern occurs frequently in the Swiss-Prot database. 
Even without the aid of a prediction tool, such as Prosite, a high-quality dataset 
of cross-annotations can still be obtained by setting a high sequence identity 
threshold in a chosen window length.  As an aid to selecting an appropriate 
threshold a comparison was provided between the sequence identities of 
homologous sites that already have the same modification annotations.  This 
comparison demonstrated that in the PTMDB there was a relatively high degree 
of sequence identity between such sites.  This could simply be an artefact of 
curators only annotating homologous sites where the sequence identity is high.  
After analysing this comparison, a somewhat arbitrary threshold of > 70 PSI in a 
sequence length of 12 amino acids was chosen to create a set of cross-
annotations, which were discussed in the previous section – all results 
discussed below also used this threshold.   25% of cross-annotations were 
made between sequences with > 70 PSI in a window size of 12 aa. 
The majority of new cross-annotations have been made for eukaryotic proteins.  
A much smaller number of bacterial and archaeal proteins have been annotated 
with PTMs.  The large number of inter-super-kingdom cross-annotations 
(without thresholds applied) shows that residues which are modified (particular 
those in eukaryotes) are homologous to those in proteins of different super-
kingdoms.  Such inter-super-kingdom cross-annotations have not yet been 
included in the PTMDB.  They have been excluded on the basis  that few 
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modification sites appeared conserved between proteins of different super-
kingdoms before this process was carried out, which suggests that what is 
being observed is a high degree of sequence conservation that doesn‟t 
necessarily correlate with the presence of a conserved modification.  This 
conclusion isn‟t particularly surprising given that only modification sites in 
conserved protein domains have been cross-annotated.  A rather shocking 
example of this is provided by the glycosylation annotations of eukaryote 
species that have been cross-annotated to bacteria.  479,161 bacterial residues 
received a glycosylation annotation; before this process was carried out, only 26 
such residues had a glycosylation annotation.  Note that although glycans have 
been widely observed on bacterial proteins (Hitchen and Dell 2006) they have 
not been reported to this level.  
As a cross-annotation can only be made between residues annotated to the 
same domain, it is obvious that this procedure is vulnerable to missing domain 
annotations.  A missing domain annotation would manifest itself as a 
modification not being conserved between two homologous positions.  A related 
problem occurs when the domain annotations are based on a set of sequences 
that differ from those used in the PTMDB.  For example, both Pfam and the 
PTMDB are based on sequences in UniProtKB.  Issues appear when these two 
databases are based on different versions of UniProtKB.  For example a 
modified protein in the PTMDB may lack domain annotations in the Pfam 
database, because they were simply missing from the version of the UniProtKB 
upon which it is based. 
The Pfam database annotates domains on the primary sequence of UniProtKB 
entries.  The UniProtKB and Pfam databases are not released at the same time 
it is therefore possible that the domain annotations were made on a sequence 
which is different from that in the PTMDB.  Domain annotations which have a 
different sequence version number in the Pfam database compared with the 
PTMDB have not been incorporated into the PTMDB.  Such annotation 
mismatches are however recorded, allowing future analysis software to take 
into account annotations that have been removed. 
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As already mentioned, Lee et al. 2006 created a negative dataset that was 
specific to each PTM class for which they made predictions.  For each such 
class, they extracted residues from proteins with experimentally determined 
annotations of the given class that were themselves compatible with the same 
modification but had not yet been annotated as such.  They are clearly implying 
that proteins that have known experimentally-determined PTM sites of a given 
class are likely to have had the majority of their PTMs characterised.  Although 
the cross-annotation procedure did annotate some sites that would fit their 
definition of a non-acceptor site, these annotations are in the minority.  In the 
future, groups might want to check the cross-annotation set with an appropriate 
selection of thresholds to identify sites that they could exclude from their 
negative dataset.  
In conclusion, the cross-annotation procedure has resulted in an explosion in 
the number of annotations present in the PTMDB.  These cross-annotation 
results can be constrained by sequence identity to provide a high quality 
dataset.  62,450 (70% SI threshold) TrEMBL entries now have at least one 
modification annotation in the PTMDB compared with just 204 previously (all of 
which were for phosphorylation, extracted from the Phospho.ELM database).  In 
total 163,763 (70% SI threshold) cross-annotations have been incorporated into 
the PTMDB. 
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Chapter 5  
 
PTM Browser 
Section 5.1  Summary 
There are currently few bioinformatics tools that allow users to interrogate post-
translational modification datasets.  In particular it is difficult for researchers 
outside the field of bioinformatics to ask simple questions regarding the 
conservation and co-occurrence of PTMs.  This has necessitated the 
development of a novel tool and associated algorithms to answer such 
questions.  The new tool described in this chapter – PTM Browser – is freely 
available for non-commercial use at the following URL: 
<http://www.ptmbrowser.org>.  The PTMDB provides annotations to this tool, 
which includes the cross-annotations and CoPaO orthologue/paralogue 
assignments discussed previously.  Simple questions such as: what percentage 
of the H. sapiens phosphoproteome is conserved in M. musculus or which H. 
sapiens glycosylation sites do M. musculus lack can be asked.  This tool should 
be extremely useful to scientists who find that the proteins of their organism of 
interest are predominantly in the TrEMBL database – as the PTMDB now 
contains annotations for a large number of such proteins.  Finally a web service 
has been provided in the hope that bioinformaticians will be able to build on the 
analysis pipeline in PTM Browser. 
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Section 5.2  Application implementation details 
PTM Browser has been written as a web application using the Ajax 
(Asynchronous JavaScript and XML) methodology.  The client side of PTM 
Browser makes use of CSS (Cascading Style Sheets) and the JQuery (JQuery-
Community 2010) JavaScript framework.  The server side component of PTM 
Browser has been programmed on top of the MVC (Model View Controller) 
framework Ramaze (Fellinger 2010).   This framework has been written in the 
Ruby language although PTM Browser has been deployed on the Java 
implementation of the Ruby language, JRuby (JRuby-Community 2010).  This 
decision allows PTM Browser to access Java objects from its Ruby code.  
Additional graphing routines have been written in the Perl language utilising the 
Cairo graphics library (Cairo-Community 2010).  As with the PTMDB already 
discussed, PTM Browser uses MySQL (Oracle 2010) (RDBMS) for data 
storage.  PTM Browser is hosted on a Ruby web server that has Apache 2 
(Apache-Community 2010) acting as its proxy to the outside world. 
PTM Browser is divided into a client and server side component.  The server 
side component exposes a public web service API (see Section 5.4) that can be 
used to create user interaction and data analysis software.  The PTM Browser 
client is an example of an application that uses this API.  The source code for 
PTM Browser has been made available at the following URL 
<http://code.google.com/p/ptmbrowser>.  Further details on the implementation 
of PTM Browser are supplied as required throughout the rest of this chapter. 
The PTM Browser client web interface is shown in Figure 35. 
Section 5.2.1  PTMDB inclusion 
The PTM Browser tool has been designed to utilise only a subset of the 
features available in the PTMDB that have thus far been described.  Users are 
able to select from two datasets.  The first, referred to as PTMDBFull, contains all 
the annotations from the PTMDB with the exception of those derived from the 
PDB.  The second, referred to as PTMDBPfamA, contains only those annotations 
that have been successfully mapped onto a Pfam A domain.  Note that this 
second dataset excludes all annotations imported from the PDB.  
 
 
 
Figure 35: PTM Browser client web interface. 
PTM Browser left accordion contains a number of expandable panels that show results and other information to users.  The Experiment browser is shown, which displays the annotation sets 
that the user has selected.  This component is also used to group, delete and apply constraints to experiments. The right accordion contains panels to add annotation sets to the query browser 
and select the query type
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A comparison of the features provided by these two databases and the original 
PTMDB and the SwissProt database is shown in Table 37.   
Note that permission has been obtained from the Phospho.ELM authors to 
distribute their data through PTM Browser.  Additionally permission was 
required from the authors of the original InParanoid method to distribute the 
orthologue/paralogue clusters produced by the CoPaO program.  This was 
required as CoPaO makes use of the BLAST parsing routine (does not perform 
the actual detection of orthologues and in-paralogues) written by the authors of 
the InParanoid algorithm.  Permission has been obtained to distribute the 
CoPaO assignments through PTM Browser.   
Database UniProtKB Phospho.ELM PDB-2-
Linucs 
Cross 
annotations 
Pfam 
Annotations 
Homology 
assignments 
 SwissProt TrEMBL   inter intra A B  
SwissProt ✓ ✗ ✓ ✗ ✗ ✓ ✓ ✓ KEGG 
PTMDB ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ CoPaO 
PfamA ✓ ✓ ✓ ✗ ✓ ✓ ✓ ✗ CoPaO 
Full ✓ ✓   ✓ ✗ ✓ ✓ ✗ ✗ CoPaO 
Table 37: Comparison showing the information present in Swiss-Prot, PTMDB and its subset databases: PfamA and 
Full, that are used by the PTM Browser application 
During the development of PTM Browser it became evident that the PTMDB 
schema did not have the performance characteristics required to allow for 
certain queries to be performed in a reasonable time frame.  A static 
representation of the PTMDB was therefore created, according to the schema 
shown in Table 38.  At the time of writing PTM Browser was deployed on a 
virtual server with poor disk IO performance compared with that of a dedicated 
server.  This issue was partly addressed by the new schema which converted 
many fields from a varchar type to an enum to reduce the size of the database – 
allowing the database to be loaded into a MySQL Hash table (stored in RAM).  
To reduce the number of table joins performed by PTM Browser, Pfam 
alignment coordinates are stored directly in this table.  In addition the alignment 
window statistics, calculated for the cross-annotated PTM sites (discussed in 
Section 4.4.3(a), have been merged into the same table.  Therefore this table 
will contain one row for each combination of cross-annotated PTM annotation 
and window alignment length. 
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Field name Type 
AnnotationId int(11) 
UniProtKBAccession char(9) 
Start mediumint(8) unsigned 
AlnPosition smallint(5) unsigned 
PfamAccession varchar(8) 
PtmDescription enum('Phosphohistidine',...) 
MethodDescription enum('By similarity,...) 
DatabaseName enum('tremblPfamA',...) 
KwDescription enum('Phosphoprotein',...) 
NetId int(11) 
AlnLength tinyint(4) 
Identities tinyint(4) 
Table 38:  PTM Browser PTMDB modified table structure. 
Section 5.2.2  Pfam complications 
It is stated that no two PfamA domain assignments may have overlapping 
alignment coordinates (Finn et al. 2010).  However some PfamA assignments 
appear to violate this rule thus complicating any analysis that is dependent upon 
this rule.  This central rule appears to be violated under two different conditions.  
To understand the first mechanism it is necessary to understand what the Pfam 
authors actually mean by an “alignment coordinate”.  The HMMER package is 
used to produce possible domain annotations for protein sequences (see 
<http://hmmer.janelia.org/>and (Eddy 1998).  HMMER outputs two aligned 
regions for each possible domain match: a low and high confidence region 
referred to as the “envelope” and “alignment” windows (Finn et al. 2010).  An 
overlap is explicitly allowed between the envelope regions of domain 
assignments, but not the alignment regions (Pfam-Consortuim 2010).  
Unfortunately the PTMDB is based on those annotations found in the provided 
flat files, which contain the envelope coordinates.  There are therefore 
overlapping domain assignments in the PTMDB.  The second mechanism is 
explained in the documentation that accompanies the Pfam web site.  It states 
that nested domain annotations are allowed when it is believed that the 
insertion of one domain into another does not affect the tertiary structure of the 
domain (Pfam-Consortuim 2010) (see Figure 36 for an example). 
To simplify the analysis routines written for PTM Browser, all overlapping Pfam 
domain assignments in the PTMDB have been resolved to a single assignment.  
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Overlapping assignments have been resolved by keeping only the assignment 
whose start coordinate is closest to the modification annotation.  
 
Figure 36:  Domain layout of the protein IMDH1_HUMAN (SwissProt ID).  Alignment coordinates are suffixed with 
“a” and envelope with “e”.  This protein has two CBS domains which are nested in a single IMPDH domain. 
Section 5.3  Conservation analysis workflows  
PTM Browser is a web application that can perform either a protein family or 
taxonomic PTM conservation analysis.  This tool has been designed to use the 
new PTMDB that was described in the three previous chapters.  This database 
contains the total set of modification annotations from Swiss-Prot (v55.3) and 
Phospho.ELM (v7.0).  The following sections outline how these two types of 
analysis can be performed using existing tools and how new workflows have 
been created by the PTM Browser tool.   
Section 5.3.1  Protein family analysis 
Section 5.3.1(a)  Current workflow 
The first step in analysing the conservation of PTMs in a family of proteins is to 
identify family members.  Note that the term “protein family” is being used here 
to describe any group of related proteins (e.g. orthologues, in-paralogues, and 
out-paralogues).  There are many different methods that can be used to obtain 
this list of family members.  One of the most simplistic approaches is to search 
a protein database (e.g. UniProtKB) with a gene name.  There are obvious 
issues with this approach caused by synonyms, missing gene names and 
coincidental gene names (genes with the same name that are not homologous).  
An alternative would be to identify family members from the results of 
BLAST/PSI-BLAST queries.  There are also databases that specialise in 
identifying proteins that belong to specific families (e.g. Pfam, COG, KOG, 
KEGG and InParanoid). 
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Once a list of family members has been obtained the next step is to obtain their 
corresponding PTM annotations.  The new interface to the UniProtKB (which 
was released after the PTM Browser interface was designed) makes this 
process far simpler than some of the more specialised databases.  The 
UniProtKB interface can be queried for UniProtKB accessions with protein 
family identifiers (e.g. a Pfam accession).  The UniProtKB interface allows users 
to select the entries they are interested in from the returned results (via a 
checkbox beside each entry). 
Users then have two choices they can either download all the information the 
UniProtKB contains on the selected entries (which includes PTM annotations) 
or they can perform a multiple sequence alignment.  Getting to this step is 
slightly different if the user has a list of UniProtKB accessions (rather than a 
protein family accession).  To download all the information that the UniProtKB 
contains for the corresponding entries they must enter the accessions into the 
“retrieve query box”.  To perform a multiple sequence alignment the accessions 
must be entered into the “alignment query box”. 
By performing a multiple sequence alignment in the UniProtKB interface users 
can choose to highlight residues with known modification sites. It is then up to 
the user to deduce which modifications are conserved.  If a user wishes to know 
what PTM type(s) a particular highlighted residue is annotated with, they must 
manually calculate the residue number (i.e. by counting in the alignment) and 
then refer back to the original UniProtKB web page for the corresponding entry.   
The alternate route is for users to manually extract the PTM annotations from 
the downloaded UniProtKB flat file (specific to the accessions they requested 
annotations for) - for large protein families this will almost certainly require a 
small amount of programming.  The benefit of downloading the annotations is 
that users can merge the UniProtKB annotations with those downloaded from 
other sources.  Note that most other PTM databases will require each 
UniProtKB accession to be entered separately.  Of course the main 
disadvantage is that the user is now responsible for both creating an alignment 
and highlighting which residues are modified. 
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It should be pointed out that the user must also be careful to check whether 
they believe that a missing annotation truly represents the likely absence of a 
modification.  For example if the protein family contains entries from the 
TrEMBL database they will by definition have no PTM annotations in the 
UniProtKB, although they could of course have annotations in other databases 
(e.g. Phospho.ELM). 
PhosphoSitePlus (<http://www.phosphosite.org>) is interesting because it 
explicitly provides users with information regarding the conservation of 
modifications (predominately for phosphorylation and acetylation PTM classes) 
for a specific protein.  Conservation results are shown in a simple table 
structure.  Note that the majority of PTM annotations in this database are 
associated with H. sapiens, M. musculus and R. norvegicus.  This does limit the 
scope of any conservation analysis performed with this database to these three 
species, however this database does appear to contain many PTM annotations 
not found in Swiss-Prot.  The conservation results generated directly by this 
database can only be used to analyse the conservation between orthologues.  
For example the database does not allow for a direct comparison of the p53 
family of proteins, although it does contain separate entries for p53, p63 and 
p73 (see Section 6.2 for more information on PTM conservation in the p53 
family of proteins). 
Section 5.3.1(b)  PTM Browser workflow 
The PTM Browser workflow that has been created to analyse protein families is 
shown in Figure 37.  Users can either supply a predefined list of proteins, or 
provide a single protein (see Figure 38) and request that a new protein list is 
created from the orthologues present in the CoPaO dataset.  Note that the 
second route is limited to proteins from species that were included in the 
CoPaO analysis presented in Chapter 3 (30 species).    Users can restrict the 
CoPaO route analysis to only include proteins from a pair of specific species - 
otherwise all orthologues are added to the protein list.     
The user defined protein list is restricted to proteins that were present in the 
cross-annotation query set (see Chapter 4) and have had Pfam annotations 
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imported into the PTMDB.  This restriction has been put in place to prevent the 
display of misleading results. 
Once the protein list has been defined the corresponding modification 
annotations are extracted from the PTMDB.  Note that at present only those 
annotations that fall in a Pfam domain are accepted.  Figure 37 shows that the 
next step is to overlay Pfam domain alignment columns onto the initial 
modification dataset (indexed by amino acid residue number).  In reality this 
information is permanently stored in the PTMDB alongside each annotation 
(see Section 5.2.1).   
The Pfam indexed modification dataset is then converted into a number of 
different formats.  A conservation table is generated that lists the modifications 
present in the protein family (by Pfam domain accession, alignment position and 
PTM class) against the members of the protein family (listing if the modification 
is present and at which residue(s).  This table is produced in both an Excel and 
HTML format (see Figure 39 for an example).  This conservation table 
addresses the previously raised issue with the proposed UniProtKB workflow, 
whereby a user had to manually calculate residue numbers and manually 
identify the modifications present.   
For each Pfam domain that is present in the protein family a separate starred 
alignment is created (see Figure 40).  Note that a multiple sequence alignment 
of each domain is not performed as those alignments produced by the Pfam 
project are stored in the PTMDB.  These stored alignments are used to create a 
new alignment which only contains those proteins in the original protein list.  
Residues that have modification annotations are starred in these alignments. 
Finally the Pfam indexed modification dataset is exported to an XML and SQL 
dump file – predominantly aimed at users of the web service API. 
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Figure 37:  PTM Browser protein family workflow. 
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            Figure 38:  PTM Browser accession entry component.  
            This component can be used to enter either a single UniProtKB entry or a list (space or comma separated)    
            of entries.  A conservation analysis can be performed on this list with the “Show Conservation” button. 
 
Figure 39:  PTM Browser conservation table format 
To aid the user in understanding the evolutionary relationships that exist 
between the proteins in the original protein list, a phylogenetic tree is produced 
from a full length multiple sequence alignment.  The multiple sequence 
alignment is produced by CLUSTAL W (Thompson, Higgins, and Gibson 1994) 
and the phylogenetic tree by Phylip (Felsenstein 1989).  Modification positions 
are starred in the CLUSTAL W multiple sequence alignment.  It is extremely 
important to note that the CLUSTAL W alignment will not necessarily match the 
Pfam domain alignments in the corresponding regions.  This can lead to an 
increase in the number of alignment columns being starred in one alignment 
versus the other.  Therefore the CLUSTAL W alignment may indicate that 
different residues are homologous to each other than those indicated by the 
Pfam domain alignments.  Note that the conservation summary table always 
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agrees with the Pfam domain alignments and not that generated by CLUSTAL 
W alignment. 
|O09185|Cricetulus griseus [Chinese hamster]           Q*SDL*SIELPL*SQE*TF*SDLWKLLPPN 
|P07193|Xenopus laevis [African clawed frog]           S*SET~GMDPPL*SQE*TF~EDLWSLLPDP 
|P67938|Bos indicus []                                 Q~AEL~NVEPPL*SQE*TF*SDLWNLLPEN 
|P67939|Bos taurus [cattle]                            Q~AEL~NVEPPL*SQE*TF*SDLWNLLPEN 
|Q29537|Canis lupus familiaris [dog]                   Q*SEL~NIDPPL*SQE*TF*SELWNLLPEN 
Figure 40:  PTM Browser Pfam domain starred alignment example. 
Note that this alignment is for the p53 transcriptional activation domain -  PF08563. 
An example of the format that results are returned to users conducting a protein 
family analysis is shown in Figure 41. 
 
Figure 41: PTM Browser conservation results panel. 
Section 5.3.2  Taxonomic comparisons 
Section 5.3.2(a)  Current workflow 
With current resources it is nearly impossible for end-users to carry out a global 
conservation analysis between species let alone taxonomic groups (e.g. 
Eukaryotes and Bacteria).  The only exception is for species that have very few 
PTM annotations – which makes manual inspection and analysis possible.  
Large scale analysis between species is likely to prove most valuable to end-
users in identifying potential new avenues of research, without the requirement 
to select a protein family of interest.    
Section 5.3.2(b)  PTM Browser workflow 
A simplified version of the PTM Browser taxonomic comparison workflow is 
shown in Figure 42.    The taxonomic workflow has been implemented in PTM 
Browser on top of a more generic workflow that enables users to compare PTM 
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annotations from two collections (or groups of annotations) that they define.  
Using the taxonomic workflow users select which species they would like to be 
present in each of the two groups (the simplest analysis would involve one 
species in each group).  In PTM Browser this workflow is able to accept any 
node from the NCBI Entrez Taxonomy, thus enabling the comparison of 
mammals and amphibians for instance.  By default PTM Browser will analyse 
the conservation of modifications between the two groups based on Pfam 
domain alignments.  Alternatively users can demand that an annotation is only 
conserved when it is found in the corresponding orthologue from the CoPaO 
dataset.  Forcing the conservation analysis to be carried out between 
orthologues, rather than inside a Pfam domain, restricts the analysis to the 30 
species present in the CoPaO dataset (and makes it impossible to carry out an 
analysis for taxonomic groups, such as mammals).  Note that when PTM 
Browser compares annotations between orthologues, Pfam domain alignments 
are still used to identify homologous residues.   
XML and SQL dumps are produced that contain the conserved PTM 
annotations.  In addition a scrollable HTML results page as well as summary 
graphs and tables are produced. 
The next section describes in more detail the generic workflow that has been 
created in PTM Browser that can be used to compare modifications between 
species. 
Section 5.3.3  Generic conservation workflow 
The generic workflow is centred on the idea of placing PTM datasets, called 
experiments, into two groups.  Users cannot currently define their own PTM 
annotation datasets directly (i.e. with annotations from their own database of 
PTMs) – although this is being considered as a future addition to the current 
workflow.  Instead users define parameters that are used to populate a PTM 
dataset with annotations from the PTMDB. 
Section 5.3.3(a)  Defining PTM datasets 
An experiment has the following six query attributes that determine which 
annotations are included in a set: PTMDB subset (PTMDBFull, PTMDBPfamA), 
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origin database (Swiss-Prot, Phospho.ELM, spPfamA, and tremblPfamA), 
taxonomic node, evidence qualifier, PTM class, and PTM type.  Note that 
spPfamA and tremblPfamA contain all those cross-annotations made to 
proteins in Swiss-Prot and TrEMBL databases, respectively. 
Figure 43 shows the PTM Browser “Add Experiment” component, which is used 
to select the desired values for each of the six search parameters an individual 
experiment contains.  All attributes are selected using the provided dropdown 
menus except for the taxonomic node.  Note that users must choose a PTM 
class before they can select a PTM type. 
To aid the user in their selection of a valid value for the species field, possible 
selectable matches in the PTMDB are displayed to the user as they type.  The 
species attribute of an experiment must contain either a valid ID or scientific 
name from the NCBI Entrez Taxonomy (NET).  The NCBI Entrez taxonomy web 
site has been embedded in PTM Browser, to allow users to search for taxa they 
would like to investigate.  PTM Browser supports the notation of a directly and 
indirectly annotated taxon.  For example H. sapiens is a directly annotated 
taxon because there are UniProtKB entries tagged with this species name.  In 
contrast Mammalia is an indirectly annotated taxon as UniProtKB does not 
contain any entries tagged with this taxon name, but rather taxa that descend 
from this node in the NCBI Entrez Taxonomy tree (e.g. M. musculus).  To 
include all annotations indirectly annotated to descendent taxa, the provided 
checkbox “Include child nodes” must be selected.  Note that PTM Browser does 
not check whether a taxon selected by a user is directly, or indirectly, annotated 
- therefore it cannot enable/disable this option automatically. 
Once all attributes have been selected the user simply clicks the plus icon, 
which inserts the experiment into the experiment browser - this is discussed 
shortly. 
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Figure 42:  PTM Browser taxonomic comparison workflow. 
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The server side component of PTM Browser creates all PTM annotation 
datasets as new MySQL tables.  To prevent the same dataset being created 
multiple times (either for the same user or different users) this component keeps 
a record of the query parameters used to create a new table.  One benefit of 
storing the datasets as MySQL tables is that PTM Browser can take advantage 
of the built-in indexing facilities of MySQL to speed up queries involving multiple 
datasets.  Note that the server side component has been programmed to 
automatically index these tables as required.   
(a) 
 
(b) (c) (d) 
 
 
 
Figure 43: (a) User interface to add experiments to the experiment browser panel. (b) Auto-completion of a directly 
annotated taxon.  (c) Auto-completion of an NCBI Entrez Taxonomy identifier. (d) Auto-completion of an indirectly 
annotated taxon. 
Section 5.3.3(b)  Grouping PTM datasets 
As previously stated this workflow requires that users place PTM datasets into 
two groups.  Requiring PTM datasets to be placed into two groups may seem 
unnecessary when only comparing the annotations of two species.  However it 
becomes useful when a user wishes to run more complex queries.  For example 
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a user may want to know which modification annotations are present in E. coli 
and either H. sapiens or M. musculus.  This is easy to accomplish with PTM 
Browser, by placing the E. coli dataset into one group and those of H. sapiens 
and M. musculus into the other.  More examples are provided throughout this 
chapter of placing multiple PTM datasets into the same group. 
When a PTM dataset is created by the user they are automatically added to the 
experiment browser component.  The experiment browser is located in the left 
panel of PTM Browser.  Figure 50 (a) shows an image of the experiment 
browser after four experiments had been created.  This component allows users 
to review the experiments they have created as well as carry out the following 
actions: grouping, deletion and application of additional constraints (which are 
described in Section 5.3.3(e)).  Left-clicking on an experiment selects it and 
activates many of the actions just described.  Figure 50 (b) and (c) demonstrate 
the process of selecting and grouping experiments.  Note that the two groups of 
experiments are highlighted in two separate colours. 
(a) 
 
(b) 
 
Figure 44: PTM Browser experiment component. (a) showing two selected experiments, (b) view after group action 
has been carried out. 
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Section 5.3.3(c)  Conservation analysis types 
This workflow supports both an intersection and complementation conservation 
analysis.  The first, intersection, can be used to return only those annotations 
that are found in both groups of PTM annotations.  The second, 
complementation, does the opposite by returning only those PTM annotations 
that are present in group one and not group two.  A limitation of the 
complementation analysis is that it must be run twice if the user wishes to know 
which annotations are unique to each group.  This requires the grouping to be 
manually inverted by the user (i.e. group one, becomes group two). 
 
Figure 45: Query selection panel.  Query mode can be selected as union, intersect and complement.  When intersect 
or complement are selected the field constraints can be selected.  When the user has entered orthologue/paralogue 
mode the user is able to select whether they wish to retrieve annotations for orthologues, paralogues or both. 
The fields that are used to identify matching annotations are controlled by the 
user.  Users can select any combination of the following fields Pfam domain, 
Pfam alignment position, PTM class, PTM type, UniProtKB accession and 
primary sequence residue number.   The final two fields (UniProtKB accession 
and residue number) are not relevant when comparing PTM datasets from 
different species.  In PTM Browser users select the conservation mode 
(intersect or completement) and fields to match against, using the “Query 
selection panel” shown in Figure 45.   
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The server side component of PTM Browser begins a taxonomic conservation 
analysis by first creating each PTM annotation dataset.  The annotations from 
each dataset are then merged into corresponding group PTM datasets 
(represented by new MySQL tables).  Following this, two new “unique value” 
MySQL tables are created, one for each group, which include all unique values 
observed for the user selected fields in the corresponding merged group table.  
For example consider the small PTM annotation dataset shown in Table 39.  If a 
user had requested an intersect between this dataset and another using the 
fields Pfam accession and Pfam alignment position – the contents of the 
corresponding “unique value” table would match that shown in Table 40.  Finally 
a third new MySQL table is created, which either contains all rows present in 
both “unique value” tables (for an intersection query) or those present in the 
group one “unique value” table not present in that for group two (for a 
complementation query).  Note that throughout this process a record is kept of 
which new tables have been created and the arguments that have been used 
(for example the “unique value” tables) – therefore were possible PTM Browser 
will use existing tables to process a user conservation query. 
Accession Start PTM Class PTM Type 
Pfam 
Accession 
Aln 
Position 
P05813 82 Methylation S-methylcysteine PF00030 120 
P07315 23 Methylation S-methylcysteine PF00030 39 
Q5VXM1 348 Methylation Methylhistidine PF00431 689 
Q9BY79 389 Methylation Methylhistidine PF00431 689 
O75367 18 Methylation N6-methyllysine PF00125 3 
P62807 47 Methylation N6-methyllysine PF00125 19 
P58876 47 Methylation N6-methyllysine PF00125 19 
Table 39: Example annotation set for an experiment. 
Pfam 
Accession 
Aln 
Position 
PF00030 120 
PF00030 39 
PF00431 689 
PF00125 3 
PF00125 19 
Table 40: List of the unique combinations of the fields Pfam Accession and Aln Position observed in the annotation 
set shown in Table 39. 
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Section 5.3.3(d)  Results 
The workflow returns the list of “unique values” that either matched (intersect) or 
did not (complement); this is equivalent to the third conservation table described 
in the previous section.   The workflow has been designed so that users can 
request a list of all the raw annotations (from the merged group tables) that 
correspond to the entries in the “unique value” table.  The PTM Browser client 
side component displays these annotations in the format shown in Figure 46.  
Note that users can also request only those annotations that match specific 
rows in the “unique value” table.  In addition all annotation result sets are 
automatically converted into SQL and XML dumps. 
The server side component of PTM Browser automatically generates summary 
statistics and graphs.  The summary tables describe the degree of conservation 
between the two groups by the number of sites, proteins and domains – 
grouped by PTM class.  Note that the summary graphs are produced as SVG 
(Support Vector Graphic) files from the summary tables.  The summary tables 
are returned in HTML and Excel format.  An example summary table for an 
intersection experiment is shown in Figure 47 and an example graph is shown 
in Figure 48. 
It was considered likely that users might want to search for particulary proteins 
in the returned intersect or complement result sets.  The “accession entry” box 
(shown in Figure 38) can be used for this purpose – by entering the accession 
list and selecting “Constraint current result set”. 
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(a) 
 
(b) 
 
Figure 46:  (a) A complement has been performed between Homo sapiens Phosphorylation annotations and those of 
Mus musculus.  The intersection fields Pfam accession and Pfam alignment column have been selected.  The Homo 
sapiens annotations were placed into group one.  Therefore the shown Pfam domain positions have at least one 
phosphorylation annotation in the Homo sapiens phosphorylation annotation set and none in the Mus musculus set.  
(b) The expand button has been pressed on the panel shown in (b) which displays those annotations that are 
connected to those complement/intersection rows that have their checkbox ticked.   
 
Figure 47 PTM Browser example of a summary of an intersection experiment between two species. 
 
 
 
Figure 48: PTM Browser example intersection graph – shows the percentage of each modification in each group that intersects with annotations in the other group.  The group number is 
appended to each PTM class – to show data for each group
150 
 
Section 5.3.3(e)  Constraints 
PTM Browser allows for one experiment to be used as a constraint upon the 
annotations retrieved for another.  The constraint can be setup to exclude or 
restrict the annotations in the “real experiment” that match those in the 
“constraint experiment”.  Multiple constraints are allowed for each experiment.  
No attempt is made by PTM Browser to prevent overlapping conflicting 
constraints from being applied to the same experiment (i.e. an attempt to both 
exclude and restrict the same annotation).  Conflicts are instead resolved on the 
server by allowing exclude constraints to override restrictions. 
The constraint includes a list of user-chosen fields that should be used to 
identify matching annotations.  Users can select any combination of the 
following fields: UniProtKB accession, residue number, Pfam accession, Pfam 
alignment column, PTM class and PTM type.  Matching annotations are 
identified using the same technique discussed in Section 5.3.3(c) 
There are two ways to apply constraints to experiments: i) as an intragroup 
constraint using existing experiments, and ii) by creating a new constraint that is 
applied to the selected experiments.   
The first method allows for one experiment, which is part of a group, to be 
applied as a constraint against all the other members.  Intragroup constraints 
can be applied by checking the required restrict or exclude checkbox found next 
to each experiment in the experiment browser (as shown in Figure 44).   
Alternatively a new experiment can be directly applied as a constraint from the 
“Add experiment” panel to any experiments that are selected in the experiment 
browser.  The “Add as constraint” checkbox must be ticked before the 
experiment is added for it to be applied as a constraint.  Multiple constraints can 
be applied to each experiment and are viewed by simply selecting a single 
experiment in the experiment browser (see Figure 49).  These constraints 
default to identifying matching annotations simply by the UniProtKB accession 
field.  This can be changed with the procedure discussed below. 
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Figure 49: Experiment browser showing one selected experiment and its associated constraint. 
The fields which are used to identify matching annotations can be changed by 
checking the exclude or restrict checkboxes next to each experiment.  Checking 
either box displays the dialog box shown in Figure 50.  This dialog box allows 
the user to select which fields they would like to use to identify matching rows 
between experiments.  Note that, as already discussed, the PTMDBFull 
database does not contain any Pfam annotations.  Therefore if either the 
constraint or real experiment has been set to use this database the Pfam 
accession and Pfam alignment column fields are not selectable. 
 
Figure 50: Dialog box presented to the user when an exclude or restrict constraint checkbox is ticked.  This dialog box 
allows the user to select the fields over which matching annotations should be identified. 
Example constraint 
Exclude and restrict constraints are synonymous with the mechanism used to 
carry out intersect and complement queries – as discussed later.  What follows 
is therefore only a brief account of how these constraints are applied.   
A user wishes to include only those methylation sites from M. musculus that are 
also methylated in H. sapiens in a single experiment.  They have also decided 
that they are going to identify matching sites based on Pfam accession and 
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Pfam alignment column position.  First they create the M. musculus/methylation 
experiment.  Next they select this experiment in the experiment browser and 
check the “Add as constraint” checkbox found on the “Add experiment” panel.  
They now enter all the values into the “Add experiment” panel for the H. 
sapiens/methylation experiment and click add.  Finally they check the “restrict” 
checkbox beside the new experiment and select the two fields “Pfam accession” 
and “Pfam alignment column”. 
Section 5.3.3(f)  Restricting to orthologues 
This workflow also allows users to request that annotations are matched only 
between orthologues.  PTM Browser requires that users decide at the start of 
their query if they would like to run an orthologue based query.  This is to allow 
the client software to make sure that only valid taxonomic comparisons are 
requested (i.e. between species in the CoPaO dataset). 
The user starts by entering an experiment for the first species they wish to 
compare with the “Add experiment” panel.  Only those species that have been 
compared with another using the CoPaO program are suggested to the user.  
After adding this experiment to the experiment browser, it is automatically 
added to group one.  The user is then immediately prompted to enter the 
experiment for their second species (with which they want to compare the first).  
Only those species which have been compared using the CoPaO program with 
the species selected for the first experiment will be suggested to the user.  
Once this experiment is added, it is automatically added to group two.   
Now that two experiments have been created and PTM Browser knows which 
species the user wishes to compare further experiments can be added to each 
group.  To add another experiment to a group an experiment in the destination 
group must first be selected.  Once it is selected the species field, present on 
the “Add experiment” panel, is greyed out and set to the value of the species 
field of the selected experiment.  Clicking “add” at this point will insert the new 
experiment into the destination group.  Note that intragroup constraints function 
as previously described.  New experiments can be added directly as constraints 
to those experiments selected in the experiment browser as described before 
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but when the “Add as constraint” checkbox is ticked you can choose any 
species (including indirectly annotated taxa). 
As an additional option, users can select whether they wish to compare 
orthologues, paralogues or both (with the first and last options being most likely) 
using the accordion shown in Figure 45.  In addition the paralogues that are 
included in the query can be restricted based on the InParanoid confidence 
values (See Section 3.3.1). 
Conceptually intersects and complements in CoPaO-mode function by 
automatically adding the field in the PTMDB that stores the CoPaO cluster, to 
which a protein belongs, to the list of fields used to identify matching 
annotations (the constraint fields set by the user). 
Whenever a cluster identifier is presented to a user, these can be clicked on to 
show further information regarding the conservation and membership of the 
cluster (see Figure 51).  
 (a) 
 
(b) 
 
Figure 51: Viewing a CoPaO cluster. (a) Cluster identifiers are always shown as hyperlinks (b) Clicking on a cluster 
identifier displays: the members of the cluster, associated class, bit score and confidence value where the class is a 
paralogue. 
Section 5.3.3(g)  Constraining cross-annotations 
It was previously shown that the cross-annotation dataset appears to contain a 
large number of annotations that are highly unlikely to be valid, based on both 
the number of inter-super-kingdom cross-annotations that have been observed 
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and the propensity of low scoring alignments.  Therefore PTM Browser has 
been designed with the ability for the cross-annotations to be constrained based 
on window size and identity count (see Section 4.4.3(a).  These constraints can 
be entered using the dropdown menus shown in Figure 45. 
PTM Browser will select all cross-annotation by default (including inter-
superkingdom annotations).  This decision was taken as it is very easy for users 
to constrain cross-annotations to only those with matching sites in the species 
of their choice.  For example if an experiment contains all H. sapiens 
annotations (from all databases including those belonging to spPfamA and 
tremblPfamA cross-annotation sets) a constraint can be added that forces the 
removal of annotations that do not match at least one (from the Swiss-Prot or 
Phospho.ELM sets) belonging to a Eukaryote species (i.e. all those Eukaryote 
annotations that are not derived from the cross-annotated process described in 
Chapter 4). 
Section 5.4  Web service 
Bioinformatics developers have a great history of integrating web services into 
their applications and databases.  Most of the major databases currently used 
all provide some form of programmatic access to their resources.  For example 
the KEGG (KEGG 2010) and NCBI Entrez (NCBI-Entrez 2010) projects both 
provide access via the Simple Object Access Protocol (SOAP) and UniProtKB 
provides access via Representational State Transfer (REST).  Systems have 
also been designed to bridge the gap between different bioinformatics web 
services – including the Distributed Annotation System (DAS) (see 
http://www.biodas.org)  (Dowell et al. 2001) and BioMoby project (Wilkinson and 
Links 2002).   
As mentioned previously the PTM Browser tool is composed of a server side 
and client side component.  The server side component exposes a web service 
API for the retrieval and analysis of PTMs in the PTMDB.  The client side 
component provides a web application for users to interact with this server side 
component. 
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A set of web services has been integrated into the PTM Browser tool that 
should allow bioinformaticians to access almost all of the data with which a user 
is usually provided when they run queries manually.  This API simply involves 
sending POST requests to the server, which responds with the results in an 
XML format.  Note that this web service currently requires the use of cookies, as 
session state has to be stored for some of the queries.  To allow 
bioinformaticians to get started quickly with the PTM Browser API, example 
code is shown whenever a query is made using the PTM Browser client.  The 
API calls can simply be shown by clicking on the “Show API” buttons that 
appear when queries have been made – see Figure 52.  The full API is 
documented at the following URL <http://wiki.ptmbrowser.org/index.php/API>.
 
 
  
 
(a) 
 
(b) 
 
Figure 52: API calls that can be used to generate the currently displayed results can always be shown by clicking the “Show API call” button.  (a) Basic URL for the currently displayed results – if 
the URL exceeds the limit for GET requests users will need to POST the query parameters.  (b)  An example Perl script that can be used to retrieve the currently displayed – cookie support is 
included as some PTM Browser actions require state to be stored on the server  
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Section 5.5  Discussion 
A tool has been presented that allows users to perform conservation and co-
occurrence analyses that were previously almost impossible for non-
bioinformaticians to carry out.   It should be pointed out that PHOSIDA is able to 
carry out a similar analysis (using a similar orthology pipeline) for 
phosphorylation sites (Gnad et al. 2007).  In addition UniProtKB is able to show 
modification sites when multiple sequence alignments are performed between 
entries in the said database.  This tool should prove to be extremely useful for 
scientists that work on species that have not had the bulk of their proteins 
incorporated into the Swiss-Prot database (and hence have very few 
modification annotations), by virtue of the cross-annotations that have been 
made into the TrEMBL database. 
PTM Browser had initially been designed around the concept that one residue 
in a protein could not be annotated in the PfamA boundary of multiple domain 
assignments.  The presence of overlapping domain boundaries was only 
discovered late in the development of PTM Browser where they manifested 
themselves as inconsistencies between the results of intersect and complement 
queries on identical experiments.  It was for this reason that the previously 
mentioned procedure to resolve each PTM annotation to a single PfamA 
domain was implemented.  However there is likely to be some biologically 
significant information being lost with regards to, for instance, one domain being 
modified by virtue of a nested domain.   It will therefore be important for future 
editions of PTM Browser to be able to correctly handle and incorporate such 
overlapping domain assignments. 
There is a great deal of scope for PTM Browser to be further developed – many 
of these potential features will be discussed in Chapter 7 – the general 
discussion. 
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Chapter 6  
 
PTM Browser in action 
Section 6.1  Summary 
In this chapter an analysis is presented on the conservation of PTMs, which has 
been carried out using the PTM Browser tool.  An example of using PTM 
Browser to analyse the conservation of modifications between protein family 
members is first presented.  This analysis looks at the conservation of 
modifications between members of the p53 tumour suppressor family.  
Members of this family are found in many distantly related eukaryotes, from H. 
sapiens to N. vectensis.  p53 undergoes phosphorylation, methylation, 
acetylation, ubiquitination and sumoylation.  This analysis focused on 
phosphorylation, as all other PTM class annotations fell out of conserved Pfam 
domains.  The majority of bony fish and their descendants possess three p53 
paralogues, p73, p63 and p53.  The analysis presented in this chapter 
demonstrated that a core set of phosphorylation sites are conserved across all 
family members.  In addition p53 orthologues appear to possess additional 
phosphorylation sites not found in the other two paralogues.  Following this 
analysis, data is described regarding the conservation of modifications between 
all three super-kingdoms.  According to this analysis only six modification sites 
are conserved across all three super-kingdoms.  An analysis into the 
conservation of proteins between eukaryote species based on the PTM classes 
that they have annotations for is presented next.  The results of this analysis 
showed that proteins with particular modifications appear to be more highly 
conserved than the average conservation observed between species.  For 
example 62.48% of H. sapiens proteins were found to have an orthologue in M. 
musculus, compared to 77.11% of H. sapiens phosphoproteins.  This chapter 
concludes with an analysis that focuses specifically on the conservation of 
modifications between H. sapiens and M. musculus. 
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Section 6.2  Protein family analysis – p53 
In this section the following question is asked:  Are phosphorylation sites 
conserved across p53 protein family members and can this type of analysis 
reveal potential novel phosphorylation sites as yet unverified?  Such an analysis 
might for instance suggest that phosphorylation sites that were previously 
thought to be essential for function may not be, as they are absent in either a 
close or distant relative. 
The analysis presented makes extensive use of the PTM Browser tool 
discussed previously (Chapter 4).  As part of this analysis the strengths and 
weaknesses of the PTM Browser tool have become apparent, which may be 
addressed in the future.   
The apoptosis control protein, p53, is regulated by multiple post-translational 
modifications, including phosphorylation, acetylation and ubiquitination (Brooks 
and Gu 2003).  It has even been shown to include methylation (Chuikov et al. 
2004), sumoylation (Rodriguez et al. 1999) and neddylation (Xirodimas et al. 
2004).  The p53 protein is classified as a tumour suppressor, as its loss of 
function, by mutation or deletion, results in tumorigenesis (Brooks and Gu 
2003).  Phosphorylation and acetylation of p53 are linked to its activation, and 
subsequent cell cycle arrest, in order to permit DNA-damage repair pathways to 
correct errors in DNA replication (Brooks and Gu 2003).  Whereas cell cycle 
progression is associated with p53 ubiquitination (Brooks and Gu 2003).  
Phosphorylation in response to DNA damage is mediated by serine/threonine-
specific protein kinases: Chk1 and Chk2 (check-point proteins) (Shieh et al. 
2000).  Ubiquitination of p53, to promote its degradation, is mediated by Mdm2, 
a specific E3 ubiquitin ligase (Honda, Tanaka, and Yasuda 1997). 
Members of the p53 family have been identified in a wide range of eukaryotes 
from H. sapiens, to C. elegans and N. vectensis (Pankow and Bamberger 
2007).  Humans possess three paralogues from this family, p63, p53 and p73 
(Belyi et al. 2010).  The sea anemone (N. vectensis) possesses a single p53 
family gene which most closely resembles a p63/p73-like gene (Pankow and 
Bamberger 2007).  Current evidence suggests that the p53 ancestral gene was 
duplicated in the early vertebrate lineage; resulting in a p53-like and p63/p73-
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like gene (Belyi et al. 2010).  The bony fish are the oldest group that appear to 
possess all three paralogues, p63, p53 and p73 (Belyi et al. 2010).  This 
suggests that a second duplication event occurred during the evolution of bony 
fish (Belyi et al. 2010). 
p53, p63 and p73 all contain a transcriptional activation domain (TA), DNA 
binding domain and an oligomerization domain (Arrowsmith 1999) (See Figure 
53 for the arrangement).  In addition p63 and p73 contain an extra c-terminal 
SAM domain (Sterile alpha motif domain) (Arrowsmith 1999).  
 
(a) 
 
(b) 
Figure 53: Domain structure of an idealised p53 (a) and p63 (b) protein.  TA=Transcriptional activation domain, DNA 
Binding=DNA binding domain, Oligo=Oligomerization domain, SAM=Sterile alpha motif.  Images produced using the 
mydomains tool http://www.expasy.ch/cgi-bin/prosite/mydomains/. 
The p53 family members were identified in the PTMDB sequence space by 
gene name and orthologous relationships to previously identified p53 family 
members in the CoPaO dataset (see Chapter 3).  Those proteins that were not 
subjected to the cross-annotation procedure (see Chapter 4) were removed 
from the list of p53 family members identified.  In total 42 proteins were 
identified originating from 32 different species, of these 31 proteins were 
identified as p53, six as p63 and four as p73.  The final protein identified in this 
way belonged to N. vectensis, which, as mentioned previously, has been 
characterised as a p63/p73-like protein.  See Appendix 1 for the list of 
corresponding UniProtKB accessions.  The PTM Browser tool was then used to 
identify which modification positions were conserved amongst the p53 family 
proteins.  The automatically generated phylogenetic tree that PTM Browser 
creates is shown in Figure 54.   This tree clusters the p63 and p73 genes 
together, and separates the p53 proteins into those from bony fish and those 
from mammals.  Table 41 shows which PTM sites are present and which are 
conserved in the list of p53 family members.  The PTM sites identified lie in two 
Pfam domains PF00870 (DNA binding domain) and PF08563 (TA domain).  
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The conservation of modifications across each of these domains will now be 
discussed separately. 
 
 
 
 
Figure 54: Phylogenetic tree showing one possible set of ancestral relationships between those proteins in the PTMDB identified as being part of the p53 family (p63, p53 and p73).  This tree 
was produced by the PTM Browser tool using the Phylip program protpars; graphical version of this tree was produced by the FigTree program (<http://tree.bio.ed.ac.uk/software/figtree/>).  
Members of this family were identified by gene name and orthologous relationships in the CoPaO dataset.   
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Pfam accession
Alignment position 4 171 1 4 10 13 15
p63/p73|A7SFL1|Nematostella vectensis [starlet sea anemone] 
p63|Q8JHZ6|Danio rerio [zebrafish]
p63|Q98SW0|Xenopus laevis [African clawed frog]
p63|Q9DEC7|Gallus gallus [chicken]
p63|Q9H3D4|Homo sapiens [human] 
p63|Q9JJP6|Rattus norvegicus [Norway rat]
p63|O88898|Mus musculus [house mouse]
p73|Q5KQU6|Danio rerio [zebrafish]  
p73|Q9JJP2|Mus musculus [house mouse] 
p73|Q9XSK8|Chlorocebus aethiops [African green monkey]
p73|O15350|Homo sapiens [human]  
|Q92143|Xiphophorus maculatus [southern platyfish]
|O57538|Xiphophorus hellerii [green swordtail]
|P79820|Oryzias latipes [Japanese medaka]
|Q4SF81|Tetraodon nigroviridis [spotted green pufferfish]
|Q9W679|Tetraodon miurus []  
|O12946|Platichthys flesus [European flounder]  
|P25035|Oncorhynchus mykiss [rainbow trout]
|O93379|Ictalurus punctatus [channel catfish]
|Q9W678|Barbus barbus [barbel]  
|P79734|Danio rerio [zebrafish]  
|P07193|Xenopus laevis [African clawed frog] 
|P10360|Gallus gallus [chicken]
|Q9WUR6|Cavia porcellus [domestic guinea pig]
|O09185|Cricetulus griseus [Chinese hamster] 
|Q00366|Mesocricetus auratus [golden hamster]
|P10361|Rattus norvegicus [Norway rat]
|Q9TUB2|Sus scrofa [pig] 
|Q8SPZ3|Delphinapterus leucas [beluga whale]
|P51664|Ovis aries [sheep] 
|P67939|Bos taurus [cattle]
|P67938|Bos indicus [] 
|Q29537|Canis lupus familiaris [dog] 
|P41685|Felis catus [domestic cat]
|Q9TTA1|Tupaia belangeri [northern tree shrew]
|P04637|Homo sapiens [human] 
|P13481|Chlorocebus aethiops [African green monkey] 
|P61260|Macaca fuscata fuscata [Japanese macaque]
|P56423|Macaca fascicularis [crab-eating macaque] 
|P56424|Macaca mulatta [rhesus monkey]
|Q95330|Oryctolagus cuniculus [rabbit]
|O36006|Marmota monax [woodchuck] 
PF00870 PF08563
 
Table 41: The conservation of PTMs in the p53 TA and DNA binding domains.  Table was generated from the Excel 
file produced by the PTM Browser tool. 
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Section 6.2.1  p53 DNA binding domain (PF00870) 
All members of the p53 family identified in the PTMDB dataset contain the p53 
DNA binding domain (PF00870).  The PTMDB contains annotations for two 
positions which are modified in this domain: 99(4) and 215(171).   
Serine 99(4) is found in all p53 homologues except those belonging to the bony 
fish (with the exception of rainbow trout).  Figure 55 shows an alignment of the 
region surrounding this residue.  However despite being present in the Swiss-
Prot database, and therefore having the potential for PTM annotations, none of 
the p63/p73 homolgues have a phosphorylation annotation at this position. The 
only PTM annotation for either of these proteins in the Swiss-Prot database is 
for a phosphorylation on Tyr-99 of the human p73 (O15350). 
The cross-annotation procedure has however created annotations at this 
position for this group of proteins in the PTMDB.  The alignment shows that the 
p63/p73 sites are more similar to each other than they are to sites from p53 
homologues.  No literature references could be found that referred to the 
phosphorylation of this position for p63/p73 homologues.  The PhosphoSite 
(Hornbeck et al. 2004) database (<http://www.phosphosite.org>) contains 
phosphorylation annotations for the Human, Mouse, and Rat p63/p73 
homologues but not for this particular position.   
The PhosphoMotif_finder (Amanchy et al. 2007) tool (<http://www.hprd.org/ 
PhosphoMotif_finder>) was used to identify potential phosphorylation sites in 
the Human p63 /p73 homologues; based on known kinase recognition motifs.  
This tool matched the p63 and p73 residue 99(4) site to that recognised by 
casein kinase II, the p73 site was also matched to that recognised by pyruvate 
dehydrogenase kinase.  In comparison the same site from Human p53 was 
found to match the motifs of the following enzymes: DNA dependent kinase, 
ATM kinase, PKA kinase, and PKC kinase.  There is some evidence that the 
Human p53 is phosphorylated by the ATM kinase (Matsuoka et al. 2007).  
However, a literature search revealed no evidence that p63/p73 have been 
observed to be phosphorylated by casein kinase II.  In contrast casein kinase II 
has been reported to be able to phosphorylate p53 (Filhol et al. 1992). 
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p63-p73|A7SFL1|Nematostella vectensis [starlet sea anemone]      VIAP*SSDEVPGEYSF 
p63|O88898|Mus musculus [house mouse]                            PAIP*SNTDYPGPHSF 
p63|Q9H3D4|Homo sapiens [human]                                  PAIP*SNTDYPGPHSF 
p63|Q8JHZ6|Danio rerio [zebrafish]                               PAIP*SNTDYAGPHTF 
p63|Q98SW0|Xenopus laevis [African clawed frog]                  PAIP*SNTDYPGPHSF 
p63|Q9DEC7|Gallus gallus [chicken]                               PAIP*SNTDYPGPHSF 
p63|Q9JJP6|Rattus norvegicus [Norway rat]                        PAIP*SNTDYPGPHSF 
p73|Q9XSK8|Chlorocebus aethiops [African green monkey]           PVIP*SNTDYPGPHHF 
p73|O15350|Homo sapiens [human]                                  PVIP*SNTDYPGPHHF 
p73|Q5KQU6|Danio rerio [zebrafish]                               PAIP*SNTDYPGPHNF 
p73|Q9JJP2|Mus musculus [house mouse]                            PVIP*SNTDYPGPHHF 
p53|Q9WUR6|Cavia porcellus [domestic guinea pig]                 SSVP*SHKPYRGSYGF 
p53|P04637|Homo sapiens [human]                                  SSVP*SQKTYQGSYGF 
p53|Q9TTA1|Tupaia belangeri [northern tree shrew]                SSVP*SQKTYQGSYGF 
p53|P13481|Chlorocebus aethiops [African green monkey]           SSVP*SQKTYHGSYGF 
p53|P56423|Macaca fascicularis [crab-eating macaque]             SSVP*SQKTYHGSYGF 
p53|P56424|Macaca mulatta [rhesus monkey]                        SSVP*SQKTYHGSYGF 
p53|P61260|Macaca fuscata fuscata [Japanese macaque]             SSVP*SQKTYHGSYGF 
p53|P10361|Rattus norvegicus [Norway rat]                        SSVP*SQKTYQGNYGF 
p53|O36006|Marmota monax [woodchuck]                             SSVP*SQNTYPGVYGF 
p53|Q00366|Mesocricetus auratus [golden hamster]                 SSVP*SYKTYQGDYGF 
p53|O09185|Cricetulus griseus [Chinese hamster]                  SSVP*SYKTYQGDYGF 
p53|Q9TUB2|Sus scrofa [pig]                                      SFVP*SQKTYPGSYDF 
p53|Q8SPZ3|Delphinapterus leucas [beluga whale]                  SFVP*SQKTYPGSYGF 
p53|Q29537|Canis lupus familiaris [dog]                          SSVP*SPKTYPGTYGF 
p53|P41685|Felis catus [domestic cat]                            SFVP*SQKTYPGAYGF 
p53|Q95330|Oryctolagus cuniculus [rabbit]                        SSVP*SQKTYHGNYGF 
p53|P51664|Ovis aries [sheep]                                    SFVP*SQKTYPGNYGF 
p53|P67938|Bos indicus []                                        SFVP*SQKTYPGNYGF 
p53|P67939|Bos taurus [cattle]                                   SFVP*SQKTYPGNYGF 
p53|P07193|Xenopus laevis [African clawed frog]                  CAVP*STDDYAGKYGL 
p53|P10360|Gallus gallus [chicken]                               PVVP*STEDYGGDFDF 
p53|P25035|Oncorhynchus mykiss [rainbow trout]                   STVP*TTSDYPGALGF 
p53|O93379|Ictalurus punctatus [channel catfish]                 STVP~VTSDYPGLLNF 
p53|O12946|Platichthys flesus [European flounder]                STVP~VVTDYPGEYGF 
p53|O57538|Xiphophorus hellerii [green swordtail]                PTVP~AISNYAGEHGF 
p53|P79734|Danio rerio [zebrafish]                               STVP~ETSDYPGDHGF 
p53|Q92143|Xiphophorus maculatus [southern platyfish]            PTVP~AISNYAGEHGF 
p53|Q9W678|Barbus barbus [barbel]                                ASVP~VATDYPGEHGF 
p53|Q9W679|Tetraodon miurus []                                   PTVP~VTTDYPGEYGF 
p53|Q4SF81|Tetraodon nigroviridis [spotted green pufferfish]     PTVP~VTTDHPGEYDF 
p53|P79820|Oryzias latipes [Japanese medaka]                     TTVP~VTTDYPGSYEL 
Figure 55:  Alignment of Ser-99(4) region from various members of the p53 family present in the PTMDB.  Alignment 
was generated automatically by the PTM Browser tool from the alignment extracted from Pfam.  Note that this 
alignment contains a subset of those sequences present in the original Pfam alignment of this domain. Under this 
circumstance it’s possible for an individual alignment column to be a gap column for all sequences in the alignment 
subset; such columns have been removed from this alignment. 
Serine 215(171) is present in a highly conserved region of the p53 DNA binding 
domain (see Figure 56), none of the p53 family aligned are missing this residue.   
This residue has been shown to be phosphorylated by the Aurora-A 
serine/threonine kinase, with homologues having been identified in many 
different species (Liu et al. 2004).  Phosphorylation by Aurora-A prevents p53 
from binding to DNA and is linked to the prevention of apoptosis after DNA 
damage (Liu et al. 2004). 
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P63-p73|A7SFL1|Nematostella vectensis [starlet sea anemone]      ERCAQSGRL*SVKIPFHV 
p63|O88898|Mus musculus [house mouse]                            VEDPITGRQ*SVLVPYEP 
p63|Q9H3D4|Homo sapiens [human]                                  VEDPITGRQ*SVLVPYEP 
p63|Q8JHZ6|Danio rerio [zebrafish]                               VEDSITGRQ*SVLVPYEP 
p63|Q98SW0|Xenopus laevis [African clawed frog]                  VEDPITGRQ*SVLVPYEP 
p63|Q9DEC7|Gallus gallus [chicken]                               VEDPITGRQ*SVLVPYEP 
p63|Q9JJP6|Rattus norvegicus [Norway rat]                        VEDPITGRQ*SVLVPYEP 
p73|Q9XSK8|Chlorocebus aethiops [African green monkey]           VDDPVTGRQ*SVVVPYEP 
p73|O15350|Homo sapiens [human]                                  VDDPVTGRQ*SVVVPYEP 
p73|Q5KQU6|Danio rerio [zebrafish]                               VDDPVTGRQ*SVLVPYES 
p73|Q9JJP2|Mus musculus [house mouse]                            VDDPVTGRQ*SVVVPYEP 
p53|Q9WUR6|Cavia porcellus [domestic guinea pig]                 VDDRTTFRH*SVVVPYEP 
p53|P04637|Homo sapiens [human]                                  LDDRNTFRH*SVVVPYEP 
p53|Q9TTA1|Tupaia belangeri [northern tree shrew]                SDDRNTFRH*SVVVPYEP 
p53|P13481|Chlorocebus aethiops [African green monkey]           SDDRNTFRH*SVVVPYEP 
p53|P56423|Macaca fascicularis [crab-eating macaque]             SDDRNTFRH*SVVVPYEP 
p53|P56424|Macaca mulatta [rhesus monkey]                        SDDRNTFRH*SVVVPYEP 
p53|P61260|Macaca fuscata fuscata [Japanese macaque]             SDDRNTFRH*SVVVPYEP 
p53|P10361|Rattus norvegicus [Norway rat]                        LDDRQTFRH*SVVVPYEP 
p53|O36006|Marmota monax [woodchuck]                             LDDRNTFRH*SVVVPYEP 
p53|Q00366|Mesocricetus auratus [golden hamster]                 LDDKQTFRH*SVVVPYEP 
p53|O09185|Cricetulus griseus [Chinese hamster]                  LDDKQTFRH*SVVVPYEP 
p53|Q9TUB2|Sus scrofa [pig]                                      LDDRNTFRH*SVVVPYEP 
p53|Q8SPZ3|Delphinapterus leucas [beluga whale]                  LDDRNTFRH*SVVVPYEP 
p53|Q29537|Canis lupus familiaris [dog]                          LDDRNTFRH*SVVVPYEP 
p53|P41685|Felis catus [domestic cat]                            LDDRNTFRH*SVVVPYEP 
p53|Q95330|Oryctolagus cuniculus [rabbit]                        LDDRNTFRH*SVVVPYEP 
p53|P51664|Ovis aries [sheep]                                    FDDRNTFRH*SVVVPYES 
p53|P67938|Bos indicus []                                        LDDRNTFRH*SVVVPYES 
p53|P67939|Bos taurus [cattle]                                   LDDRNTFRH*SVVVPYES 
p53|P07193|Xenopus laevis [African clawed frog]                  MEDVNSGRH*SVCVPYEG 
p53|P10360|Gallus gallus [chicken]                               HDDETTKRH*SVVVPYEP 
p53|P25035|Oncorhynchus mykiss [rainbow trout]                   MEDGNTLRH*SVLVPYEP 
p53|O93379|Ictalurus punctatus [channel catfish]                 QEDGNTQAH*SVVVPYEP 
p53|O12946|Platichthys flesus [European flounder]                FEDPHTKRQ*SVTVPYEP 
p53|O57538|Xiphophorus hellerii [green swordtail]                FEDPNTRRH*SVTVPYER 
p53|P79734|Danio rerio [zebrafish]                               REDNITLRH*SVFVPYEA 
p53|Q92143|Xiphophorus maculatus [southern platyfish]            FEDPNTRRH*SVTVPYER 
p53|Q9W678|Barbus barbus [barbel]                                REDDVNSRH*SVVVPYEV 
p53|Q9W679|Tetraodon miurus []                                   FEHPHTKRQ*SVTVPYEP 
p53|Q4SF81|Tetraodon nigroviridis [spotted green pufferfish]     FEDPHTKRQ*SVTVPYEP 
p53|P79820|Oryzias latipes [Japanese medaka]                     FEDPYTKRQ*SVTVPYEP 
Figure 56: Alignment of Ser-215(171) region from various members of the p53 family present in the PTMDB.  
Alignment was generated automatically by the PTM Browser tool from the alignment extracted from Pfam.  Note 
that this alignment contains a subset of those sequences present in the original Pfam alignment of this domain. 
Under this circumstance it’s possible for an individual alignment column to be a gap column for all sequences in the 
alignment subset; such columns have been removed from this alignment. 
Section 6.2.2  p53 Transcriptional activation domain 
(PF08563) 
Of the 31 p53 homologues identified in the PTMDB sequence space 25 are 
annotated with the Pfam domain PF08563 (p53 TA domain).  Five of the p53 
homologues that lack this domain annotation are fish species and the final 
protein belongs to chicken.  None of the p63 or p73 homologues have Pfam 
annotations for this domain, however it has been widely reported that both p63 
and p73 contain TA domains.  The Pfam dataset incorporated into the PTMDB 
was therefore manually interrogated to check for PF08563 annotations on the 
six p53 homologues and all of the p63 and p73 proteins - no annotations were 
found.  To check the integrity of the data incorporated into the PTMDB the Pfam 
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database was searched using the following web site 
<http://pfam.sanger.ac.uk/>, which confirmed the absence of PF08563 
annotations on these proteins in the Pfam database.  The CLUSTAL W 
alignment produced by the PTM Browser tool for the p53 family proteins was 
manually checked for obvious signs of homology between the p63/p73 and the 
p53 proteins in the region assigned to the PF08563 domain.  Based on the 
alignment the p63/p73 TA region appears to be poorly conserved with that of 
the p53 proteins.  However residues surrounding known p53 phosphorylation 
sites do appear to show evidence of conservation, although no attempt has 
been made to quantify and validate this. 
Table 41 shows that all those p53 homologues which have an annotation for 
this domain have at least one PTM in the PTMDB.  The alignment shown in 
Figure 57, produced by PTM Browser, highlights the modification sites located 
in this domain.  Five residues have modification annotations, which correspond 
to the following positions in the Human p53 homologue: 6(1), 9(4), 15(10), 
18(13) and 20(15). 
The residues at positions 9(4), 15(10) and 18(13) have Swiss-Prot 
phosphorylation annotations to many p53 homologues (including Human).  Prior 
to the cross-annotation procedure only the Rat p53 homologue (P10361) had a 
phosphorylation annotation for 6(1), which was imported from the Phospho.ELM 
database (low-throughput evidence qualifier).  
The cross-annotation procedure transferred this single annotation to the 
following species Human, African green monkey, crab-eating macaque, 
Japanese macaque, rhesus monkey, northern tree shrew, golden hamster, 
Chinese hamster, woodchuck, dog, pig, domestic guinea pig and rabbit.  The 
Phospho.ELM website associates this site in the Rat protein to the Casein 
kinase I motif.  To add further validation to the transferred annotations these 
sites were searched for kinase phosphorylation site motifs using the 
PhosphoMotif_finder tool. The same Casein kinase I motif was identified at this 
position in all but the dog and pig sites.  Note that the following five mammalian 
species are missing a phosphorylation compatible residue at this position, 
sheep, cow (both B. taurus and Bos indicus), beluga whale and cat.  The 
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African clawed frog was the most distantly related species to Human that had 
both a cross-annotation and a match to the casein kinase I motif.  All of the fish 
homologues were also lacking a phosphorylation compatible residue at this 
position. 
|P04637|Homo sapiens [human]                              Q*SDP*SVEPPL*SQE*TF*SDLWKLLPEN 
|P13481|Chlorocebus aethiops [African green monkey]       Q*SDP*SIEPPL*SQE*TF*SDLWKLLPEN 
|P56423|Macaca fascicularis [crab-eating macaque]         Q*SDP*SIEPPL*SQE*TF*SDLWKLLPEN 
|P61260|Macaca fuscata fuscata [Japanese macaque]         Q*SDP*SIEPPL*SQE*TF*SDLWKLLPEN 
|P56424|Macaca mulatta [rhesus monkey]                    Q*SDP*SIEPPL*SQE*TF*SDLWKLLPEN 
|Q9TTA1|Tupaia belangeri [northern tree shrew]            Q*SDP*SVEPPL*SQE*TF*SDLWKLLPEN 
|Q00366|Mesocricetus auratus [golden hamster]             Q*SDL*SIELPL*SQE*TF*SDLWKLLPPN 
|O09185|Cricetulus griseus [Chinese hamster]              Q*SDL*SIELPL*SQE*TF*SDLWKLLPPN 
|O36006|Marmota monax [woodchuck]                         Q*SDL*SIEPPL*SQE*TF*SDLWNLLPEN 
|Q9WUR6|Cavia porcellus [domestic guinea pig]             H*SDL*SIEPPL*SQE*TF*SDLWKLLPEN 
|Q95330|Oryctolagus cuniculus [rabbit]                    Q*SDL*SLEPPL*SQE*TF*SDLWKLLPEN 
|P10361|Rattus norvegicus [Norway rat]                    Q*SDM*SIELPL*SQE*TF*SCLWKLLPPD 
|Q29537|Canis lupus familiaris [dog]                      Q*SEL~NIDPPL*SQE*TF*SELWNLLPEN 
|P41685|Felis catus [domestic cat]                        P~LEL*TIEPPL*SQE*TF*SELWNLLPEN 
|Q9TUB2|Sus scrofa [pig]                                  Q*SEL~GVEPPL*SQE*TF*SDLWKLLPEN 
|P07193|Xenopus laevis [African clawed frog]              S*SET~GMDPPL*SQE*TF~EDLWSLLPDP 
|O57538|Xiphophorus hellerii [green swordtail]            M~EEA~DLTLPL*SQD*TF*HDLWNNVFLS 
|P51664|Ovis aries [sheep]                                Q~AEL~GVEPPL*SQE*TF*SDLWNLLPEN 
|P67938|Bos indicus []                                    Q~AEL~NVEPPL*SQE*TF*SDLWNLLPEN 
|P67939|Bos taurus [cattle]                               Q~AEL~NVEPPL*SQE*TF*SDLWNLLPEN 
|Q8SPZ3|Delphinapterus leucas [beluga whale]              Q~AEL~GVEPPL*SQE*TF*SDLWKLLPEN 
|P25035|Oncorhynchus mykiss [rainbow trout]               D~LAE~NVSLPL*SQE*SF~EDLWKMNLNL 
|Q4SF81|Tetraodon nigroviridis [spotted green pufferfish] M~EEE*TFSLPL*SQD*TF~QDLWENVAAP 
|Q92143|Xiphophorus maculatus [southern platyfish]        M~EEA~DLTLPL*SQD*TF*HDLWNNVFLS 
|Q9W679|Tetraodon miurus []                               M~EEE~NISLPL*SQD*TF~QDLWDNVSAP 
Figure 57: Conservation of modifications in the p53 transcriptional activation domain (PF008563).  Alignment 
produced by the PTM Browser tool using the raw Pfam alignment incorporated into the PTMDB. 
Residue 9(4) is modified in all primate and small mammal species p53 
homologues.  All of these species have their p53 homologues in the Swiss-Prot 
section of the UniProtKB and all contain a phosphorylation annotation at this 
position.  Residue 9(4) has been shown to be phosphorylated by Casein kinase 
I when serine residue 6(1) is phosphorylated in response to DNA damaging 
agents (including UV light and Ionising Radiation (IR) (Higashimoto et al. 2000).  
The following mammals are missing the modification site at positions 9(4) and 
6(1): sheep, cow (B. taurus and B. indicus) and beluga whale.  The cross-
annotation procedure has transferred annotations at this position to the cat p53 
homologue.  However note that instead of a serine the cat homologue has a 
threonine at this position.  The PhosphoMotif_finder tool was used to identify 
possible phosphorylation site motifs at this position in the protein.  The site in 
this protein was matched to the G protein-coupled receptor kinase motif.  Note 
that the PhosphoMotif_finder tool matched the Human site to the Casein kinase 
II and the G protein-coupled receptor kinase 1 motifs.  Of the fish species only 
the spotted green pufferfish has a residue at this position, which is compatible 
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with phosphorylation (annotated by the cross-annotation procedure).  This site 
was matched to the following motifs (using the same tool as before): the beta-
adrenergic receptor kinase substrate, the G protein-coupled receptor kinase 1 
substrate and the Casein kinase I substrate. 
Residues 15(10) and 18(13) are conserved amongst all p53 homologues with a 
PF08563 domain annotation.  All species except those which are fish have 
annotations for both of these positions in the Swiss-Prot database.  The PTMDB 
contains annotations for the remaining species (all fish), these were created by 
the cross-annotation procedure.  The surrounding residues are highly 
conserved hinting at the conservation of a kinase recognition site.  Residue 
18(13) is phosphorylated by Casein kinase I in the presence of DNA-PK (DNA 
dependent protein kinase) phosphorylated residue 15(10) (Dumaz, Milne, and 
Meek 1999). 
Residue 20(15) is interesting because only the mammalian homologues have a 
residue that can be phosphorylated at this position.  Between the mammalian 
sequences there are only 6 amino acid differences observed in a window size of 
17 amino acids - affecting only five of the 19 mammlian species.  Note that in 
addition to the fish p53 homologues the only amphibian represented (Xenopus 
laevis) is also missing this site.  This residue has been shown to be 
phosphorylated by Casein kinase II, which causes the stabilisation of p53 
through the loss of the E3 ubiquitin ligase Mdm2 (Hirao et al. 2000).  Residue 
20(15) has been shown to be essential for the stabilisation of p53 in response to 
IR and UV light (Chehab et al. 1999).  Mdm2 is not restricted to mammalian 
species and has for example been identified and characterised in the African 
clawed frog as being able to bind to p53 homologues (Marechal et al. 1997).  
The obvious question is how p53 is stabilised (via the release of Mdm2) in 
species which lack Ser-20(15). 
Section 6.2.3  Discussion 
It is unfortunate that this analysis could only be conducted for phosphorylation 
sites.  However it does raise a very interesting question.  Why are the residues 
that have annotations for other modification classes not present in Pfam 
domains?  It was previously stated that only 52% of annotation sites imported 
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from Swiss-Prot (excluding predicted sites) and Phospho.ELM could be overlaid 
onto a Pfam domain.  It was also shown in Section 4.4.2  that the probability of 
a residue position being present in a Pfam domain decreased the closer it was 
to the n or c terminus of a protein.  The PTMDB contains annotations for five 
residues in the H. sapiens p53 orthologue with annotations for methylation and 
acetylation.  Four of these residues are close to the c-terminal of the protein and 
one is found between the DNA binding domain and the tetramerization domain.  
The obvious hypothesis is that these residues are located in regions that show 
high variability between orthologues (likely to be disordered regions). 
Seven phosphorylation sites were identified in the PTMDB database for 42 p53 
family members from 24 species.  Two sites, at residues 99 and 215, reside in 
the DNA binding domain; serine 215 was present in all p53 family members.  
The Swiss-Prot database contains phosphorylation annotations for residue 99 in 
a number of p53 proteins, but not any p63 or p73 proteins.  Residue 99 
corresponds to a serine residue in all p63 and p73 proteins and all p53 proteins 
(except those from the bony fish (although in O. mykiss this residue is a 
threonine).  A literature search revealed no reports of residue 99 being 
phosphorylated in p63 or p73 proteins.  Although a report was found for the 
modification of residue 99 in p53 by casein kinase II, one of the enzymes 
predicted by the PhosphoMotif_tool to modify this residue in p63 and p73 
proteins. 
Five phosphorylation sites (6, 9, 15, 18, and 20) were identified in the TA 
domain of p53 proteins.  It is interesting that not all p53 proteins have 
annotations for the corresponding Pfam domain.  Five fish p53 proteins and one 
from G. gallus were missing corresponding annotations.  In addition none of the 
p63 and p73 proteins had annotations for the corresponding Pfam domain.  It is 
has widely been reported that p63 and p73 proteins have TA domains.  Based 
on multiple sequence alignments of the p53 family, it appears as though 
significant divergence has occurred between p53 and p63 and p73 proteins in 
this domain.  It is therefore probable that the Pfam p53 TA domain has been 
trained on only p53 protein sequences.  Obviously it could be argued that if it is 
proving difficult to identify homologous residues between the TA domains of p53 
proteins and p63 and p73 proteins that a new Pfam domain should be created. 
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The phosphorylation of residue 20 has been shown to result in the dissociation 
of Mdm2, leading to the stabilisation of p53.  A phosphorylation compatible 
residue at position 20 is only present in mammalian p53 proteins.  Mdm2 
homologues have been identified in other species, for instance in X. laevis.  
This raises the question of how Mdm2 is triggered to dissociate from non-
mammalian p53 proteins.  Phosphorylation compatible residues at positions 6 
and 9 appear to be absent from all ungulate species (e.g. O. aries, B. taurus, 
etc.) and related species (e.g. D. leucas).  In contrast the majority of non-
ungulate mammalian species possess such residues.  The exceptions being C. 
lupus, which is missing site 9, and F. catus, which is missing site 6.  
Phosphorylation compatible residues at positions 15 and 18 are seen across all 
p53 proteins. 
Using PTM Browser an analysis into the conservation of a subset of p53 family 
member phosphorylation sites has been performed.  The tool makes this type of 
analysis relatively straight forward by automatically generating multiple 
sequence alignments, which are starred to show modification sites.  In addition 
the phylogenetic trees that are constructed aid in understanding the 
relationships between proteins.  One of the main benefits of using PTM Browser 
is that it produces a table that documents which sites have been observed in 
individual proteins.  The main drawback of using PTM Browser is that it is only 
able to compare modification annotations for residues that are located in Pfam 
domains.  This restriction prevented many p53 modifications from being 
analysed.  Going forward it will be very important to allow PTM Browser to 
analyse the conservation of modifications outside of Pfam domains.  This would 
be a relatively straight forward process as PTM Browser already creates 
multiple sequence alignments of the proteins that it has been asked to analyse 
the conservation between.  There is the obvious temptation to remove the 
dependency on the Pfam domain alignments entirely for protein family analysis.  
However it was noted during the p53 analysis that many modified residues 
aligned in the Pfam domains alignments, but not in the CLUSTAL W, generated 
multiple sequence alignments.  Manual inspection of the differences suggested 
that, for the most-part, it was the CLUSTAL W alignment that was incorrect 
(although of course this is only speculative). 
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Section 6.3  Taxonomic comparisons 
Section 6.3.1 Conservation between super-kingdoms 
In this section the following question is asked:  Are there any PTMs that are 
conserved across super-kingdom boundaries?  Asking this question should 
reveal a set of PTMs that are most likely essential to the majority of Bacteria 
and Eukaryotes.  This question can be likened to that which scientists have 
previously asked regarding the minimal genome that can sustain life.  Indeed if 
some of the conserved PTM sites are missing from a minimal genome, it might 
suggest that a gene has been missed out. 
PTM Browser has been used to identify which experimentally verified 
modification sites are conserved between Bacterial and Eukaryotic species 
(based on Pfam domain, alignment column, and PTM class).  A total of 26 
conserved modification positions were identified in 16 different Pfam domains – 
list shown in Figure 58.  The majority of the domains are involved in energy 
metabolism, transcription and translation.  The following PTM classes had at 
least one conserved residue in the extracted PTM annotation set: 
Phosphoprotein, Methylation, FMN, TPQ, Oxidation and Other. 
Pfam 
Accession 
Description 
PF00016 Ribulose bisphosphate carboxylase large chain, catalytic domain 
PF00069 Protein kinase domain 
PF00072 Response regulator receiver domain 
PF00113 Enolase, C-terminal TIM barrel domain 
PF00334 Nucleoside diphosphate kinase 
PF00472 RF-1 domain 
PF00502 Phycobilisome protein 
PF00512 His Kinase A (phosphoacceptor) domain 
PF00884 Sulfatase 
PF00989 PAS fold 
PF01116 Fructose-bisphosphate aldolase class-II 
PF01179 Copper amine oxidase, enzyme domain 
PF01627 Hpt domain 
PF01965 DJ-1/PfpI family 
PF02866 lactate/malate dehydrogenase, alpha/beta C-terminal domain 
PF03143 Elongation factor Tu C-terminal domain 
Figure 58:  Pfam domains with experimentally verified PTM annotations conserved between Bacterial and Eukaryotic 
proteins 
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A comparison was also performed by using all annotations extracted from the 
Swiss-Prot and Phospho.ELM databases, thus excluding all cross-annotated 
sites, regardless of evidence qualifier.  This comparison revealed 43 conserved 
modification annotations located on 28 Pfam domains.  In addition to the 
previous list of PTM classes, this dataset also had the following: Pyruvate, 
Glycosylation_N_Linked, Nucleotide-binding and Organic radical.  Just under 
half of the residues with a conserved modification were phosphorylated (see 
Figure 59). 
PTM Class Number of modified 
residues 
Phosphoprotein 21 
Other 8 
FAD 3 
Methylation 3 
Glycosylation_N_Linked 2 
FMN 1 
Nucleotide-binding 1 
Organic radical 1 
Oxidation 1 
Pyruvate 1 
TPQ 1 
Figure 59: Number of modified residues conserved between Eukaryotic and Bacterial species, grouped by PTM class. 
Original dataset included all PTM annotations from the Swiss-Prot and Phospho.ELM databases, regardless of 
evidence qualifier. 
In this dataset two N-linked glycosylation sites appear to be conserved between 
Bacteria and Eukaryotes.  Both sites fall in the Pfam Peptidase_S8 (PF00082, 
Subtilase, serine protease family) domain at alignment positions 1063 and 
1303.  An alignment of the surrounding sequences from proteins that have N-
linked glycosylation annotations at these two positions is shown in Figure 60. 
1063 has an N-linked glycosylation annotation for a peptidase from Thermus sp. 
(strain Rt41A) and Magnaporthe oryzae (Rice blast fungus).  1303 has N-linked 
glycosylation annotations from one Bacterial (Thermus sp. (strain Rt41A) and 
seven Eukaryote species.  All of these N-linked glycosylation site annotations 
have been imported from the Swiss-Prot database with the evidence qualifier 
Potential.  The UniProtKB entry for the Thermus sp. peptidase states that the 
protein is a glycoprotein (Peek et al. 1992).  The regions surrounding both sites 
appear to be well conserved between Thermus sp. Rt41A and the Eukaryote 
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species.   However a literature search revealed no direct evidence for the 
glycosylation of proteins by a species of the genius Thermus.  
A comparison was also performed between Eukaryote and Archeal PTM 
annotations (extracted from Swiss-Prot and Phospho.ELM).  Nine conserved 
sites were identified from nine different Pfam domains (Figure 61).  Like in the 
previous comparison the domains are predominantly involved with energy and 
nucleotide metabolism. 
234 Thermus sp.(strain Rt41A)(1063) 
|P58371|Magnaporthe grisea []                 VKVLKS*NGSGT 
|P80146|Thermus sp. Rt41A []                  VRVLDC*NGSGS 
 
305 H. sapiens(1303) 
|P12547|Aspergillus oryzae []                 AI*NMSLG- 
|P28296|Aspergillus fumigatus []              AI*NMSLG- 
|P35211|Aspergillus flavus []                 AI*NMSLG- 
|P80146|Thermus sp. Rt41A []                  VI*NMSLG- 
|Q14703|Homo sapiens [human]                  VL*NLSIGG 
|Q9WTZ2|Mus musculus [house mouse]            VL*NLSIGG 
|Q9WTZ3|Rattus norvegicus [Norway rat]        VL*NLSIGG 
|Q9Z2A8|Cricetulus griseus [Chinese hamster]  VL*NLSIGG 
Figure 60:  Alignment of a conserved N-linked glycosylation site in the Pfam domain PF00082.   
Alignment column 1063 corresponds to position 254 in P58371 and 234 in P80146 
Pfam 
Accession 
Description 
PF00016 Ribulose bisphosphate carboxylase large chain, catalytic domain 
PF00072 Response regulator receiver domain 
PF00113 Enolase, C-terminal TIM barrel domain 
PF00180 Isocitrate/isopropylmalate dehydrogenase 
PF00221 Phenylalanine and histidine ammonia-lyase 
PF00467 KOW motif 
PF00543 Nitrogen regulatory protein P-II 
PF01979 Amidohydrolase family 
PF03764 Elongation factor G, domain IV 
Figure 61:   Pfam domains with PTM annotations conserved between Eukaryotic and Archeal species. 
Includes only those PTM annotations imported from the Swiss-Prot and Phospho.ELM databases. 
 
A three-way-comparison was also performed between the three 
superkingdoms.  This comparison identified six modification sites that were 
found in all three superkingdoms (shown in Figure 62).   
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Pfam Accession Alignment Position PTM Class 
PF00072 317 Phosphoprotein 
PF00113 333 Phosphoprotein 
PF00016 67 Other 
PF00221 467 Other 
PF01979 747 Other 
PF00543 100 Nucleotide-binding 
Figure 62:  Modification sites conserved across all three superkingdoms 
Includes only those modifications extracted from the Swiss-Prot and Phospho.ELM databases. 
Section 6.3.2  Conservation between Eukaryote species 
In this section the following question is asked:  To what extent are post-
translationally modified proteins conserved between different Eukaryote 
species?  The answer to this question could, for instance, suggest that a 
particular species is a poor model of the H. sapiens phosphoproteome. 
The first part of this section looks at the conservation of proteins between eight 
species and H. sapiens, based on five different modification classes.  The 
second part of this section looks in more detail at the conservation of 
modifications between H. sapiens and M. musculus. 
Section 6.3.2(a)  Conservation of modified proteins between 
Eukaryote species 
To keep the number of comparisons being discussed to a manageable level all 
species have been compared to H. sapiens.  Eukaryote species were first 
selected whose non-redundant protein sets (for simplicity referred to as 
proteomes), as created in Chapter 3, approximately matched the number of 
protein coding genes.  The following seven species had almost a 1:1 ratio 
between the number of proteins and protein coding genes: M. musculus, T. 
nigroviridis, D. melanogaster, C. elegans, N. vectensis, A. thaliana, S. 
cerevisiae and S. pombe.  Note that the estimated number of protein coding 
genes for T. nigroviridis has previously been discussed as being a gross 
underestimate - this species will therefore also be looked at in this section.  A 
brief analysis of the conservation of the proteins from these species and H. 
sapiens was previously presented in Table 27 - these numbers can also be 
found in Table 42 along with the estimated proteome completeness.  PTM 
Browser was used to calculate the conservation of proteins with different PTM 
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class annotations between H. sapiens and each of the other eight Eukaryote 
species.  To accomplish this PTM Browser makes use of the orthologue and in-
paralogue assignments added to the PTMDB using the CoPaO software (see 
Chapter 3).  Only results for the following five PTM classes are discussed here: 
Phosphorylation, N-linked Glycosylation, O-linked Glycosylation, GPI anchor, 
and Acetylation.  Results from this analysis are shown in Table 42.   
The most obvious result is that Phosphorylated and Acetylated proteins appear 
to be more conserved than the proteomes as a whole between all eight species 
and H. sapiens.  Another interesting result is that even after the cross-
annotation process neither S. cerevisiae nor S. pombe have any proteins with a 
GPI-anchor annotation.  It‟s interesting to note that H. sapiens has 64 proteins 
with a GPI-anchor, the only species with similar numbers were M. musculus 
(74) and T. nigroviridis (40).   
The number of proteins with O-linked Glycosylation sites seems to dramatically 
fall as the evolutionary distance to H. sapiens increases.  For example, 1,104 H. 
sapiens proteins have O-linked Glycosylation annotations, which is similar to 
the number for M. musculus (1,005).  T. nigroviridis had 633, which falls to 188 
for A. thaliana and finally falls to only 11 and 9 for S. cerevisiae and S. pombe, 
respectively.  For all but two species (M. musculus and T. nigroviridis) N-linked 
glycosylated proteins are conserved to a greater extent than O-linked.  It does 
at first sight appear rather strange that proteins predominately involved in cell-
cell signalling are more highly conserved in single celled organisms, compared 
to O-linked proteins whose functions almost exclusively exist within the cell.  
Further work will need to be done to understand why N-linked glycosylated 
proteins show a higher degree of conservation.  For the majority of PTM classes 
a larger percentage of the other species‟ modified proteins are homologous to 
proteins from H. sapiens, rather than the other way around.  There are some 
exceptions, for example 51.5% of T. nigroviridis phospho-proteins have H. 
sapiens orthologues compared to 61.3% in the reverse orientation. 
 
 
 Proteome 
Completeness 
Proteome 
conservation 
Phosphorylation N-linked Glycosylation O-linked Glycosylation GPI-anchor Acetylation 
Mus musculus 104.63% 72.57% 80.30% 63.95% 78.71% 61.33% 88.23% 
Homo sapiens  62.48% 77.11% 65.42% 73.73% 67.19% 82.33% 
Tetraodon nigroviridis 172.55% 39.47% 51.50% 38.38% 44.55% 20.00% 54.58% 
Homo sapiens  45.97% 61.34% 49.75% 55.89% 25.00% 61.43% 
Drosophila melanogaster 108.72% 39.85% 56.24% 34.34% 34.63% 0.00% 67.98% 
Homo sapiens  31.20% 42.82% 25.29% 20.02% 14.06% 56.76% 
Caenorhabditis elegans 99.23% 25.33% 46.31% 27.08% 27.73% 16.67% 44.33% 
Homo sapiens  28.82% 41.55% 29.72% 17.03% 12.50% 53.74% 
Nematostella vectensis 100.03% 31.50% 42.44% 23.96% 27.01% 14.29% 58.62% 
Homo sapiens  33.74% 43.88% 35.13% 21.29% 15.63% 55.61% 
Arabidopsis thaliana 104.80% 27.02% 48.50% 28.17% 43.62% 0.00% 56.93% 
Homo sapiens  19.33% 26.34% 10.73% 4.08% 17.19% 45.11% 
Saccharomyces cerevisiae 99.91% 32.72% 51.22% 29.37% 27.27%  64.91% 
Homo sapiens  13.57% 19.72% 5.89% 0.36% 0.00% 30.56% 
Schizosaccharomyces pombe 99.14% 45.29% 58.62% 27.10% 77.78%  66.98% 
Homo sapiens  12.71% 16.82% 6.04% 0.45% 0.00% 30.04% 
Table 42:  Conservation of modified proteins between H. sapiens and a selection of other Eukaryote species. 
Proteome completeness, expresses the correlation between the number of proteins in the non-redundant protein set created from UniProtKB release 13.3 (as extracted using the protocol in 
Section 3.4.3) and the number of protein coding genes listed for an organism in the Ensembl database (and other resources); values extracted from Table 23.  Proteome conservation, 
represents the percentage of an organisms proteome that has an orthologous partner in another organisms proteome.   The methodology used to incorporate orthologue annotations into the 
PTMDB has already been described in Chapter 3.  The proteome conservation values shown in this table have been extracted from Table 27; note that in-paralogues have been included in the 
underlying counts (in-paralogues are by definition orthologues).  The remaining columns show the conservation of proteins subdivided by PTM class; these values where obtained from PTM 
Browser.  Note that the following PTM annotations were included in the PTM Browser analysis; Swiss-Prot [Probable, Experimental, and By similarity], Phospho.ELM [LTP and HTP], and all 
cross-annotations that were homologous to Eukaryote sites from Swiss-Prot [excluding predicted sites] or Phospho.ELM. 
.   
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Section 6.3.2(b)  H. sapiens and M. musculus 
H. sapiens and M. musculus are the only mammals in the PTMDB whose 
proteome size matches or exceeds their estimated number of protein coding 
genes (see Section 3.4.3(f).   The H. sapiens proteome was previously 
estimated to be 121% complete and the M. musculus 105%.  Proteomes in the 
PTMDB may exceed the estimated number of protein coding genes where 
splice variants are counted, or the number of protein coding genes is an 
underestimate.  
A conservation analysis was first performed at the domain level – the aim of 
which was to identify conserved modifications based on the triplet Pfam 
accession, Pfam alignment position, and PTM class.  It must be stressed that 
this analysis does not involve the direct comparison of orthologues, as identified 
by the CoPaO software.  The percentage of conserved domain level sites was 
calculated for each different PTM class.   An annotation was considered to be 
conserved if the corresponding values for the fields Pfam accession, Pfam 
alignment position, and PTM class could be found together in the dataset for the 
other species.   This analysis was first carried out using only those annotations 
that had been imported from Swiss-Prot and Phospho.ELM – the core set.  The 
analysis was then carried out by adding annotations from the cross-annotation 
set to those used in the first analysis – the main set.  Note that cross-
annotations for sites that didn‟t have a homologue in either the H. sapiens or M. 
musculus Swiss-Prot or Phospho.ELM datasets were excluded. 
The percentage of conservation observed for a number of particularly important 
PTM classes is shown in Table 43.  The final column of this table shows the 
degree of conservation that was observed for the core set.  Palmitoylation, 
myristoylation, and prenylation are all lipid modifications that are important in 
the localisation of proteins to plasma membranes.  Almost all of the modification 
sites for these three PTM classes are conserved between H. sapiens and M. 
musculus.  32% of the H. sapiens phosphorylation sites do not have a 
corresponding site in the M. musculus core dataset.  After the cross-annotation 
process only 7% of the H. sapiens phosphorylation sites do not have a 
homologue in M. musculus.  The core dataset appears to show that only 43% of 
the H. sapiens O-linked glycosylation sites are conserved with M. musculus – 
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after cross-annotation this number jumps to 87%.  This analysis clearly showed 
an exceptional level of conservation for all PTM classes – that for many 
approaches 100%.   
 Main set Core 
PTM Class Total Intersect % % 
Phosphoprotein-H. sapiens 3618 
3373 
93.23 68.31 
Phosphoprotein-M. musculus 3500 96.37 87.93 
Glycosylation_N_Linked-H. sapiens 4692 
4314 
91.94 70.43 
Glycosylation_N_Linked-M. musculus 4644 92.89 76.78 
Glycosylation_O_Linked-H. sapiens 207 
179 
86.47 42.64 
Glycosylation_O_Linked-M. musculus 193 92.75 77.78 
Acetylation-H. sapiens 267 
260 
97.38 93.77 
Acetylation-M. musculus 295 88.14 84.27 
Methylation-H. sapiens 41 
40 
97.56 94.87 
Methylation-M. musculus 41 97.56 92.50 
Myristate-H. sapiens 11 
11 
100.00 63.64 
Myristate-M. musculus 11 100.00 100.00 
Palmitate-H. sapiens 52 
52 
100.00 100.00 
Palmitate-M. musculus 52 100.00 98.08 
Prenylation-H. sapiens 3 
3 
100.00 100.00 
Prenylation-M. musculus 3 100.00 100.00 
Table 43:  Conservation of modified domain residues between H. sapiens and M. musculus. 
Swiss-Prot and Phospho.ELM PTM annotations were extracted from the PTMDB for both species – forming the core 
set.  In addition PTM annotations were extracted from the cross-annotation section of the PTMDB for both species.  
Cross-annotations were limited to those that had a matching PTM annotation in the core set.  The core set and the 
restricted cross-annotation set form the main set. 
Some of the cross-annotations will of course be false positives, as will some of 
the PTM annotations in the core dataset (i.e. those imported from Swiss-Prot 
with the evidence qualifier: Potential).  The true degree of conservation between 
these two species most likely lies somewhere between that observed for the 
core set and that of the main set.  The main conclusion from this analysis 
appears to be that differences in the modification of residues in conserved 
domains are more likely to be caused by upstream changes in the enzymes 
responsible for carrying out the modification – rather than the absence of 
compatible residues. 
Section 6.3.3  Discussion 
This section started with an analysis into the conservation of modifications 
between super-kingdoms.  The first comparison used only PTM annotations 
with an experimental evidence qualifier.  Even though this first dataset was 
180 
 
extremely small (compared to the total number of annotations in the PTMDB) 26 
modification sites were conserved between Eukaryote and Bacterial species.  
The fact that a small number of modification positions are conserved may be 
surprising, however what is perhaps not surprising is that these sites located to 
protein domains, involved in energy metabolism, transcription and translational 
(core cellular processes).  The second comparison involved all PTM 
annotations imported from the Swiss-Prot and Phospho.ELM databases (no 
longer just the experimentally verified sites - although cross-annotations were 
still excluded).  This analysis expanded the number of conserved modification 
sites to 43 belonging to 28 Pfam domains.  Perhaps the most interesting 
conserved modification was that of an N-linked glycosylation site, that appears 
to be conserved between a Eukaryote and Bacterial protein.  The conserved 
modification was observed between the Bacterial species, Thermus sp. (strain 
Rt41A), and the Eukaryote, Magnaporthe oryzae.  The modification site was 
located in the Subtilase; serine protease family domain.  It must be emphasised 
that some Bacteria can carry out N-linked glycosylation.  Obviously the 
conservation data presented in this section, does not preclude the process of 
convergent evolution.  Note that only six modification sites were conserved 
across all three super-kingdoms. 
The second analysis presented, looked at the conservation of proteins grouped 
by PTM class.  Specifically this section looked at the percentage of H. sapiens 
proteins with particular modification classes that had orthologues in a range of 
other Eukaryote species.  The results of this analysis are presented in Table 42.  
It is worth noting that the H. sapiens proteome used is this study was estimated 
to be 121% complete.  It is unclear just how much of the 21% over-estimate is 
related to redundancy/erroneous sequences in the proteome used or an under-
estimate in the number of protein coding genes (see Section 3.6 for a more 
detailed analysis of this issue).  However, what is clear is that if a significant 
portion of the 21% represents erroneous sequences (i.e. fragments); this could 
have a profound effect on the results presented in this section.  The reason is 
simply that fragmentary sequences are unlikely to be assigned to an orthologue 
group (and nor should they), which will in turn over-estimate the number of 
proteins in the H. sapiens proteome that do not have orthologues in other 
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species.  In addition many of these erroneous sequences are likely to be 
missing Pfam domain annotations (and thus less likely to have PTM annotations 
in the PTMDB (because they were excluded from the cross-annotation 
process).  When both of these issues occur, the result would most likely 
manifest as the percentage of proteins conserved between the H. sapiens 
proteome and another species being lower than that seen for PTM specific 
groups of proteins.  This issue will not be discussed any further, but readers are 
encouraged to bear this point in mind. 
Phosphorylated and acetylated proteins appeared to show the greatest degree 
of conservation; which is not surprising given the fact that many phosphorylation 
and acetylation sites have been shown to occur on key cellular regulators (i.e. 
p53).  GPI-anchors are associated with proteins that are involved in cell 
signalling, it should therefore perhaps not come as a complete surprise that 
neither S. pombe nor S. cerevisiae contain any proteins that are orthologous to 
the H. sapiens proteins with GPI-anchor annotations.  It is interesting that this 
modification seems to be more prevalent in species that are more closely 
related to H. sapiens.  Although this was true of all PTM classes analysed in this 
section, it is just more aberrant for GPI-anchored proteins because there are so 
few of them.  Like GPI-anchored proteins, many species, have few orthologues 
to the H. sapiens O-linked glycosylated proteins.  These results suggest that not 
only are some PTM classes fairly recent evolutionary inventions but that they 
are carried by proteins that are not even present in species that cannot carry 
out such modifications. 
The final analysis looked at the conservation of modifications between H. 
sapiens and M. musculus.  Note that as this analysis was being carried out at 
the domain level it was unaffected by any potential issues with the H. sapiens 
proteome being larger than expected.  For each modification class the 
conservation was analysed both before and after the inclusion of cross-
annotation results.  Cross-annotations were excluded if a homologous 
annotation could not be found in the PTM annotations imported from the Swiss-
Prot or Phospho.ELM databases, on H. sapiens or M. musculus proteins.  For 
the majority of PTM classes analysed almost all of the modification sites were 
conserved between H. sapiens and M. musculus proteins in the original 
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annotations imported from the Swiss-Prot and Phospho.ELM databases.  One 
notable exception was that only 68.31% of the H. sapiens phosphorylated sites 
were present in the M. musculus PTM annotations imported into the PTMDB.  
After cross-annotation this number jumped up to 93.23%; of course not all of the 
cross-annotations will be correct.  Another interesting difference was that only 
42.68% of the H. sapiens O-linked glycosylation sites were conserved in the M. 
musculus PTM annotations imported into the PTMDB.  After cross-annotation 
this percentage rose to 86.47%.  The main message from these results appears 
to be that the vast majority of modification sites are shared between H. sapiens 
and M. musculus.  What is possibly more interesting however is that the cross-
annotation procedure has identified sites that are definitely not shared between 
H. sapiens and M. musculus.  These non-conserved sites should be of interest 
to scientists that have chosen M. musculus as a model organism to study 
particular H. sapiens diseases. 
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Chapter 7  
 
General Discussion 
Section 7.1  PTM Databases 
A selection of PTM annotation databases were reviewed in Section 1.2.  The 
PTM community has created a number of very useful databases.  Some of 
which are specific to particular PTM classes (e.g. Phospho.ELM), others contain 
annotations for a much wider range of PTM classes (e.g. UniProtKB).  In 
Chapter 2 the construction of a new database of PTMs, the PTMDB, was 
discussed, that includes annotations from UniProtKB, Phospho.ELM and the 
PDB.  The PTMDB contains 186,408 modifications extracted from Swiss-Prot 
for 56,074 proteins.  The Phospho.ELM database contributed 14,934 
phosphorylation annotations for 4,917 Swiss-Prot entries.  In addition 656 
phosphorylation annotations were extracted from Phospho.ELM for 292 
TrEMBL entries. 
Collating PTM annotations from pre-existing PTM databases is not always a 
straight forward process.  PTM annotations are made available in various 
different formats.  Each format requires a specific import procedure.  Although 
PTM annotation formats differ, many are now adopting either the Swiss-Prot 
PTM controlled vocabulary or PSI-MOD ontology, to describe chemical 
modifications.  During the creation of the PTMDB it became obvious that some 
databases made it difficult to unambiguously identify which residues were being 
referred to.  When annotating UniProtKB sequences it is essential for the 
annotation to include not only the UniProtKB accession, but also the sequence 
revision number.  An alternative to providing the sequence revision number is to 
provide the protein sequence. 
There are far more observed glycan structures (e.g. KEGG/Glycan contains 
11,000 structures) than all of the other PTM types put together.  Based on the 
number of predicted glycosylation sites, it should be one of the most abundant 
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PTM classes.  However determining both the position and structure of a glycan 
is a difficult process (the field of Glycoproteomics).  It was shown in Table 10 
that only 5% of Swiss-Prot glycosylation annotations were experimentally 
derived; compared to 41% of phosphorylation annotations.  Of course it could 
be argued that many of the predicted glycosylation annotation sites in Swiss-
Prot are not actually modified at all.  Almost all glycobiology papers begin by 
stating that glycosylation is the most abundant modification.  This is a 
somewhat bold statement given that most authors backup this claim by referring 
to the number of glycosylation site annotations in the Swiss-Prot database (of 
which >90% are predicted).   
Attempts have been made to make what little information is available on site 
specific glycosylation available in databases (e.g. GlycoSuiteDB (Cooper et al. 
2001) and PDB2LINUCS (Lutteke, Frank, and von der Lieth 2004)).  The Swiss-
Prot database currently annotates glycosylation sites with only the terminal-
reducing sugar.  Swiss-Prot does indirectly store a more complete record of 
glycan structures for a handful of glycosylation site annotations that have been 
cross-referenced to the GlycoSuiteDB.   
In Section 2.6 the incorporation of glycosylation sites and corresponding 
structures extracted from the PDB using the PDB2LINUCS tool was discussed.  
There were three points raised by this work.  The first was that the PDB did 
contain glycosylation sites that were not present in the Swiss-Prot database; 
although there were only 105.  The second point is that although 1,363 
residue/glycan pairs were identified, 80% of these sites were for N-linked 
glycans with only the first two GlcNAc residues present.  The final point raised 
was the importance of expanding the current PTM vocabularies so that they 
better support glycosylation PTM types.  Section 2.6.4(c) discussed how the 
PTMDB vocabulary was extended to support the data extracted from the PDB 
using the PDB2LINUCS tool.  PTM vocabularies should be expanded to: a) 
support raw glycan structure formats (e.g. GlycoCT) and b) to support some 
kind of glycan structure classification (e.g. High mannose, hybrid, complex, 
etc.).  It should also be noted that most glycosylation-specific databases also 
allow users to search databases by actually drawing a glycan structure (see 
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<http://www.glycome-db.org/database/searchSubStructure.action> for an 
example). 
Section 7.2  Cross-annotation 
In Section 2.5.1 it was pointed out that the Swiss-Prot curators transfer 
experimentally verified PTM annotations between homologous proteins.  It was 
noted that this process is only carried out between closely related species 
(where closely is never defined explicitly).  It had already been decided that the 
conservation analysis that was going to be carried out would be based solely on 
the annotations in the PTMDB.  This raised an important question regarding 
how complete the cross-annotated dataset in Swiss-Prot actually was.  A brief 
analysis of H. sapiens and M. musculus PTM annotations suggested that some 
cross-annotations were missing (from highly homologous sequence regions).  
Obviously some of the cross-annotations may have been missing because they 
were deemed inappropriate.  As the Swiss-Prot annotation process is at least 
in-part manual, it is also possible that a curator has simply not had a chance to 
transfer these annotations.  It was the discovery of these missing cross-
annotations that first led to the decision to carry out a new cross-annotation 
process.   
The next consideration was that it would be useful to include TrEMBL proteins 
in PTM conservation analysis; especially as many species are represented 
almost entirely in the UniProtKB by TrEMBL entries.  It is important to reiterate 
that the TrEMBL database does not include any PTM annotations.  In addition it 
had been decided that it would be useful to analyse PTM conservation between 
both distantly and closely related species.   To account for all of the issues just 
raised the cross-annotation process was designed to transfer all annotations 
between all proteins in the UniProtKB.  This procedure included both Swiss-Prot 
and TrEMBL proteins and did not restrict the transfer of annotations to that 
between only closely related species. The Swiss-Prot cross-annotation process 
is designed to produce a high confidence dataset.  In contrast the PTMDB 
cross-annotation process was designed to produce a dataset that could be 
constrained later, as required.  For example using the PTM Browser tool 
(discussed in Chapter 5) it is possible to create cross-annotation datasets that 
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impose the same type of constraints as used in the Swiss-Prot cross-annotation 
process.  For example, it is possible to exclude cross-annotations that have 
been made between Bacterial and Eukaryote proteins. 
The cross-annotation procedure was designed to transfer annotations based on 
the homology identified in PfamA domain alignments.  Pfam domain alignments 
were used as these are guided by a manually curated seed alignment; which 
was considered to be more reliable than those generated automatically by 
programs such as CLUSTAL W.  In addition by using the Pfam domain 
alignments the cross-annotation procedure did not need to include a lengthy 
sequence alignment step.  The procedure also calculated the sequence identity 
between acceptor and donor sites in sequences of various window sizes.  PTM 
Browser can be used to also constrain cross-annotations by both window size 
and identity count. 
The obvious criticism of the cross-annotation dataset is that no attempt was 
made to confirm that the new PTM annotation sites conformed to known 
enzyme acceptor sites.  Indeed during the analysis of the p53 family of proteins 
(see Section 6.2) this process had to be carried out manually.  It should be 
pointed out that traditional prediction programs make no use of homology 
information to weight predictions higher if a modification has previously been 
observed at a homologous residue in another protein.  Therefore in the future it 
should prove beneficial to combine homology based cross-annotation 
techniques with traditional prediction tool chains.    
As the cross-annotation procedure was essentially only constrained by the 
Pfam domain alignments it should come as no surprise that it generated a very 
large number of cross-annotations.  Even when cross-annotations made 
between super-kingdoms were excluded there were still over 2 million.  It is 
clear from the work shown in Table 43 that the cross-annotation dataset 
significantly reduces the percentage of modifications that do not appear to be 
conserved (as always with the caveat that some of the cross-annotated sites 
may not be modified in real life) between some species. 
The version of the Swiss-Prot database that was used in the PTMDB was 
frozen at the start of development as one released in 2008.  At the end of this 
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study a newer version of the PTMDB was created that contained PTM 
annotations from the December 2010 release of Swiss-Prot.  It is interesting to 
note that 3,159 of the cross-annotations are present in the newer version of 
Swiss-Prot. 
The PTMDB cross-annotation dataset should prove to be of interest to a wide 
audience.  Especially for scientists who work with species whose proteome is 
predominantly or completely represented by TrEMBL entries.  For instance the 
PTMDB contains the first large scale PTM annotation (of which the author is 
aware) for the two fish D. rerio and T. nigroviridis.  Another benefit of the 
PTMDB cross-annotation dataset is that it provides the user with everything 
they need to define their own constraints on what cross-annotations to allow 
(obviously many may argue that this is also a drawback).  There is another 
benefit of carrying out the cross-annotation process that may not be 
immediately obvious.  Many users might be dissuaded from using the cross-
annotation dataset in its current form as it does not attempt to validate cross-
annotated acceptor sites with known enzyme acceptor sites.  These users might 
want to remember that the lack of a cross-annotation in the dataset tells them 
immediately that a site is almost certainly not conserved (i.e. the residue at the 
homologous position is not compatible with the PTM type at all).  The only 
caveat to this point is that it assumes that its Pfam domain annotation set is 
complete (i.e. that domain boundaries are correct and that a domain annotation 
is not simply missing).  This issue was previously discussed in Section 6.2.2 
where almost all of the p53 proteins had Pfam TA domain annotations but 
neither the p63 nor p73 proteins did (although as discussed this may be 
deliberate). 
Section 7.3  Proteomes and orthology detection 
Chapter 3 was completely devoted to the construction of non-redundant protein 
sets and the detection of orthologous proteins in the PTMDB.  It is worth re-
stating that throughout this thesis the terms proteome and non-redundant 
protein set have been used interchangeably.  Hopefully it is somewhat obvious 
that a non-redundant protein set is not by definition a proteome; although a 
proteome has to be a non-redundant protein set.  The procedure outlined in 
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Chapter 3 creates non-redundant protein sets that are for the most part devoid 
of splice variant sequences (and thus for Eukaryote species they are not 
technically proteomes). 
One of the main issues found with the proteome construction technique 
described in Chapter 3 is that it resulted in proteomes that exceeded the 
number of protein coding genes for a number of species.  For some species 
such as H. sapiens it appeared as though a number of redundant Swiss-Prot 
sequences had been included in the proteome (remember that Swiss-Prot 
entries are meant to be non-redundant).  For others, such as T. nigroviridis, it 
appears as though the estimated number of protein coding genes was incorrect. 
In order to detect orthologues in the PTMDB the InParanoid technique was 
adopted.  Although we had obtained the InParanoid software from the original 
authors to run across our database – it failed to produce any orthologue 
assignments.  The decision was therefore taken to re-implement the InParanoid 
algorithm as a new Perl program called CoPaO.  Initial results comparing H. 
sapiens and M. musculus suggested that the new Perl program would benefit 
from being multi-threaded.  A new Java version of CoPaO has since been 
created, which shows little benefit in the application of threading to the 
InParanoid algorithm. 
During the development of PTM Browser the only other PTM resource that 
combined orthologue assignments with PTM annotations was PHOSIDA.  At the 
start of 2011 new InParanoid orthologue annotations seem to have been added 
to the UniProtKB.  It will therefore be important to monitor the inclusion of these 
annotations into the UniProtKB.  This will most likely allow for future versions of 
the PTMDB to include InParanoid annotations directly from the UniProtKB.  This 
will in turn free up resources so that additional species pairs can have their 
orthologues identified using the CoPaO software.   
Section 7.4  PTM Conservation analysis tools 
PTM Browser is novel in that it has been specifically designed to allow for the 
conservation of modifications to be analysed.  PHOSIDA (Gnad et al. 2007; 
Gnad, Gunawardena, and Mann 2011) is a predominately phosphorylation 
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related resource that does however share some of the same functionality as 
PTM Browser.  For a specific modification site PHOSIDA can show users which 
homologues (identified as being in the same IPI (International Protein Index) 
group) share the modification.  PHOSIDA can only be used to analyse the 
conservation of modification sites between nine species.  The number of 
species that are available for comparison with PTM Browser depends on the 
query being performed.  When a user is comparing modifications between 
orthologues, as defined by the CoPaO software (refer to Section 3.3), they are 
limited to 35 species.  However when they are comparing modifications based 
only on Pfam domain homology they have access to 7,088 species that were 
included in the cross-annotation process (some 2,768,148 proteins were 
included in this process).  PHOSIDA contains 80,000 mass spectrometry 
derived Acetylation, Phosphorylation, and N-linked Glycosylation annotations 
(Gnad, Gunawardena, and Mann 2011).  The majority of PTM Browser queries 
are likely to be limited to those sites in Pfam domains.  When this constraint is 
in effect PTM Browser has access to 10,092 experimentally verified modification 
sites (26,332 when Swiss-Prot by similarity annotations are included).  
Obviously in addition to the experimentally derived annotations PTM Browser 
can also include annotations from the new cross-annotation process and those 
marked as Potential in the Swiss-Prot database.  PHOSIDA has been designed 
to show users the conversation of individual modifications.  In contrast PTM 
Browser shows users which modification sites are present in a group of proteins 
and most importantly which proteins have which modification sites.  PHOSIDA 
can only display the conservation of a modification between members of the 
same IPI group.  PTM Browser can be given a list of proteins for which 
modification conservation should be shown.  It is worth noting that the p53 
family analysis described in Section 6.2 would have been much more complex 
using PHOSIDA as it lacks this functionality.  PTM Browser can also be asked 
to show the conservation for the orthologues of a particular set of proteins 
(using the CoPaO dataset).   
PTM Browser is the first resource that enables users to identify both conserved 
and non-conserved modifications at the taxonomic level.  In Section 6.3 such an 
analysis was performed to identify which modification sites were shared 
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between each of the three super-kingdoms.  PTM Browser can also be used to 
calculate the percentage of proteins with particular modifications that have 
orthologues in other species.  Such an analysis is presented in Section 6.3.2(a). 
In conclusion PTM Browser presents users with new workflows (see Section 
5.3) that should dramatically reduce the amount of time taken to analyse PTM 
conservation. 
Section 7.5  Conservation analysis conclusions 
In Section 6.2 a review was presented on the conservation of PTMs between 
members of the p53 tumour suppressor family.  The analysis provides an 
example of using PTM Browser to compare the conservation of PTMs both 
across species (i.e. H.sapiens p53 compared to M.musculus) and between 
paralogues (i.e. H.sapiens p53 compared to the related p63 protein).  p53 has 
been documented as being subjected to at least six different PTM processes 
(i.e. phosphorylation, methylation, acetylation, ubiquitination, sumoylation, and 
neddylation).  One of the first conclusions from this analysis was that only the 
phosphorylation sites were located in conserved protein domains (Pfam A 
domains).  A brief analysis of the other sites appeared to show that they were 
located on the periphery of the conserved protein domains.  Further work could 
characterise the regions in which the other sites are located (i.e. substitution 
rate, secondary structure, etc.).  Of course a PTM conservation analysis that is 
only able to include sites found in conserved protein domains is incomplete.  In 
the future it will be important to develop PTM Browser so that it can analyse the 
conservation of PTMs found at sites not annotated to conserved protein 
domains.  The most obvious methodology to implement this feature would be to 
deduce homologous sites between orthologues using a multiple sequence 
alignment tool such as CLUSTAL W (Thompson, Higgins, and Gibson 1994). 
The analysis (see Section 6.2.1) showed that the p53 DNA binding domain 
doesn‟t appear to have gained new phosphorylation sites over evolutionary 
time.  The PTMDB contains only two phosphorylation sites for this domain.  
These two sites are present in all proteins identified as p63 and p73.  These two 
phosphorylation sites are also found in all copies of the p53 protein except 
those belonging to the bony fish.  Considering that it is thought that p53 and a 
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p63/p73-like gene (which was subsequently duplicated to form p63 and p73 
genes) were the products of a single gene duplication event (Belyi et al. 2010), 
this result raises further questions.  This result suggests that sometime after the 
divergence of the ancestor of mammals and amphibians from that of the extant 
bony fish, the latter lost one of the two phosphorylation sites.   This analysis 
showed that the phosphorylation site located at residue 215 on the H.sapiens 
p53 orthologue can be found in all members of the p53 protein family.  This 
residue has been shown to be important in preventing apoptosis after DNA 
damage (Liu et al. 2004). 
The analysis of the p53 TA domain presented a more complex pattern of PTM 
conservation than that of the p53 DNA binding domain.  A comparison between 
all three members of the p53 family was not possible as Pfam lacks 
corresponding domain annotations for p63 as well as p73 orthologues.  In 
addition five of the bony fish p53 orthologues didn‟t have corresponding 
annotations.  It was previously speculated that poor sequence conservation is 
likely to be the cause of these proteins not receiving TA domain annotations 
(see Section 6.2.2).  Of course if an analysis routine were to be implemented 
that could utilise CLUSTAL W alignments in addition to Pfam domains these 
proteins could have been included in the analysis.  Although the CLUSTAL W 
alignments would need to be treated with caution where sequence identity is 
low.   
The PTMDB contains five phosphorylation annotations for the p53 TA domain.  
Three of these are conserved across all mammalian species analysed.  The 
remaining two were found in all of the primates and other non-ungulate species 
(with F. catus and C. lupus being exceptions – where they each are missing one 
of these two sites).  It is therefore possible to speculate that the non-ungulate 
ancestor evolved these two sites not seen in the corresponding ungulate 
ancestor.  Although Sus. Scrofa (an ungulate) and X. laevis (an amphibian) 
violate this model of evolution as they both appear to possess one of these two 
sites.  Of course more complex models of evolution could be suggested that 
attempt to explain these observations (i.e. convergent evolution and/or loss of 
sites from the ungulate ancestor).  However it must be stressed that since many 
of these phosphorylation sites have been cross-annotated many may not 
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actually be modified in vivo.  Indeed many of the sites which received a cross-
annotation showed a markedly different kinase prediction profile (i.e. the 
enzymes that were predicted to be able to modify such sites) to that of the 
donor site.  This of course highlights one of the issues of analysing PTM 
conservation with a dataset that contains predicted PTM annotations.  The 
analysis of this domain raised an interesting question regarding the mechanism 
that causes MDM2 to disassociate from p53 (see Section 6.2.2).   
Phosphorylation of residue 20 on the H. sapiens p53 orthologue has been 
shown to be essential for the dissociation of MDM2.  However X. laevis is 
missing this phosphorylation site even though it has been shown to have a 
MDM2 orthologue. 
In Section 6.3.1 an analysis of the conservation of modifications between the 
super-kingdoms showed only a few modifications to be conserved.  Macek et al. 
(2008) has previously looked at the conservation of phosphorylation sites 
between Eubacteria and Archaea.  They also reported that some 
phosphorylation sites are conserved between Archaea and Eukaryotes.  The 
study in Section 6.3.1 described two phosphorylation sites that are potentially 
conserved across all three superkingdoms. 
Macek et al. (2008) also looked at the conservation of phosphoproteins 
between E. coli and other bacterial species.  They discovered that 
phosphoproteins are more highly conserved than their non-phosphorylated 
counterparts.  They found that >50% of E. coli phosphoproteins were conserved 
compared to 25% of non-phosphorylated proteins.  In Section 6.3.2(a)  a similar 
analysis was performed between Eukaryote species.  This analysis showed a 
similar pattern of modified proteins of various classes showing a higher degree 
of conservation than their non-modified counterparts. 
In Section 6.3.2(a) it was shown that species which had no PTM annotations for 
a particular class also lacked orthologues for proteins from other species that 
have annotations of the corresponding class.  For example S. cerevisiae and S. 
pombe have no orthologues to H. sapiens proteins that have GPI-anchor 
modification annotations.  Therefore the data presented here indicates that the 
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evolution of modification processes is connected to the evolution of the proteins 
which are modified.  This is a novel finding that requires further validation. 
Section 7.6  Biological relevance 
PTM Browser can be used during the design of new drugs to identify suitable 
animal models.  Consider the following case-study.  TBN1412 is a monoclonal 
antibody that was designed by TeGenero to activate regulator T-cells which it 
was hoped would aid in the treatment of autoimmune diseases and cancer 
(Attarwala 2010).  TBN1412 was designed to activate regulator T-cells by 
interacting with and activating signalling downstream of CD28 (a cell surface 
glycoprotein) (Attarwala 2010).  Before phase I clinical trials this drug was 
primarily tested using macaques as the animal model (Bhogal and Combes 
2007).  Macaques were chosen according to TeGenero as the region of CD28 
they were targeting was 100% identical to that of humans (Bhogal and Combes 
2007).  All volunteers that received the drug had an immediate adverse reaction 
to the drug that resulted in multi organ failure (Attarwala 2010).  A subsequent 
investigation into the drug trial reported that neither contamination nor miss-
management of the trial could be blamed for the unexpected side-effects 
(Attarwala 2010).  A number of theories have since been put forward to explain 
why the animal models failed.  One suggestion is that the drug resulted in a 
different set of downstream signalling events in humans than in the macaques 
(Bhogal and Combes 2007).  CD28 contains a number of putative glycosylation 
sites and has been determined to be approximately 50% carbohydrate by mass 
(Ma et al. 2004).  Ma et al. (2004)  previously showed that CD28 is negatively 
regulated by N-linked glycans.  One possible explanation is that TBN1412 was 
more responsive in humans than macaques because of differences in attached 
glycans.  Bhogal and Combes (2007) reported that Macaque CD28 wasn‟t in 
fact 100% identical to that of humans: as previously reported by TeGenero.  
However they also reported that all of the putative N-linked glycosylation sites 
were conserved; this doesn‟t rule out a difference in glycosylation site 
occupancy (i.e. which sites have which glycans).  This case-study shows how 
important it is to pay close attention to differences between orthologues.  It also 
provides a speculative example of where differences in glycosylation between 
orthologues may have resulted in the failure of a potential drug therapy.  PTM 
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Browser presents scientists with a new tool to determine if modification sites are 
conserved between orthologues which could help in the selection of animal 
models, in future drug trials. 
Section 7.7  Future direction 
New PTM databases appear on a regular basis and it will be important to make 
sure that these new developments are incorporated into the PTMDB.  For 
example a new Glycosylation database, called UniCarb-DB, was recently 
released (Hayes et al. 2011).  In addition PTM Browser doesn‟t have access to 
the PDB derived residue/glycan structure pairs incorporated into the PDB.  They 
were excluded partly because of their small number and partly because they 
add a layer of complexity to the display format of PTM Browser.  Full support for 
such datasets should be added to PTM Browser as it seems likely that over 
time the size of these datasets will expand dramatically.  PTM Browser will need 
support for displaying glycan structures and for users inputting specific 
structures.  
PTM Browser was originally designed to only be able to compare annotations 
based on PfamA domain alignment coordinates.  There is a definite need to be 
able to analyse PTM conservation outside of PfamA domains and outside of 
Pfam as a whole (only 50% of modifications fall inside a PfamA domain).  This 
issue could partly be addressed by adding support for PfamB (see Section 
4.3.1(a) for more details on the exclusion of PfamB domains).  However as was 
evident from the analysis of the p53 family of proteins modifications can lay 
outside of PfamA and PfamB domains.  To allow PTM Browser to better 
accommodate protein family analysis, it should be extended so that for 
modifications that lay outside of Pfam domains, their conservation is derived 
from new multiple sequence alignments (e.g. use the automatically generated 
CLUSTAL W alignments that PTM Browser already produces).  However it 
should be stressed that where available the Pfam domain alignments should be 
used preferentially - as these are guided by manually curated seed alignments. 
PTM Browser is a powerful application in terms of what modifications users can 
select to compare and how the comparison is actually performed.  Going 
forward it will be important to develop the PTM Browser GUI to make it much 
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easier for users to access the common types of queries.  In addition to making 
changes to the web application, it will be important to make the developer web 
service as easy to use as possible.  To this end a series of wrapper classes are 
already under development that hide a lot of the complexity of the web service 
from developers (e.g. automatically dumping datasets to a database).  There 
are many other features that could be added to the PTM Browser interface.  For 
example one idea would be to generate a tree like structure similar to that 
created by PHOG.  Instead of showing which orthologues are shared at each 
node of the taxonomic tree; the shared modifications are shown instead.    
In conclusion, the integration of diverse proteomic data sources in the 
development of PTM Browser has highlighted the need for a consensus on data 
formats and nomenclature in the field of glycomics. However, despite complex 
data integration issues, and the fact that computational glycomics is still a 
relatively „new‟ field, the PTM Browser is a powerful tool. It has applications in 
many areas of molecular biology, including the potential use in an analysis 
pipeline for the selection of animal models for new drug therapies. 
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Appendix 
Appendix 1:   p53 family UniProtKB list 
Q9W678,P67938,P67939,Q29537,Q9WUR6,P13481,O09185,P79734,Q8SPZ3,P
41685,P10360,P04637,O93379,P56423,P61260,P56424,O36006,Q00366,A7
SFL1,P25035,Q95330,P79820,P51664,O12946,P10361,Q9TUB2,Q9W679,Q9T
TA1,P07193,O57538,Q92143,Q9JJP6,O88898,Q9H3D4,Q8JHZ6,Q98SW0,Q9DE
C7,Q9JJP2,Q9XSK8,O15350,Q5KQU6, Q4SF81 
Appendix 2:  Source code 
The following is a list of some of the more important programs that have been 
created as part of this thesis.  The PTM Browser web site should be consulted 
for a list of the latest versions of these programs and other programs.  All of the 
source code that has been written as part of this project is available for 
download from a number of repositories.  Instructions pertaining to the 
download and setup of this source code can be found at the following URL: 
<http://wiki.ptmbrowser.org/index.php/BBP_Setup>   
Program: org.drd20.bioinformatics.database.ptmdb.psiModAutomate.sh 
Input:       $BBP/org/drd20/bioinformatics/database/ptmdb/PSI-MOD.obo (static) 
                   (latest version: http://psidev.sourceforge.net/mod/data/PSI-MOD.obo) 
Description 
This script is responsible for parsing an OBO formatted PSI-MOD ontology file. 
Which can be downloaded from the following URL 
Program: org.drd20.bioinformatics.database.ptmdb.PtmDbErd (class) 
Description 
Class provides methods to add new PTM annotations to the PTMDB. 
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Program: ptmDB/ncbiEntrezTaxonomy/namesToMySQL.pl 
Input:       /tmp/names.dmp (static) 
                   (latest  version: ftp://ftp.ncbi.nih.gov/pub/taxonomy/taxdump.tar.gz) 
Description 
This script imports the NCBI Entrez Taxonomy name dump file into the PTMDB. 
Program: ptmDB/ncbiEntrezTaxonomy/createRelationshipTable.pl 
Input:       /tmp/nodes.dmp (static) 
                   (lasted  version: ftp://ftp.ncbi.nih.gov/pub/taxonomy/taxdump.tar.gz) 
Description 
This script imports the NCBI Entrez Taxonomy tree from the nodes dump file 
into the PTMDB.  The most obvious way of storing the taxonomic tree in the 
database is to connect each node to its immediate ancestor.  However this 
makes the process of selecting all the descendants of a particular node very 
slow as it involves a great deal of graph traversing.   The solution that has been 
used in the PTMDB is to traverse the taxonomic tree and store every possible 
ancestor/descendent relationship that is observed (i.e. there is one row that 
connects H. sapiens to Mammalia and another that connects H. sapiens to 
Eukaryota).  An alternative would have been to create a pre-order tree, like that 
shown below, that gives each node a left and right index.   
          
 
 
 
 
 
By discovering the left and right index of the ancestor node it is then possible to 
obtain all descendants by asking for nodes with a left index which is > the 
ancestors index but who‟s right index is less than that of the ancestor. 
 
         *                   1 Home 10 
         *                           | 
         *             ----------------------------                                   
         *             |                                    | 
         *        2 First 7                     8  Fifth  9      
         *             | 
         *       -------------- 
         *       |                 | 
         * 3  Third  4   5  Fourth  6  
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Program: ptmDB/Main/UniprotUpload/uniprotToDatabaseErd.pl 
Input:        
                  -t  Database type [TREMBL or SW]  
                  -d Location of UniProtKB DAT file  
                  -e Erase tables common to Swiss-Prot and TrEMBL [0|1] 
                  -E Include additional tables (creates some additional referencing tables) 
                  -P Import annotations into the PTMDB 
 
Latested Swiss-Prot DAT file:                     
ftp://ftp.uniprot.org/pub/databases/uniprot/current_release/knowledgebase/complete/uniprot_spr
ot.dat.gz 
Latested TrEMBL DAT file: 
ftp://ftp.uniprot.org/pub/databases/uniprot/current_release/knowledgebase/complete/uniprot_tre
mbl.dat.gz 
Description 
This script imports PTM annotations into the PTMDB from UniProtKB files.  It 
also imports protein sequences, accessions and sequence version numbers. 
Program: org.drd20.bioinformatics.database.ptmdb.Phospho.ELM (class) 
Input:       Location of downloaded Phospho.ELM flat file 
                   (lasted  version: http://phospho.elm.eu.org/dataset.html) 
Description 
This script imports PTM annotations from a dump of the Phospho.ELM 
database.  Note that annotations are excluded if the provided sequence version 
number and/or sequence do not match that of the same UniProtKB entry stored 
in the PTMDB. 
Program: org.drd20.bioinformatics.database.NotPtm (class) 
Input:       Location of downloaded Swiss-Prot DAT file 
                   (lasted  version: see above) 
Description 
The original UniProtKB parser was not designed to extract negative PTM 
annotations.  This script should be used to carry out this procedure until support 
is added to the main parser 
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Program:  org.drd20.bioinformatics.database.ptmdb.GlycoSciences.importPDB2LINUCS.pl 
Description 
This script automates the process of importing glycosylation annotations into 
the PTMDB from the PDB using the PDB2LINUCS tool.  This script uploads 
PDBs from a local PDB mirror to the PDB2LINUCS web server and then 
subsequently classifiers the extracted glycans. 
Program: org.drd20.bioinformatics.alignment.copao.CoPaO.pl 
Input:       The location of the two FASTA files that you would like to detect orthologues 
                    between. 
Output:     Outputs orthologous clusters, in the file format shown below, to the file results.csv 
                    
 
 
 
 
 
Description 
This script detects orthologues and in-paralogues between two lists of proteins 
in FASTA file format using the InParanoid algorithm.  Note that a Java version 
of this program has also been created found in the same directory. 
  
CLUSTER\tclusterId 
SCORE\tscoreId 
AORTH\tUniProtKB Accession (one or many) 
BORTH\tUniProtKB Accession (one or many) 
APARA\tUniProtKB Accession\tPrimary[0|1]\tConfidence value (zero or many) 
BPARA\tUniProtKB Accession\tPrimary[0|1]\tConfidence value (zero or many) 
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Program:  
org.drd20.bioinformatics.database.ptmdb.HoBPret.Pfam.New.PfamAnnotationTransferMultiRun.pm 
Input:          
                  Pfam version [A|B] 
                      Restart flag [1|0]  
                      Run name 
                      Location of a file that lists TrEMBL proteins that should be included. 
Output:        For each Pfam domain a directory is created in the output directory  
                       $ENV{HOME}/GridBox/HoBPret/.  This directory contains a number 
                       files that can be used to debug the cross-annotation procedure.   
                       Cross-annotation results are stored in the file results.csv in the 
                       format shown below. 
 
 
 
Description 
This program is responsible for carrying out the cross-annotation process.  
Cancelled cross-annotations runs can be resumed by setting the restart flag to 
true.  This program will ignore Pfam domains that are marked as being 
complete in the output directory.  Note that the output directory is statically set 
to $ENV{HOME}/GridBox/HoBPret/.  A new C++ version of this program is 
currently in development. 
 
Target P35361 N-linked (GlcNAc...) 193 Query Q6IEX5 N-linked (GlcNAc...) 148 131 14.29 BENCHMARK NEW 
P35361-64-328           FGWSRYVPEG*N-----LTSCT 
Q6IEX5-19-265           LL-TFQLPFC*NAQVIDHYFCD 
